patient_filename,t,method_pred,method_reason,text
TCGA-3C-AALI.84E6A935-1A49-4BC1-9669-3DEA161CF6FC,1,T1,"To determine the pathologic T stage of the patient's breast cancer, we will follow the rules provided step-by-step: \\n1. Examine the report for the size of the invasive breast carcinoma. \\n2. If the size is 2 cm or less, proceed to further divide the tumor based on the given size ranges. \\n3. If the size is more than 2 cm but not more than 5 cm, it is T2. \\n4. If the size is more than 5 cm, it is T3. \\n5. Check for any direct extension to the chest wall or skin, or spread to the chest wall and/or the skin, resulting in ulceration, satellite nodules, or inflammatory carcinoma. \\n"")","Path No.: Date Obtained: (Age: ). Date Received: F. See Addendum/Procedure. SPECIMEN: A:Lymph node, right axilla sentinel node, biopsy. B:Breast, right, lumpectomy. C:Lymph nodes, right axilla, dissection. DIAGNOSIS(ES): A. Lymph node, right axilla sentinel node, biopsy: - Carcinoma in 1 sentinel node following carcinoma of right breast. B. Breast, right, lumpectomy: - Carcinoma, invasive ductal type, moderately-differentiated, with focal micropapillary features,. Nottingham's score 5 (2+2+1). - Carcinoma, intraductal, comedo type with microcalcifications. - Lobular neoplasia, focal, classical type. - Fibrocystic disease, proliferative, with apocrine metaplasia, sclerosing adenosis and. microcalcifications. - Cicatricial fibrosis and organizing granulation tissue with fat necrosis, consistent with previous. biopsy site. - Fibroadenoma, microscopic. C. Lymph nodes, right axilla, dissection: - No evidence of carcinoma in 14 lymph nodes. Date Dictated: CLINICAL INFORMATION: Breast cancer. GROSS DESCRIPTION: The specimen is received in three parts. Part A is received fresh from the operating room for frozen section diagnosis in a container labeled with the patient's. name and ""R sentinel lymph node"". It consists of one firm tan to red lymph node measuring 2.0 x 1.8 X 1,0 cm, The. specimen is serially sectioned. Submitted in toto in three cassettes labeled AFS, A1 and A2. AFS = frozen section, A1. - A2 = remaining tissue,. Part B is received unfixed in a container labeled with the patient's name and ""R breast lumpectomy"". It consists of a. piece of yellow-white fibrofatty tissue measuring 10.5 X 9.0 x 6,0 cm. An ellipse of skin is not present. An X-ray is. received. A localization needle is not noted. A short suture is noted indicating the superior margin and a row of long. sutures are noted indicating the lateral margin. A mass is palpated in the center. The superficial surface is inked yellow. and the deep surface is inked black. The specimen is serially sectioned. On cut section, the mass is tan, firm, poorly. circumscribed and measures 3.2 x 3.0 x 3.0 cm. The mass comes to 0.3 cm of the superficial, 0.5 cm of the deep and. 2.5 cm of the lateral margins. The tissue is composed of 60% fat and 40% intermixed firm tan-white parenchyma. Representative sections are submitted in 29 cassettes labeled B1 - B29. Legend: B1 = mass and closest deep surface,. B2 = mass and closest superficial surface(B1 and B2 = full thickness of mass),. B3 - B8 = mass with adjacent deep margin. B9 - B17 = superficial margin over mass. B18 - B19 = mass. B20 - B21 = superior. B22 - B23 = deep margin in lateral part(closest to mass). B24 - B25 If lateral. B26 - B27 = inferior. B28 - B29 = medial. Part C is received unfixed in a container labeled with the patient's name and ""R axillary lymph node dissection"". It. consists of two pieces of yellow-red fatty tissue measuring 4.0 x 2.7 x 1.0 cm and 10.0 x 7.0 X 1.0 cm. A suture is noted. attached to one end of the larger piece of fatty tissue. Fourteen lymph moves measuring from 0.6 X 0.5 x 0.5 cm. to. 3.5. x 1.5 x 1.0 cm are identified. The lymph nodes are submitted in toto 10 cassettes labeled C1 - C10. Legend: C1 = five intact nodes, C2 - C5 = one bisected node in each cassettes, C6 = one intact node, C7 - C8 = one. large quadrisected node, C9 - C10 = nodes closest to suture(larger node is bisected). INTRAOPERATIVE CONSULTATION: AFS: Metastatic carcinoma in lymph node. Performed by: Resident: interpreted by: Attending: MICROSCOPIC DESCRIPTION: I. TYPE OF SPECIMEN: Right breast, excisional biopsy/lumpectomy. Right axillary node dissection. II. LOCATION OF THE TUMOR: Upper outer quadrant. III. TYPE OF NEOPLASM: Carcinoma, invasive - ductal type NOS with micropapillary features. Histological Grading: Moderately differentiated. (Nuclear grade 2 and Tubular & Glandular differentiation grade 2). Ductal carcinoma in situ, nuclear grade 3, multifocal 10%. intraductal comedo subtype. Necrosis is present within the intraductal subtype. Lobular neoplasia, type A (monomorphic), Focal in 2 of 29 slides. IV. GROSS/MICRO FINAL INVASIVE TUMOR SIZE INTERPRETATION: 3.2 x 3.0 x 3.0 cm. V. BORDERS OF INVASIVE NEOPLASM: III-defined. VI. VASCULAR SPACE INVASION: Present in lymphatics. VII. CALCIFICATION: Present in both malignant and benign areas. VIII. NIPPLE: N/A. IX. SKIN: N/A. X. ADJACENT BREAST TISSUE: Fibroadenoma (size 0,2 cm.). Cystic disease, proliferative. XI. SURGICAL MARGIN: No carcinoma is identified on surgical margins. Tumor distance from closest deep (slide ""B1"") margin: 0.6 cm. XII. AXILLARY LYMPH NODES: TOTAL: 15. HIGH POINT: 2. SENTINEL NODE: 1. XIII. POSITIVE LYMPH NODES: TOTAL: 1. HIGH POINT: 0. SENTINEL NODE: 1. DEGREE OF INVOLVEMENT: Extensive replacement. EXTRANODAL EXTENSION: Present. XIV. PECTORAL MUSCLE: No pectoral muscle identified. This report has been reviewed electronically and signed on. Interpreted by: Attending: The diagnosis was rendered by the attending pathologist. Addendum. ADDENDUM. Slides were reviewed by. The diagnosis rendered is in. agreement with the original diagnosis. This procedure/addenda has been electronically reviewed and signed on. Interpreted by: Attending: Note: Immunochemistry testing performed at. was developed and Its performance characteristics determined by the. These tests were interpreted in conjunction with external positive and internal negative controla, unless otherwise noted It has not been cleared or approved by the US. FDA. This test is used for clinical purposes only, It should not be regarded as Investigational or for research."
TCGA-A2-A0YH.0C344CD7-6FAB-462B-9A8E-75B720F2D626,1,T1c,"[Step 1: Identify the size of the tumor] The report states that the size of the tumor is 2.4 x 2.2 x 2.7 cm in greatest dimensions. <br>[Step 2: Compare the size of the tumor to the T stage criteria] The tumor size is within the T1 range, which includes invasive breast carcinomas that are 2 cm or less in size. However, the T1 category can be further divided into T1mi, T1a, T1b, and T1c based on the size of the tumor. <br>[Step 3: Determine the appropriate T1 subcategory] The tumor size is greater than 0.1 cm but less than 2 cm. Therefore, the tumor falls into the T1c category, which includes invasive breast carcinomas that are 1 cm but less than 2 cm in size. <br>[Step 4: Confirm the absence of T3 and T4 criteria] The report does not mention any direct extension to the chest wall or skin, nor does it mention any ulceration, satellite nodules, or inflammatory carcinoma. Therefore, the tumor does not meet the criteria for T3 or T4. <br>[Step 5: Confirm the absence of multifocal or multicentric disease] The report does not mention any multifocal or multicentric disease. Therefore, the tumor is considered unifocal. <br>[Step 6: Confirm the absence of Tis (carcinoma in situ) or Tis (Paget's disease) as the only tumor] The report mentions the presence of duct carcinoma in situ (Tis) adjacent to the invasive tumor, but it is not the only tumor present. Therefore, the tumor is not considered Tis or Tis (Paget's disease) only. <br>[Step 7: Confirm the absence of inflammatory carcinoma] The report does not mention any signs of inflammatory carcinoma. Therefore, the tumor is not considered T4d. <br>[Step 8: Assign the final T stage] Based on the above reasoning, the final T stage for this patient's breast cancer is T1c.","Chief of. CPNSU. Specimen. Spec Type: SURGICAL p. OPERATION. DOCTOR (8) : PROCEDURE: PARTIAL MASTECTOMY/LUMPECTOMY-AXTLLARY NODE DISSECTION. TISSUE REMOVED. A. LT PARTIAL MASTECTOMY. B. LT AXILLARY NODE. C. LT BREAST INFERIOR AND SUPERFICIAL MARGIN. GROSS DESCRIUTION. PART A RECEIVED FRESH LABELED. LEFT PARTIAL MASTECTOMY LONG. EQUALS LATERAL SHORT EQUALS SUPERIOR, IS AN OVOID PORTION OF YELLOW-PINK. FATTY TISSUE MEASURING 7 x 6 x 3.5 CM. THE SPECIMEN IS ORIENTED BY TWO. SUTURES AND MARKED AS FOLLOWS LATERAL ORANGE, MEDIAL RED, SUPERIOR. GREEN, INFERIOR BLUE, SUPERFICIAL BLACK, DEEP YELLOW. A LARGE PALPABLE. MASS IS FELT WITHIN THE SPECIMEN INFERIOR AND MEDIALLY. SECTIONING. REVEALS A ROUNDED PINK-TAN MASS MEASURING 2.4 x 2.2 x 2.7 CM IN GREATEST. DIMENSIONS. THIS APPROACHES THE SUPERFICIAL, DEEP AND INFERIOR MARGINS,. GROSSLY EXTENDING TO WITHIN 0.2 CM OF EACH OF THESE. IT IS GREATER THAN. 1 CM FROM THE OTHER MARGINS. THE SPECIMEN CONSISTS OF PINK-TAN FIBROUS. TISSUE IN THE MEDIAL ASPECT OF THE SPECIMEN AND YELLOW FATTY TISSUE MORE. LATERALLY. A RIBBON CLIP IS IDENTIFIED WITHIN THIS LESION. SECTIONS ARE. SUBMITTED AS FOLLOWS: A1 --REPRESENTATIVE PERPENDICULAR MEDIAL MARGIN,. A2 - -REPRESENTATIVE - PERPENDICULAR LATERAL MARGIN, A3 - --TUMOR (MIRROR IMAGE. TO PROTOCOL), A4--TUMOR AND INFERIOR MARGIN (MIRROR IMAGE TO PROTOCOL). A5 - -LESION AND INFERIOR MARGIN, A6--TUMOR AND SUPERFICIAL MARGIN,. A7--TUMOR AND DEEP MARGIN. NOTE THAT A5 THROUGH A6 IS ONE FULL. CROSS-SECTION OF LESION, WITH A6 MIRROR IMAGE TO TISSUE TAKEN PER. PROTOCOL. A8 --TISSUE - AND SUPERFICIAL MARGIN CORRESPONDING TO THE TUMOR. IN A3 (MIRROR IMAGE TO PROTOCOL TISSUE), A9--TISSUE TO INCLUDE THE DEEP. AND SUPERIOR MARGINS CORRESPONDING TO THE CROSS-SECTION DEPICTED IN A5. THROUGH 7, A10--THE CORRESPONDING DEEP MARGIN TO THE TUMOR TAKEN IN A3,. All --THE LATERAL ASPECT OF THE TUMOR TO INCLUDE THE INFERIOR SUPERFICIAL. MARGIN. PART B RECEIVED FRESH LABELED. LEFT AXILLARY NODE. DISSECTION, IS A PORTION OF YELLOW-RED FATTY TISSUE MEASURING 10 x 7.6 x. 4.8 CM IN GREATEST DIMENSIONS. THIS IS EXAMINED FOR LYMPH NODES WHICH. ARE THEN SUBMITTED AS FOLLOWS: 1--GROSSLY UNREMARKABLE LYMPH NODE,. B2 - - SECTION OF GROSSLY POSITIVE LYMPH NODE, B3 --SECTION - OF GROSSLY. POSITIVE LYMPH NODE WITH COIL CLIP. NOTE: SPECIMENS B1 THROUGH 3 ARE. MIRROR IMAGES TO PROTOCOL SECTIONS. B4 AND ---ONE NODE TOTAL, B6--TWO. NODES EACH BISECTED, B7--TWO NODES EACH BISECTED, B8 - THREE - NODES EACH. BISECTED, B9 - THREE NODES, B10--ONE NODE BISECTED, B11--ONE NODE. BISECTED, B12 - ONE NODE BISECTED. AFTER A SHORT TIME OF ACETIC FORMALIN FIXATION, ADDITIONAL NODES ARE. Chief of Pathology. specimen: spec Type: SURGICAL p. GROSS DESCRIPTION. IDENTIFIED AND SUBMITTED AS FOLLOWS: B13--ONE NODE BISECTED, B14 - -FIVE -. NODES, B15--THREE NODES EACH BISECTED, B16--TWO NODES EACH BISECTED. PART C RECEIVED LABELED LEFT BREAST INFERIOR AND. SUPERFICIAL MARGIN STITCH AT NEW MARGIN, IS AN OVOID PORTION OF. YELLOW-PINK FATTY TISSUE MEASURING 6.4 x 5.4 x 1.1 CM. SUTURE DENOTES A. NEW MARGIN. THIS SIDE IS MARKED WITH BLUE INK WITH A PERIMETER OF BLACK. INK. THE SPECIMEN IS SECTIONED AND ENTIRELY SUBMITTED LABELED C1 THROUGH. 10. PATH PROCEDURES. PROCEDURES: 88307/3, A BLK/11, B BLK/16, C BLK/10. FINAL DIAGHONTS. PART A LEFT PARTIAL MASTECTOMY: IN SITU AND POORLY DIFFERENTIATED. INFILTRATING DUCT CARCINOMA, NUCLEAR GRADE III/III WITH A HIGH MITOTIC. INDEX. THE INVASIVE TUMOR IS 2.- 4 CM IN MAXIMUM MICROSCOPIC DIMENSION. A 0.9 CM FOCUS OF DUCT CARCINOMA IN SITU OF THE MICROPAPILLARY AND. COMEDOCARCINOMA TYPES IS PRESENT ADMIXED WITH AND ADJACENT TO THE. INVASIVE TUMOR. DUCT CARCINOMA IN SITU IS PRESENT 1 MM FROM THE. SUPERFICIAL MARGIN, WITH INVASIVE CARCINOMA 1.5 MM FROM THE SUPERFICIAL/. MARGIN. INVASIVE CARCINOMA IS ALSO PRESENT IN A MICROSCOPIC SATELLITE. NODULE 1 MM FROM THE DEEP MARGIN. THE INFERIOR MARGIN IS CLEAR BY A. DISTANCE OF 3 MM. THE SUPERIOR, MEDIAL, AND LATERAL MARGINS ARE ALL. CLEAR OF TUMOR BY DISTANCES EXCEEDING 1 CM. THERE IS A SMALL FOCUS OF. ATYPICAL DUCT HYPERPLASIA 3 MM FROM THE MEDIAL MARGIN. PART B LEFT AXILLARY LYMPH NODE DISSECTION: METASTATIC CARCINOMA. IDENTIFIED IN 5 OF 28 AXILLARY LYMPH NODES. PART C LEFT BREAST SUPERFICIAL AND INFERIOR MARGIN, REEXCISION: FRAGMENTS OF BENIGN FATTY BREAST TISSUE AND A MICROSCOPIC FOCUS OF. INFILTRATING DUCT CARCINOMA. THIS 1 MM FOCUS OF CARCINOMA HAS A. CAUTERIZED MARGIN AND IS SEPARATE FROM THE ADJACENT ADIPOSE TISSUE. THE. AREA IS NOT INKED, BUT ITS RELATIONSHIP TO THE MARGIN CANNOT BE. ACCURATELY DETERMINED BECAUSE IT IS NOT ATTACHED TO THE INKED MARGIN. PORTION OF THE SPECIMEN. THIS FOCUS OF TUMOR IS PRESENT IN 1 OF 10. TISSUE BLOCKS (BLOCK C10). CODE. 1. (prelim.)."
TCGA-A2-A0YT.1C420F6B-8720-4CB0-9FB3-86A0EC05FBBD,3,T3,"Based on the pathology report, the patient's breast cancer is described as an 'infiltrative duct carcinoma' with a 'confluent region that measures 13.6 cm.' This indicates that the tumor is larger than 5 cm, which rules out T1 and T2 stages.  The report also mentions 'focal extension of the tumor into the epidermis without ulceration' and 'a satellite nodule' in the skin. These findings correspond to T4b and T4c stages, respectively. However, the report also states that 'the inked margins are free' which suggests that the tumor has not invaded the surrounding skin beyond the margin. Therefore, based on the information provided, the patient's breast cancer is most likely to be in T3 stage, as it is larger than 5 cm but has not invaded the chest wall or caused skin ulceration or satellite nodules beyond the margin. However, it is important to note that the actual T stage should be determined by a healthcare professional based on a variety of factors, including clinical examination, imaging studies, and pathological findings.","SURGICAL REPORT. Sex: F. Date Collected: Date Received: M.R. Number: Doctor: Account Number: PRE-OPERATIVE DIAGNOSIS. LEFT BREAST CANCER. POST-OPERATIVE DIAGNOSIS. LEFT BREAST CANCER. PROCEDURE. LEFT MODIFIED RADICAL MASTECTOMY. TISSUES. A. BREAST MASTECTOMY (WANO) NODES - LEFT BREAST & AXILLARY CONTENTS. B. MARGINS - ADDITIONAL INFERIOR SKIN LEFT BREAST. WRI TISSUE. FINAL DIAGNOSIS. A. LEFT BREAST AND AXILLARY CONTENTS, 1619 GMS. -. INFILTRATIVE DUCT CARCINOMA (CONFLUENT REGION MEASURES 13.6 CM.). SCARFF-BLOOM-RICHARDSON GRADING: GRADE 3 OF 3 (ABSENT TUBULAR FORMATIONS, HIGH NUCLEAR GRADE. AND MODERATE MITOTIC INDEX). DCIS: NONE IDENTIFIED. ANGIOLYMPHATIC INVASION: PRESENT, MULTIFOCAL. TUMORAL CALCIFICATION/NECROSIS: PRESENT. SURGICAL MARGINS: UNINVOLVED. NON-NEOPLASTIC BREAST -. FIBROADENOMA 0.3 CM. FIVE POSITIVE LYMPH NODES WITH EXTRACAPSULAR EXTENSION (6/5). THE LARGEST NODE MEASURES 1.6 CM. AND THE TUMOR INVOLVES THREE-FOURTHS. OF THE NODE. OVERLYING NIPPLE, AREOLA AND SKIN: FOCAL EXTENSION OF THE TUMOR INTO EPIDERMIS WITHOUT ULCERATION. B. ADDITIONAL INFERIOR SKIN LEFT BREAST -. POSITIVE FOR INFILTRATIVE DUCT CARCINOMA, THE TUMOR INVOLVES THE DERMIS. WITHOUT EXTENSION TO EPIDERMIS. (SATELLITE SKIN NODULE). THE INKED MARGINS ARE FREE. PTNM CLASSIFICATION: SURGICAL REPORT. T4B, N2a, MX, STAGE GROUPING IIIB. Diagnosed by: and. COMMENT. The multiple sections from the tumor reveal a poorly differentiated infiltrative duct carcinoma with. widespread angiolymphatic invasion. The satellite nodule grossly observed appears to be a direct. extension from the primary tumor with peripheral tumefaction. The overlying epidermis is involved by the. tumor but does not exhibit ulceration. The Bloom-Richardson grading was upgraded to 3 based on. complete evaluation of the entire tumor mass. The ER, PR, and Her-2/neu have been performed on the previous surgical. This case Is discussed with. on. GROSS DESCRIPTION. The specimen is received in two separate containers labelec. esignated A and B. A. The container is received fresh unfixed labeled ""left breast and axillary contents - suture on. upper outer quadrant"". The specimen consists of a 1,519 gm. apparent left breast which is 30 x. 20 x 7.5 cm. in greatest overall dimension. There is an attached suture indicating upper outer. quadrant inked with orange dye, lower outer quadrant is inked yellow, upper inner quadrant is. inked with green dye, lower inner quadrant is inked with red dye. The deep margin is inked black. Sectioning reveals a tumor mass directly beneath the nipple which is 13.5x 7 x 4 cm. in greatest. overall dimension and is 1.5 cm. from the deep margin, 2 cm. from the upper outer margin, 2.5. cm. from the lower outer margin, 2 cm. from the upper inner margin, and 4 cm. from the lower. inner margin. There is a satellite nodule which is 0.6 cm. in greatest dimension and is 1.5 cm. from the main tumor mass and has a distance of 0.6 cm. from the upper inner margin. Sectioning. through the remaining breast stroma reveals fatty and fibrous-encased tissue. Sectioning through. the attached axillary fat reveals rare tan-gray nodules varying up to 1 cm. in greatest dimension. The specimen is submitted in twelve blocks. Key Note Block Summary: 1-nipple with underlying tumor, 2 through 4-tumor mass, 5-. satellite nodule and upper inner quadrant, 6-lower inner quadrant, 7-lower outer quadrant, 8-. upper outer quadrant, 9-deep, 10 through 12-rare nodules. B. The container is received fixed labeled ""additional inferior skin left breast"". The specimen. consists of a skin ellipse which is 7 x 1x 1 cm. in greatest overall dimension. The skin. has been previously marked with purple-blue dye. The specimen is serially sectioned. revealing no apparent gross abnormalities. The entire specimen is submitted in two. blocks. MICROSCOPIC EXAM. MICROSCOPIC EXAMINATION CONDUCTED BY PATHOLOGIST CONFIRMS FINAL DIAGNOSIS. SURGICAL REPORT."
TCGA-A2-A1G4.5AD3B697-F097-496C-978B-F73BDA5394A7,2,T1,"[{""step"":1,""info"":""From the pathology report, we can see that there are two separate specimens: right breast deep margin and left breast. We will focus on the left breast specimen as it contains the invasive breast carcinoma.""},{""step"":2,""info"":""The left breast specimen is a simple mastectomy with an infiltrating lobular carcinoma, nuclear grade I, and a low mitotic index. The estimated tumor dimension is 21 mm or 2.1 cm."",""rule"":""T1: This stage includes invasive breast carcinomas that are 2 cm or less in size.""},{""step"":3,""info"":""The tumor size is 2.1 cm, which falls under the T1 category. However, there are no further details about the tumor size to classify it into T1mi, T1a, T1b, or T1c."",""decision"":""T1""}]","chief of Pathology. Specimen: Reg# 2. Spec Type: SURGICAL P. BREAST CANCER INVASIVE. DOCTOR (ยง) : PROCEDURE: A. RT BREAST DEEP MARGIN. B. LT BREAST. c. RT PREAST AND AXILLARY NODES. RECRIVED. RTS. LABELED. RIGHT DEEP MARGIN INK MARKS NEW. .RREGULAR PORTION OF YELLOW FATTY AND BRONN MUSCULAR TISSUE. ME. LNG 4.8 x 2.2 x 0.6 CM IN GREATEST DIMENSIONS. ONE SIDE OF THE. SPECIMEN IS RECEIVED MARKED WITH BLUE INK. THIS SIDE IS FURTHER MARKED. NTTU PITE INV. TH A PERIMETER OF RED INK. THE SPECIMEN IS SECTIONED AND. 3D LABELED A1 THROUGH A3. PA. ABELED. LEFT BREAST IS A SIMPLE. MAS1. EN MEASURING 24.5 x 21 x 3.8 CM. A SUTURE DENOTES 12. O'CLO. THE NI PLE IS FLAT WITHIN A 23.7 x 15.3 CM SKIN ELLIPSE. IN. THE 9 O'CLOCK AREA OF THE BREAST THERE IS A 0.5 CM IN DIAMETER. FLONER-SHAPED RED-BROWN SKIN LESION. THE SUPERFICIAL ASPECT IS MARKED. NITH BLUE INK, THE DEEP WITH BLACK INK. SECTIONING REVEALS THE SPECIMEN. TO CONSIST OF BLAND YELLOW FATTY TISSUE WITH FINE FIBROUS BANDS. THERE. ARE NODULAR FIRM AREAS NOTED CENTRALLY THAT DO NOT FORM DISCRETE MASSES. SECTIONS ARE SUBMITTED AS FOLLOWS: 31--NIPPLE AND DESCRIBED SKIN LESION,. B2 - CENTRAL DEEP MARGIN, B3 AND B4 --UPPER OUTER QUADRANT, B5 AND. 86--UPPER INNER QUADRANT, B7 AND B8--LOWER INNER QUADRANT, B9 AND. B10--LOWER - OUTER QUADRANT, B11--TISSUE CENTRAL. NOTE THAT B1, B3, B5,. B7, B9, AND B11 ARE MIRROR IMAGE TISSUE TAKEN PER PROTOCOL. ADDITIONAL SECTIONS FROM THE LOWER INNER QUADRANT ARE SUBMITTED LABELED. B12 THROUGH B14, A SECTION FROM THE SUBAREOLAR AREA IN B15, AND. ADDITIONAL TISSUE FROM THE UPPER OUTER QUADRANT B16 AND 17. PART c RECEIVED LABELED. RIGHT BREAST AND AXILLARY LYMPH. NODE IS A RIGHT MODIFIED RADICAL MASTECTOMY SPECIMEN WITH FRAGMENTS OF. LOOSE TISSUE WHICH ALSO DEMONSTRATE PALPABLE LYMPH NODES. THE OVERALL. DIMENSIONS ARE 30 x 22 x 4.3 CM. THE NIPPLE IS FLATTENED. IMMEDIATELY. Chief of Pathology. Tax. Specimen: spec Type: SURGICAL P. LATERAL TO THE NIPPLE IS A PALPABLE MASS. THE SKIN ELLIPSE MEASURES 22.6. x 14. 0 CM. A SMALL RAISED PIGMENTED LESION IS FOUND IN THE LOWER OUTER. QUADRANT ADJACENT TO THE SKIN RESECTION MARGIN MEASURING 0.4 CM IN. DIAMETER. THE SUPERFICIAL ASPECT IS MARKED IN BLUE INK, THE DEEP. ASPECT WITH BLACK INK. WHERE THE AXILLARY TAIL IS REMOVED, IT IS MARKED. IN RED AND DOES NOT REPRESENT TRUE MARGIN. THE AXILLARY TAIL IS EXAMINED. FOR LYMPH NODES. IN THE LOW AXILLARY TAIL, THERE IS A 2.8 CM CENTRALLY. 7AT-REPLACED LYMPH NODE WITH A COIL CLIP. ONE HALF IS SUBMITTED PER. PROTOCOL. THE REMAINDER IS SUBMITTED AS C1. A SECOND LOW NODE IS. GROSSLY POSITIVE 1.6 CM IN GREATEST DIMENSION. ONE HALF IS SUBMITTED AS. C2 WITH THE REMAINDER SUBMITTED PER PROTOCOL. ADDITIONAL NODES ARE THEN. SUBMITTED AS FOLLOWS: C3--ONE HALF GROSSLY UNREMARKABLE LYMPH NODE. (MIRROR IMAGE TO PROTOCOL), C4--TWO NODES EACH BISECTED, C5--ONE NODE. BISECTED, C6--ONE NODE BISECTED, C7--ONE NODE BISECTED, C8--TWO NODES. EACH BISECTED, C9--FOUR NODES, C10--TWO NODES EACH BISECTED, C11 AND. C12--ONE NODE TOTAL. SECTIONING REVEALED THE BREAST TO CONSIST OF BLAND. YELLOW FATTY TISSUE WITH FINE FIBROUS BANDS. THE PALPABLE MASS IS. ILL-DEFINED WITH PINK-TAN TISSUE INTERSPERSED IN THE YELLOW-FATTY TISSUE. THIS EXTENDS FROM THE SUBAREOLAR AREA IN THE LONER OUTER QUADRANT. MEASURING 6 CM FROM MEDIAL TO LATERAL BY PALPATION 6.5 CM FROM SUPERIOR. TO INFERIOR AND 4 CM FROM SUPERFICIAL TO DEEP IN AN ILL-DEFINED MANNER. GROSSLY THIS EXTENDS TO WITHIN 0.5 CM OF THE DEEP MARGIN. SECTIONS ARE. SUBMITTED AS FOLLOWS: C13--NIPPLE (MIRROR IMAGE TO PROTOCOL), C14 AND. C15--LESION AND CLOSEST GROSS DEEP MARGIN, C16--THE MOST LATERAL ASPECT. OF THE LESION (MIRROR IMAGE TO PROTOCOL), C17--THE MOST CENTRAL AND. MEDIAL PORTION OF THE LESION (MIRROR IMAGE TO PROTOCOL) NOTE THAT C16. AND C17 ARE 6 CM APART, C18--TUMOR (MIRROR IMAGE TO PROTOCOL), C19--THE. MOST INFERIOR ASPECT OF THE LESION WITH INFERIOR SUPERFICIAL MARGIN,. C20--THE SUPERIOR PORTION OF THE LESION OR ADJACENT TO MARGIN CENTRAL. SPECIMEN, C21--UPPER OUTER QUADRANT, C22--LOWER INNER QUADRANT,. C23--UPPER INNER QUADRANT, C24 AND C25--ADDITIONAL SECTIONS OF CENTRAL. TUMOR (MIRROR IMAGE TO PROTOCOL) . PROCEDURES: 88307/2, 88309, A BLK/3, B BLK/17, C BLK/25, ER PR KI67 HER2. PART A RIGHT BREAST DEEP MARGIN REEXCISION: FIBROADIPOSE TISSUE AND. SKELETAL MOSCLE WITH NO EVIDENCE OF MALIGNANCY. THE NEW INKED MARGIN IS. FREE OF NEOPLASM. PART B LEFT BREAST, SIMPLE MASTECTOMY: 1. INFILTRATING LOBULAR CARCINOMA, NUCLEAR GRADE I WITH LOW MITOTIC. INDEX, IDENTIFIED IN THE LOWER INNER QUADRANT WITH AN ESTIMATED TUMOR. DIMENSION OF 21 MM (SLIDES B7, B8, B12-14). Chief of yathology. Speciment. status: Spec Type: SURGICAL P. 2. THE NIPPLE AND DEEP MARGIN ARE FREE OF NEOPLASM. 3. LYMPHATIC INVASION IS NOT IDENTIFIED. 4. PROLIFERATIVE FIBROCYSTIC DISEASE WITH A FOCUS OF LOBULAR CARCINOMA. IN SITU IDENTIFIED IN THE UPPER OUTER QUADRANT ALONG WITH SCLEROSING. ADENOSIS, DUCT HYPERPLASIA OF THE OSUAL TYPE, APOCRINE METAPLASIA AND. CYST FORMATION. PART C RIGHT BREAST, MODIFIED RADICAL MASTECTOMY: 1. LARGE MODERATELY DIFFERENTIATED INTRADUCTAL AND INFIL/TRATING DUCT. CARCINOMA, NUCLEAR GRADE II WITH LOW MITOTIC INDEX NITH FOCI OF. MUCINOUS DIFFERENTIATION SPANNING A DISTANCE OF 65 MM. 2. THE DEEP MARGIN IS FREE OF NEOPLASM. DUCTAL CARCINOMA IN SITU. INVOLVES THE NIPPLE. 3. LYMPHATIC INVASION IS PRESENT. 4. METASTATIC CARCINOMA TO 1 OF 15 AXILLARY LYMPH MODES. ONE LYMPH NODE. DEMONSTRATES PREVIOUS BIOPSY SITE CHANGE BUT NO RESIDUAL NEOPLASM. 5. HEMANGIOMA, SKIN OF BREAST. RECEPTOR AND PROGNOSTIC FACTOR DETERMINATION WILL BE PERFORMED ON BLOCK. B7. -. ESTROGEN RECEPTOR: POSITIVE. Nuclei Stained: 100%. Intensity: 3. Reference Range Negative <1%. Positive >= 1t. PROGESTERONE RECEPTOR: NEGATIVE. Nuclei stained: o. Intensity: 1. Reference Range: Negative <1%. Positive >= 1%. Her-2/neu: NEGATIVE. Score: 1+. Reference Range: Negative 0 - 1+. Equivocal 2+. Chief of Fatholegy. specimen: Spec Type: SURGICAL P. Positive 3+. Ki-67: LOW. Nuclei Stained: 3. Intensity: Reference Range: Low <10%. Borderline 10-20%. High >20%. See full scanned report for details. 1. 1. SENT TO: 2. REQUESTED BYs. 3. DATE SEST: 4. KETHOD or. 5. NO. or BLOCKS: 7. KATERIAL (#) TO BE RETURNED: 14. SPECINEE SENT (x/m) $ 1. (prelim.). (signature on file). 0."
TCGA-A2-A25C.1D4CA1BA-B534-4CEA-ABA5-EF9B31694204,1,T1,"Based on the pathology report, the patient has invasive breast carcinomas in the left breast. The size of the tumors is specified as follows: a 1.5 cm tumor at the 3 o'clock location and a 2.2 cm lesion in the 6 o'clock portion. These tumors are separated by at least 1.5 cm of benign breast tissue. Therefore, the total tumor size is 3.7 cm. According to the rules provided, this falls under T1, as it is less than 2 cm in size. The report does not mention any direct extension to the chest wall or skin, or any ulceration, satellite nodules, or inflammatory carcinoma. Therefore, the T stage for this patient is T1.","Specimen: spec Type: SURGICAL P. LEFT BREAST CANCER INVASIVE. DOCTOR (S) : PROCEDURE: SENTNEL, NODE BX/STMPLE MASTRCTOMY. A. LT BREAST SIMPLE MASTECTOMY. B. LT SENTINEL NODE #1. C. LT SENTINEL NODE #2. RECEIVED IN 3 PARTS. PART A RECEIVED LABELED. SIMPLE LEFT BREAST. MASTECTOMY STITCH AT 12 O' CLOCK, IS A SIMPLE MASTECTOMY SPECIMEN. MEASURING 17.5 x 16 x 2.8 CM. THE NIPPLE IS UNREMARKABLE WITHIN A 9 x. 2.5-CM SKIN ELLIPSE. ADDITIONALLY WITHIN THE CONTAINER ARE 2 IRREGULAR. FRAGMENTS OF FATTY TISSUE WITH NO PALPABLE MASSES TOGETHER MEASURING 4.5. x 3 x 0.5 CM. THE SUPERFICIAL ASPECT IS MARKED WITH BLUE INK, THE DEEP. WITH BLACK. SECTIONING REVEALS 2 DISCRETE GRAY FIBROUS NODULES; THE MOST. LATERAL IS AT 3 O'CLOCK MEASURING 1.5 x 1.1 x 1.5 CM. ADJACENT TO THIS. SEPARATED BY 1.5 CM IN THE 6:30 AREA IS A MASS WITH A COIL CLIP MEASURING. 2.2 x 1.8 x 2.1 CM. THESE ARE BOTH 0.5 CM FROM THE DEEP MARGIN. CENTRALLY, THE BREAST HAS DENSE TAN FIBROUS TISSUE, BUT THE PERIMETER OF. THE SPECIMEN AND THE TISSUE ADJACENT TO THE DEEP MARGIN IS YELLOW FATTY. TISSUE. THE 3 O'CLOCK LESION IS 0.7 CM FROM THE SUPERFICIAL MARGIN. THE. 6 O'CLOCK LESION EXTENDS TO WITHIN 0.6 CM OF THE SUPERFICIAL MARGIN. SECTIONS ARE SUBMITTED AS FOLLOWS: 11--NIPPLE; 12--TISSUE BETWEEN THE. TWO LESIONS; A3--3 O' CLOCK LESION TO INCLUDE DEEP MARGIN; A4--3 O'CLOCK. LESION TO INCLUDE SUPERFICIAL MARGIN; A5 AND 6--FULL CROSS-SECTION OF 6. O' CLOCK LESION TO INCLUDE THE DEEP AND SUPERFICIAL MARGIN, RESPECTIVELY;. A7--6 O'CLOCK LESION; A8--UPPER OUTER QUADRANT; A9--UPPER INNER QUADRANT;. A10 - -LOWER INNER QUADRANT; A11--LOWER OUTER QUADRANT. TISSUE FROM EACH. LESION IS SUBMITTED PER PROTOCOL. PART B RECEIVED LABELED. LEFT SENTINEL NODE #1 HOT. AND BLUE, IS AN OVOID FRAGMENT OF YELLOW-RED SOFT TISSUE MEASURING 1.7 x. 1.0 x 0.9 CM. SECTIONING REVEALS A GROSSLY UNREMARKABLE 1.3-CM LYMPH. NODE WITH CENTRAL FAT REPLACEMENT AND BLUE COLORATION. THIS IS SUBMITTED. LABELED B, BISECTED. PART C RECEIVED LABELED. LEFT SENTINEL NODE #2 HOT. 1. Specimen: Spec Type: SURGICAL P. CPA : AND BLUE, IS A 1.5 x 0.6 x 0.4-CM OVOID PORTION OF RED-TAN TISSUE. SECTIONING REVEALS THIS TO BE A GROSSLY UNREMARKABLE LYMPH NODE WITH BLUK. COLORATION SUBMITTED LABELED C, BISECTED. PROCEDURES: 88307/3, IMMUNOPEROXIDAS/2, A BLK/11, BBX X6, CBX X6. PART A LEFT BREAST, SIMPLE MASTECTOMY : 1. MODERATELY DIFFERENTIATED INFILTRATING DUCT CARCINOMA, NUCLEAR GRADE. II/III, MODERATE MITOTIC INDEX AND TUBULE FORMATION 2, WITH A TOTAL. NOTTINGHAM SCORE OF 6. RARE FOCI OF DCIS OF THE CRIBRIFORM AND SOLID. TYPES, NUCLEAR GRADE II WITH LOW MITOTIC INDEX, ARE SEEN AT THE. PERIPHERY OF THE TUMOR. 2. A 1.5-CM TUMOR IS IDENTIFIED IN THE 3 O' CLOCK LOCATION AND A 2.2-CM. LESION IS IDENTIFIED IN THE 6 D'CLOCK PORTION WHICH ARE SEPARATED BY. AT LEAST 1.5 CM OF BENIGN BREAST TISSUE. 3. THE MARGINS OF EXCISION, NIPPLE SKIN AND RANDOM SECTIONS OF REMAINING 2.2cm I Scm. QUADRANTS ARE FREE OF TUMOR. 4. LYMPHOVASCULAR INVASION IS IDENTIFIED. 5. BIOPSY CHANGES. ARE PRESENT. PART B LEFT AXILLA, SENTINEL LYMPH NODE BIOPSY #1: METASTATIC BREAST. CARCINOMA IS MULTIFOCALLY IDENTIFIED ON H&E STEP SECTIONS AND CYTOKEBATIN. STAINS IN 1 LYMPH NODE EXAMINED, THE LARGEST FOCUS OF WHICH MEASURES 3 MM. IN GREATEST MICROSCOPIC DIMENSION. NO EVIDENCE OF EXTRANODAL EXTENS FON. PART C LEFT AXILLA, SENTINEL LYMPH NODE BIOPSY #2: MULTIFOCAL. METASTATIC BREAST CARCINOMA IS IDENTIFIED ON H&E STEP SECTIONS AND. CYTOKERATIN STAINS IN 1 LYMPH NODE EXAMINED, THE LARGEST FOCUS OF WHICH. MEASURES 2 MM IN GREATEST MICROSCOPIC DIMENSION. EXTRANODAL EXTENSION IS. NOT PRESENT. Specimen: Spec Type: SURGICAL P. Her-2/neu: NEGATIVE. Score: 1+. Reference Range : Negative o - 1+. Equivocal 2+. Positive 3+. M.D. See full scanned report for details. 1. SENT TO: 2. REQUESTED BY: DR. 3. DATE SENTs. 4. KETHOD or COURIER. 5. NO. OF BLOCKS: 1 BLOCR A3. 7. MATERIAL(S) TO BE RETURNED. 14. SPECIMEN SENT (Y/X) $. x. M.D. (prelim.). M.D."
TCGA-A2-A25E.B81555D4-78D9-4235-AABE-F852CA6F15B5,1,T4,"[{""step"":1,""description"":""Examining the pathology report, we can see that there are two separate tumors present in the breast. The first tumor is located in the lower outer quadrant and has an estimated size of at least 3.0 cm based on previous needle localization biopsies. The second tumor is located in the upper outer quadrant and has a gross size of 2.0 cm. We will consider the size of both tumors when determining the T stage."",""rule"":null},{""step"":2,""description"":""According to rule 1 (T1), the first tumor is larger than 2 cm, so it cannot be classified as T1. The second tumor meets the criteria for T1c (1-2 cm) but we need to consider the size of both tumors together."",""rule"":""T1""},{""step"":3,""description"":""The report states that there is no direct extension to the chest wall or skin, so we can exclude T3. The report also states that there is no inflammatory carcinoma, so we can exclude T4d."",""rule"":""T3, T4d""},{""step"":4,""description"":""The report states that there is no ulceration or satellite nodules, so we can exclude T4b and T4c. However, the report states that there are metastases to 6/10 axillary lymph nodes with extracapsular extension. This indicates that the tumor has spread to the axillary lymph nodes, which is classified as T4."",""rule"":""T4b, T4c""},{""step"":5,""description"":""Considering all the information, the T stage for this patient is T4. This is because the report states that there are metastases to 6/10 axillary lymph nodes with extracapsular extension, which is classified as T4."",""rule"":null}]","Specimen #: (Age: F Race: Physician (s) : AMENDED. SPECIMEN: LEFT BREAST MASTECTOMY AND AXILLARY CONTENTS. FINAL DIAGNOSIS: A. BREAST, LEFT RADICAL MASTECTOMY: - RESIDUAL INVASIVE DUCTAL CARCINOMA, MODERATELY DIFFERENTIATED BY. COMBINED HISTOLOGIC CRITERIA, PRESENT IN THE AREA OF BIOPSY CAVITY. AND LOWER OUTER QUADRANT. ESTIMATED TUMOR SIZE BASED ON PREVIOUS NEEDLE LOCALIZATION. BIOPSIES AT LEAST 3.0 CM. - SEPERATE TUMOR MASS IN THE UPPER OUTER QUADRANT: INFILTRATING DUCTAL CARCINOMA, POORLY DIFFERENTIATED. TUMOR SIZE: 2.0 CM (GROSS). MARGIN: TUMOR WITHIN 1MM OF SUPERIOR SUPERFICIAL MARGIN. DUCTAL CARCINOMA IN SITU, INTERMEDIATE-GRADE, PREDOMINANTLY SOLID. AND CRIBRIFORM TYPES. DEEP MARGIN: TUMOR (DCIS) EXTENDS WITHIN 1.0 MM OF DEEP SURGICAL. MARGIN IN ONE SECTION (SLIDE A12) . - METASTASIS TO 6/10 AXILLARY LYMPH NODES WITH EXTRA CAPSULAR. EXTENSION. - SKIN AND NIPPLE NEGATIVE FOR CARCINOMA. - FIBROCYSTIC CHANGES. BIOPSY SITE CHANGES. - AJCC STAGE: T2N2MX. COMMENT:The amendment is made to report that there is a seperate tumor. mass in the upper outer quadrant and also the deep margin status. The amendment is made in the absence of the primary pathologist. Specimen #: FINAL DIAGNOSIS (continued) : CLINICAL DIAGNOSIS AND HISTORY: Left breast carcinoma. GROSS DESCRIPTION: Received fresh is a 167 gm modified radical mastectomy specimen with the. following measurements: breast 12.6 x 11.6 x 1.6 cm, overlying ellipse of. nipple-bearing skin 7.2 x 5.5 cm, attached axillary contents 12.5 x 3.5 x. 0.9 cm. Ink code: blue = superior superficial, green = inferior. superficial, black = posterior. The skin is notable for a 2.0 cm well. healed scar near the lateral edge of the ellipse. Examination of the. axilla reveals multiple firm lymph nodes. A seperate mass is present in. the upper outer quadrant measuring 2.0 x 1.4 x 1.4 cm. The breast is then serially sectioned revealing extensive white fibrous. tissue with a 1.2 cm multiloculated biopsy cavity with associated. hemorrhage and fat necrosis in the lower outer quadrant . Sections of the tumor mass and skin and breast samples for. protocol with matching paraffin sections are follows: cassette A1 grossly. normal skin (medial tip). cassettes A2 and A3 2.0 cm tumor mass from upper. outer quadrant, cassette A4 1.7 cm lymph node, high axilla (grossly. positive), cassette A5 1.8 cm grossly normal lymph node, high axilla,. cassette A6 biopsy cavity site, lower outer quadrant, cassette A7 grossly. normal fibrous tissue, lower outer quadrant (approximately 2.0 cm from. biopsy cavity) cassette A8 grossly normal fibrous tissue, upper outer. quadrant, cassette A9 grossly normal fibrous tissue upper inner quadrant,. cassette A10 grossly normal fibrous tissue lower inner quadrant, cassette. A11 representative sections of nipple and scar from skin, cassette A12. biopsy cavity deep margin lateral, cassette A13 biopsy cavity superior. medial, A14 biopsy cavity inferior medial, A15 four additional lymph nodes. from axillary tail, A16 two additional lymph nodes from axillary tail,. cassette A17 one lymph node bisected from axillary tail."
TCGA-A2-A4RY.2D6815B5-7704-4D67-93D1-78EDD924F131,2,T2,"To determine the pathologic T stage of the patient's breast cancer, we will follow the rules provided and focus on the size and extent of the tumor in the right modified radical mastectomy specimen (Part D). The left mastectomy (Part C) showed no evidence of malignancy, and the lymph nodes are discussed in the context of N stage, not T stage.""T1"": This stage includes invasive breast carcinomas that are 2 cm or less in size. There is no mention of any tumor size in Part D being 2 cm or less, so the T1 stage is not applicable.""T2"": This stage includes invasive breast carcinomas that are more than 2 cm but not more than 5 cm in size. The report states that there is a 'gray-tan mass at 9 o'clock which measures 5.5 cm from medial to lateral, 8 cm from superior to inferior by palpation, and 4.5 cm from anterior to posterior.' This mass is larger than 2 cm but not more than 5 cm, so the T stage is T2."",""T3"": This stage includes invasive breast carcinomas that are more than 5 cm in size or tumors of any size with direct extension to the chest wall or skin. The report does not mention any tumor size larger than 5 cm, and there is no explicit mention of direct extension to the chest wall or skin. Therefore, the T3 stage is not applicable."",""T4"": This stage includes invasive breast carcinomas that have spread to the chest wall and/or the skin, resulting in ulceration (T4b) or satellite nodules (T4c), or inflammatory carcinoma (T4d). The report does not mention any ulceration, satellite nodules, or inflammatory carcinoma. However, it does mention that the 'axillary portion measures 10 x 9 x 2.5 cm' and that there is a 'prominent structure... a 3.8 cm in greatest dimension grossly positive lymph node.' These findings suggest that the tumor has extended to the axillary tissue, which is part of the chest wall. However, the report does not explicitly state that the tumor has invaded the chest wall, so the T4 stage is not definitively applicable."",""conclusion"": ""Based on the information provided in the pathology report and the rules for determining the T stage, the patient's breast cancer is most likely T2. The tumor is larger than 2 cm but not more than 5 cm in size. However, there is some ambiguity regarding the T4 stage, as the report suggests that the tumor has extended to the chest wall, but it does not explicitly state that the tumor has invaded the chest wall. A definitive T4 diagnosis would require explicit evidence of chest wall invasion.""}","Specimen. ) Status: Sp type: SURGICAL P. M.D. PREOPERATIVE DIAGNOSIS. BREAST CANCER, BENIGN MAMMARY DYSPLASIA. OPERATION PERFORMED. DOCTOR (S) : PROCEDURE: MASTECTOMY MODIFIED RADICAL/TOTAL MASTECTOMY. TISSUE REMOVED. A. RIGHT AXILLARY LYMPH NODE LEVEL 2. B. RIGHT AXILLARY LYMPH NODE LEVEL 3. C. LEFT MASTECTOMY STITCH AT. D. RIGHT MODIFIED RADICAL MASTECTOMY STITCH AT. GROSS DESCRIPTION. RECEIVED IN 4 PARTS. PART A RECEIVED LABELED. RIGHT AXILLARY LEVEL 2 LYMPH. NODES IS A NODULAR PORTION OF YELLOW FATTY TISSUE MEASURING 3.7 X 2.2 X. 0.7 CM IN GREATEST DIMENSION. FOUR FIRM OVOID STRUCTURES ARE IDENTIFIED. MEASURING FROM 0.4 TO 1 CM IN GREATEST DIMENSION. THE LARGER NODES ARE. EACH SECTIONED AND GROSSLY POSITIVE. ONE-HALF OF EACH OF THESE IS. SUBMITTED ALONG WITH THE UNSECTIONED SMALLER NODE LABELED A. THE. REMAINING NODAL TISSUE IS SUBMITTED PER CLINICAL BREAST CARE PROJECT. RESEARCH PROTOCOL LABELED P1-P3. PART B RECEIVED LABELED. RIGHT AXILLARY LEVEL 3 LYMPH. NODE IS A FIRM 0.8 CM IN GREATEST DIMENSION NODULE AND AN IRREGULAR. PORTION OF NODULAR YELLOW FATTY TISSUE MEASURING 6 X 1.5 X 0.7 CM. FIVE. FIRM OVOID STRUCTURES ARE IDENTIFIED IN THIS PORTION OF FATTY TISSUE. THREE OF THE NODULES ARE SUBMITTED UNSECTIONED LABELED B1. ONE-HALF. FROM 2 SEPARATE GROSSLY POSITIVE NODES ARE SUBMITTED IN B2 WITH THE. REMAINING TISSUE FROM THESE 2 NODES SUBMITTED AS P4. THE LARGEST NODE. MEASURING 1.4 CM IN GREATEST DIMENSION IS GROSSLY FOCALLY POSITIVE. THIS. IS SUBMITTED BISECTED AS B3. PART C RECEIVED LABELED. LEFT MASTECTOMY STITCH AT 12. O'CLOCK IS A 1310 GRAM SIMPLE MASTECTOMY MEASURING 23 CM FROM MEDIAL TO. LATERAL, 23.5 CM FROM SUPERIOR TO INFERIOR, AND UP TO 5.5 CM FROM. Specimen. Sp type: GICAL P. M.D. GROSS DESCRIPTION. ANTERIOR TO DEEP. THE NIPPLE IS UNREMARKABLE WITHIN A 14 x 5 CM SKIN. ELLIPSE. A SUTURE DENOTES 12 O'CLOCK. THE ANTERIOR ASPECT IS MARKED. WITH BLUE INK, THE DEEP MARGIN WITH BLACK. SECTIONING REVEALS THE. CENTRAL 50% OF THE SPECIMEN TO CONSIST OF DENSE TAN FIBROUS TISSUE. THIS. IS SURROUNDED BY A PERIMETER OF YELLOW FATTY TISSUE. NO MASSES ARE. IDENTIFIED. REPRESENTATIVE SECTIONS ARE SUBMITTED AS. FOLLOWS: C1--NIPPLE, C2--CENTRAL DEEP MARGIN, C3 AND 4--UPPER OUTER QUADRANT, C5. AND 6--UPPER INNER QUADRANT, C7 AND 8--LOWER INNER QUADRANT, C9 AND. 10--LOWER OUTER QUADRANT. ADDITIONALLY WITHIN THE CONTAINER AND. INCLUDED THE WEIGHT ARE ADDITIONAL MULTIPLE IRREGULAR FRAGMENTS OF. YELLOW-RED FATTY TISSUE IN AGGREGATE MEASURING 10 X 10 x 2.3 CM. SECTIONING REVEALS BLAND YELLOW FATTY TISSUE AND REPRESENTATIVE SECTIONS. ARE SUBMITTED LABELED C11 THROUGH 13. NOTE: MIRROR IMAGE SECTIONS OF THE NIPPLE ARE SUBMITTED AS P15 AND. MIRROR IMAGE SECTIONS TO C3, C5, C7, AND C9 ARE SUBMITTED FROZEN IN OCT. PER CLINICAL BREAST CARE PROJECT RESEARCH PROTOCOL. PART D RECEIVED LABELED. RIGHT MODIFIED RADICAL. MASTECTOMY STITCH AT 12 O'CLOCK IS A 1460 GRAM RIGHT MODIFIED RADICAL. MASTECTOMY. THE MASTECTOMY PORTION MEASURES 24.5 CM FROM MEDIAL TO. LATERAL, 26 CM FROM SUPERIOR TO INFERIOR, AND UP TO 6.5 CM FROM ANTERIOR. TO POSTERIOR. THE AXILLARY PORTION MEASURES 10 x 9 x 2.5 CM. THE. ANTERIOR MARGIN IS MARKED BLUE. THE DEEP IS MARKED BLACK. THE NIPPLE. IS UNREMARKABLE AND SITS IN THE MORE SUPERIOR PORTION OF THE SKIN. ELLIPSE. THE SKIN ELLIPSE MEASURES 14 x 5.5 CM. THE 12 O'CLOCK SUTURE. IS JUST TO THE MEDIAL SIDE OF THE AREOLA. THE AXILLARY TAIL IS REMOVED. AND RED INK IS PLACED IN THIS AREA TO INDICATE THAT IT IS NOT TRUE. MARGIN. UPON A QUICK PALPATION OF THE AXILLARY TAIL THREE ARE 3. PROMINENT STRUCTURES. THE 1ST IS A 0.8 CM IN GREATEST DIMENSION LYMPH. NODE WHICH IS GROSSLY NEGATIVE AND IS SUBMITTED BISECTED AS D1. THE 2ND. IS A 2.5 CM GROSSLY NEGATIVE NODAL STRUCTURE SUBMITTED BISECTED AS D2. THE 3RD STRUCTURE IS A 3.8 CM IN GREATEST DIMENSION GROSSLY POSITIVE. LYMPH NODE OF WHICH ONE FULL CROSS SECTION IS SUBMITTED IN D3 AND 4. A. COIL CLIP IS IDENTIFIED AND THE AREA OF THE CLIP IS SUBMITTED IN D5. THIS IS THE SAME NODE AS D3 AND 4. PORTIONS OF THIS LARGEST NODE ARE. ALSO SUBMITTED IN P5 AND 6. SECTIONING REVEALS THE CENTRAL PORTION OF. THE BREAST TO CONSIST OF DENSE TAN FIBROUS TISSUE AND THIS EXTENDS TO AN. ILL-DEFINED GRAY-TAN MASS AT 9 O'CLOCK WHICH MEASURES 5.5 CM FROM MEDIAL. TO LATERAL, 8 CM FROM SUPERIOR TO INFERIOR BY PALPATION, AND 4.5 CM FROM. ANTERIOR TO POSTERIOR. GROSSLY IT IS 1 CM FROM BOTH THE ANTERIOR AND. DEEP MARGIN. SECTIONS ARE SUBMITTED AS FOLLOWS: D6--NIPPLE, D7 THROUGH. D9--SECTIONS OF DEEP MARGIN BENEATH LESION, D10 THROUGH D14--A CONTINUOUS. SECTION OF THE LESION FROM SUPERIOR TO INFERIOR WHERE THE RED ENDS ARE. Specimen. eq#: SP type: SURGICAL P. .D. GROSS DESCRIPTION. THE AREA WHERE THE ONE STRIP WAS SEPARATED FROM THE ADJACENT SECTION,. 015--SECTION OF THE FAR LATERAL PORTION OF THE GROSS LESION, D16--SECTION. FROM THE FAR MEDIAL PORTION OF THE GROSS LESION, D17--TISSUE DEEP TO THE. 5 CROSS SECTIONS, 018--TISSUE ANTERIOR TO TE 5 CROSS SECTIONS,. D19--RANDOM SECTION OF LESION FROM THE MIDPORTION, D20--RANDOM TUMOR. INFERIOR-EDG D21--UPPER INNER QUADRANT 2. CM.EROM GROSS TUMOR,. D22--UPPER OUTER QUADRANT 3 CM FROM GROSS TUMOR, D23--LOWER OUTER. QUADRANT 3 CM FROM GROSS TUMOR, D24--LOWER INNER QUADRANT 5 CM FROM GROSS. TUMOR. FURTHER EXAMINATION OF THE AXILLARY TAIL: EIGHTEEN (18) ADDITIONAL. NODAL STRUCTURES ARE IDENTIFIED. THESE ARE SUBMITTED AS FOLLOWS: D25-6. NODES NOT SECTIONED, D26--ONE-HALF OF 2 GROSSLY POSITIVE LYMPH NODES. PLUS 1 GROSSLY FAT REPLACED LYMPH NODE, BISECTED, D27--4 NODES, EACH. BISECTED, D28--2 NODES, EACH BISECTED, D29--3 NODES, EACH BISECTED. SECTIONS PER CLINICAL BREAST CARE RESEARCH PROTOCOL ARE SUBMITTED FROM. THE LYMPH NODE WITH THE CLIP LABELED P5 AND P6; TWO OF THE GROSSLY. POSITIVE LYMPH NODES IN CASSETTE D26 AS P16; AND SECTIONS OF THE TUMOR. AS P7 THROUGH P14 WITH MIRROR IMAGE SECTIONS FROZEN IN OCT OF P7, P8,. p9, AND 013 AS WELL AS TISSUE FROZEN IN OCT AS MIRROR IMAGE TO THE. NIPPLE (D6) AND OF THE RANDOM QUADRANT SECTIONS (D21 THROUGH D24). COMMENT: THIS SPECIMEN EXCEEDS THE MAXIMUM CAP/ASCO. GUIDELINE OF 48 HOURS FORMALIN FIXATION. PATH PROCEDURES. PROCEDURES: 88305/2, 88307, 88309, A BLK, B BLK/3, C BLK/13, D BLK/29. FINAL DIAGNOSIS. PART A RIGHT AXILLARY LEVEL 2 LYMPH NODE SAMPLING: METASTATIC. CARCINOMA CONSISTENT WITH LOBULAR CARCINOMA OF PRIMARY BREAST ORIGIN. INVOLVING 4 OF 4 LYMPH NODES WITH THE TUMOR REPLACING 80-90% OF THE. CELLS IN EACH NODE AND THE LARGEST FOCUS OF TUMOR SPANNING A DISTANCE OF. APPROXIMATELY 9 MM. PART B RIGHT AXILLARY LEVEL 3 LYMPH NODE SAMPLING: METASTATIC 6/16 LN (level 3). Specimen: eceived: ) Status: aq#. Sp type: SURGICAL P. M.D. FINAL D1AGNOSIS. CARCINOMA IDENTIFIED IN 6 OF 6 LYMPH NODES. PART C LEFT MASTECTOMY: SKIN AND FATTY BREAST TISSUE WITH FOCAL. FIBROCYSTIC CHANGES PRESENT. NO EVIDENCE OF MALIGNANCY OR ATYPIA. PART-D RIGHT MODIFIED RADICAL MASTECTOMY: MULTICENTRIC IN SITU AND. INFILTRATING LOBULAR CARCINOMA OF THE PLEOMORPHIC TYPE, NUCLEAR GRADE. 2-3 OF 3 WITH A LOW MITOTIC INDEX WITH DOCUMENTED MICROSCOPIC EVIDENCE. OF TUMOR SPANNING A DISTANCE OF AT LEAST 78 MM IN A SUPERIOR TO INFERIOR. DIRECTION. THE TUMOR WAS 8 MM FROM THE CLOSEST DEEP MARGIN. METASTATIC. CARCINOMA IDENTIFIED IN 8 OF 20 AXILLARY LYMPH NODES WITH THE LARGEST. FOCUS OF TUMOR SPANNING A DISTANCE OF 20 MM AND FOCAL MICROSCOPIC. PERINODAL SOFT TISSUE INVASION PRESENT. M.D."
TCGA-A7-A4SE.C0C49D41-AA66-435B-9312-FAD8E2DC3305,1,T1c,"Based on the pathology report, the patient's breast cancer has a greatest dimension of 2.8 cm, which falls under the T1 category. However, since the size is greater than 2 cm, it does not meet the criteria for T1mi, T1a, or T1b. Therefore, the T stage for this patient's breast cancer is T1c, which includes invasive breast carcinomas that are 1 cm but less than 2 cm in size.","Final Surgical Pathology Report. Procedure: Diagnosis. A. Breast, left, segmental mastectomy: Invasive ductal carcinoma,. grade 3, size 2.8 cm in greatest dimension; negative margins of. excision. B. Sentinel lymph node #1, biopsy: Two negative lymph nodes (0/2) . C. Sentinel lymph node #2, biopsy: One negative lymph node (0/1) . D. Breast, medial to left segmental mastectomy, biopsy: Negative for. malignancy or atypia. E. Breast, inferior to left segmental mastectomy, biopsy: Negative. for malignancy or atypia. F. Breast, posterior to left segmental mastectomy, biopsy: Skeletal. muscle; negative for malignancy or atypia. G. Breast, lateral to left segmental mastectomy, biopsy: Negative. for malignancy or atypia. H. Breast, superior to left segmental mastectomy, biopsy: Negative. for malignancy or atypia. Microscopic Description: Invasive Carcinoma. Histologic type: Ductal. Histologic grade: 3. Overall grade: 9/9. Architectural score: 3. Nuclear score: 3. Mitotic score: 3. Greatest dimension (pT) : 2.8 cm. Specimen margins: Negative. Vessel invasion: Not identified. Calcification: Present. Ductal carcinoma in situ: Histologic pattern: Solid. Nuclear grade: 3. Central Necrosis: Present. 8 DCIS of total tumor (if mixed) : 1%. Extensive intraductal component (present/absent) : Absent. Specimen margins: Negative. Calcification: Negative. Description of non-tumorous breast: Fibrocystic changes, with ductal. hyperplasia of usual type, a minute fibroadenoma, and apocrine. metaplasia, with calcification. Comments: Sentinel lymph nodes negative, confirmed by negative. cytokeratin immunostaining of blocks BFS1 and CFS2. Cytokeratin. staining was also performed on one block from part E, to exclude. involvement by carcinoma. Prior biopsy site identified. Extensive. central tumor necrosis is present. Prognostic markers: See core biopsy report,. 4x8, 14x2, 15x2, 20x3. [A few of the antibodies used in our laboratory may be classified as. analyte specific reagents. These antibodies are monitored and. controlled in our laboratory and their performance for in vitro. diagnosis is well described in the medical literature. They have not. been cleared or approved by the FDA.: Specimen. A. Left Breast. B. Left axillary sentinel lymph node #1, hot, blue,. C. Left axillary sentinel lymph node #2, not hot, not blue, but. palpable. D. Medial to segmental mastectomy left breast. E. Inferior to segmental mastectomy left breast. F. Posterior to segmental mastectomy left breast. G. Lateral to segmental mastectomy left breast. H. Superior to segmental mastectomy left breast. Clinical Information. Left breast cancer. Intraoperative Consultation. B) Left axillary sentinel node #1: Two negative lymph nodes (0/2). C) Left axillary sentinel node #2, biopsy: One negative lymph node. (0/1). Gross Description. A. Received unfixed for tissue procurement, labeled left breast. segmental mastectomy single long lateral, double long anterior, is. a 100 gram breast segmental excision that is 9 cm from anterior to. posterior, 7.5 cm medial to lateral, and 3 cm from superior to. inferior. The superior surface is inked black, and a section is. submitted for tissue procurement as requested. An additional. section of uninvolved fatty tissue is submitted from the posterior. aspect, for procurement. Additional sections after fixation. The. superior surface is inked black, medial green, lateral yellow,. inferior blue. There is a tan, firm, lobulated mass lesion in the. mid-portion of the specimen, 3.0 x 2.0 x 1.7 cm. This is 3 mm from. the green-inked medial margin (closest margin). All other margins. are grossly greater than 1 cm from the mass. Representative. sections: 1 Anterior margin, 2 adjacent section with margin, 3/4/5. contiguous tumor, possible biopsy cavity in 5, 6/7/8 contiguous,. 9-10 random medial and lateral, possible close margin, 11-14. additional posterior sections, with last section = posterior. margin. B. Received unfixed for frozen section, labeled left axillary. sentinel node #1, are 2 adjacent and attached lymph nodes, 0.9 cm. in greatest dimension each, bisected and entirely submitted in. blocks B1 and B2. C. Received unfixed for frozen section, labeled left axillary. sentinel node #2, is a single lymph node, 1.4 x 1.3 x 1.0 cm,. bisected and entirely submitted in 2 blocks. D. Received fresh and subsequently fixed in formalin labeled ""medial. to segmental mastectomy left breast ""is a 5.2 x 3.5 x 1.5 cm yellow. lobular fatty tissue fragment which has a suture designating the. new medial border. The surface is inked and the specimen is. sectioned to show yellow lobular fatty cut surface with minimal. fibrous tissue present. No discrete residual tumor is grossly. identified. The specimen is entirely submitted labeled 1 through. 10. E. Received fresh and subsequently fixed in formalin labeled. ""inferior to segmental mastectomy left breast ""is a 4.3 x 2.7 x. 2.2. cm yellow lobular fatty tissue fragment which has a suture. designating new inferior border. The surface is inked and the. specimen is sectioned to show yellow lobular fatty cut surface with. minimal fibrous tissue present. No residual tumor is grossly. identified. The specimen is entirely submitted labeled 1 through 9. F. Received fresh and subsequently fixed in formalin labeled. ""posterior to segmental mastectomy left breast ""is a 3.2 x 2.5. x. 1.0 cm yellow lobular fatty tissue fragment which is partially. covered with skeletal muscle. There is a suture designating the new. posterior margin. The surface is inked and the specimen is. sectioned to show a yellow lobular fatty cut surface with scanty. fibrous tissue present. The specimen is entirely submitted in 5. cassettes. G. Received fresh and subsequently fixed in formalin labeled ""lateral. to segmental mastectomy left breast ""is a 4.3 x 3.5 x 1.5 cm yellow. lobular fatty tissue fragment. There is a suture designating the. new lateral border. The surface is inked and the specimen is. sectioned to show yellow lobular fatty cut surface with minimal. fibrous tissue present. No residual tumor is grossly identified. The specimen is entirely submitted in 9 cassettes. H. Received fresh and subsequently fixed in formalin labeled. ""superior segmental mastectomy left breast ""is a 4.3 x 2.2 x 1.0. cm. yellow lobular fatty tissue fragment which has a suture designating. the new superior border. This is inked and the specimen is. sectioned to show yellow lobular fatty cut surface with scanty. fibrous tissue present. The specimen is entirely submitted in 4. cassettes."
TCGA-AC-A2QJ.E422C6E8-084F-42B8-84E7-4EF387F098C7,3,T3,"The report mentions that the patient is female and had a left breast mastectomy. The largest invasive carcinoma found in the breast measures 7 cm in greatest dimension (B. Breast, left, mastectomy). According to the rules provided, a T3 stage tumor is defined as an invasive breast carcinoma that is more than 5 cm in size. Therefore, based on the size of the tumor, the pathologic T stage for this patient is T3.","Sex: F. Laboratory Patient Report. Print Date/Time. Histopathological Examination. Complete: Pre-op Diagnosis : Left Breast Cancer. Specimens. : breast, left inferior skin. Breast, left. Lymph Node, Left Axillary. Lymph Node, Sentinel Left Axilla. Breast, left, inferior margin. Frozen Diagnosis : Block#. : A-1. Re-Ex?. FS-Diag. : No carcinoma identified. Comment. : none. : GROSS EXAMINATION: A. The specimen is received fresh in a container labeled. with the name of the patient and labeled as breast, left. inferior skin. Tissue: Triangular excision. Size: 0.9 x 0.9 cm. Deep: 0. 3 cm. Sutures: No. Inked No. The specimen is entirely submitted for frozen section in one. block. FROZEN SECTION DIAGNOSIS: No carcinoma identified. B. The specimen is received fresh in a container labeled. with the name of the patient and identified as breast,. left. The specimen consists of a mastectomy measuring en. bloc 19.5 x 15 x 6 cm and weighs 604 grams. There is an. anterior ellipse of skin measuring 14 x 7 cm. Medially. located on the ellipse of skin is a 5 cm areolar complex. with everted nipple. Sections of nipple areola are sampled. in block 1. 2 cm lateral to the areola is a 0.9 cm red-tan. papule which is submitted in block 2. The superficial. superior margin is inked orange and the superficial inferior. margin is inked green. The deep margin is inked blue and. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : of 4. Visit # : the specimen sectioned, showing a red-tan oval mass in the. lateral aspect of the breast. This mass measures 7 cm. greatest dimension. It grossly extends to within 0.5 cm of. the superior margin of resection which is submitted in block. 3, 0. cm of the inferior margin of resection which is. submitted in block 4, and 1 cm of the deep margin of. resection which is submitted in block 5. Additional sections. of the mass are submitted in blocks 6-9. The remaining. breast is composed of yellow lobulated adipose tissue. admixed with islands of gray-white rubbery tissue. The. breast is divided into four quadrants, upper inner, lower. inner, upper outer and lower outer and sampled in blocks. 10-13 respectively. No axillary tissue is present and no. lymph nodes are identified. Formalin fixation time is 32 hours. Ischemic time: 30 minutes. C. The specimen is received in formalin in a container. labeled with the name of the patient and labeled as lymph. node, left axillary. The specimen consists of an oval piece. of tan-pink and yellow soft tissue which measures 2. 1 x 1.8. x 1 cm. The specimen is sectioned and entirely submitted in. three blocks. D. The specimen is received in formalin in a container. labeled with the name of the patient and identified as lymph. node, sentinel left axilla. Pieces: 1. Specimen Size: 2.2 x 1.4 x 1. 1 cm. No. of Nodes: 1. Size of Nodes: 2.2 cm. The specimen is sectioned and entirely submitted in three. blocks. E. The specimen is received in formalin in a container. labeled with the name of the patient and identified as. additional left breast tissue, inferior margin. Size: 14 x 6 x 2.5 cm. Shape: Flattened oval. Spec Board: No. Radiograph: No. Sutures: Yes; short superior, long lateral. Inked: Anterior-Green, Posterior-Blue, Superior-Orange,. Inferior-Yellow, Medial-Red, Lateral- Black. Sectioning shows no discrete masses. Sections are submitted as follows : Full thickness superior. to inferior sections 1-6 with the remaining margins. submitted as follows: anterior 7, posterior 8, medial 9,. lateral 10. Formalin fixation time is approximately 30 hours. Ischemic time: Unknown. DIAGNOSIS BASED ON GROSS AND MICROSCOPIC EXAMINATION: A. Skin, left inferior breast, biopsy: - Skin with minimal patchy nonspecific chronic inflammation. - No maliqnancy identified. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : of 4. Visit # : B. Breast, left, mastectomy : - Invasive metaplastic carcinoma, grade 3 (3+3+3) 7 cm in. greatest dimension, present within 3mm (0.3 cm) of superior. margin, 5mm (0.5 cm) of inferior margin, and 10mm (1 cm) of. deep margin. - Invasive carcinoma invades dermis and is associated with. overlying epidermal ulceration. - Background nonproliferative fibrocystic including stromal. fibrosis, apocrine metaplasia, microcystic formation, and. duct ectasia. - See cancer CASA summary checklist. C. Lymph node, left axillary, biopsy: - One benign lymph node, negative for metastatic carcinoma. (0/1). - See cancer case summary checklist. D. Sentinel lymph node, left, biopsy: - One benign lymph node, negative for metastatic carcinoma. (0/1) . - See cancer case summary checklist. E. Breast, left, re-excision of inferior margin: - Benign breast tissue with nonproliferative fibrocystic. changes including apocrine metaplasia, stromal fibrosis, and. microcyst formation. - No malignancy identified. - The margins are examined microscopically and are. histologically unremarkable. - See cancer case summary checklist. CANCER CASE SUMMARY CHECKLIST. SPECIMEN: Total breast (including nipple and skin). PROCEDURE: Total mastectomy. LYMPH NODE SAMPLING: Sentinel lymph nodes and axillary lymph. node biopsy. SPECIMEN INTEGRITY: Multiple designated specimens (main. excision and identified margin). SPECIMEN LATERALITY: Left. TUMOR SITE (Invasive Carcinoma) : Upper and lower outer. quadrants. TUMOR SIZE: Size of Largest Invasive Carcinoma: 7 cm (70. mm) in greatest dimension. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: - Skin: Invasive carcinoma directly invades into the dermis. with associated skin ulceration. - Nipple: DCIS does not involve the nipple epidermis. Skeletal Muscle: No skeletal muscle is present. DUCTAL CARCINOMA IN SITU (DCIS) : No DCIS is present. LOBULAR CARCINOMA IN SITU (LCIS) Not identified. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive metaplastic. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. carcinoma. HISTOLOGIC GRADE: NOTTINGHAM HISTOLOGIC SCORE: - Glandular (Acinar)/Tubular Differentiation. 3. - Nuclear Pleomorphism: 3. - Mitotic Count: 3. Number of mitoses per 10 high-power fields: 30. Diameter or microscope field: 0.55 mm. - Overall Grade: Grade 3 (score of 9). MARGINS: - Margins uninvolved by invasive carcinoma. - Distance of invasive carcinoma to closest margin = 3 mm. (0.1 cm), superior. - All other margins greater than 1 cm from invasive. carcinoma (including specimens A and E). LYMPH-VASCULAR INVASION: Not identified. Dermal Lymph-Vascular Invasion: Not identified. LYMPH NODES: Number of sentinel lymph nodes examined: 1. Total number of lymph nodes examined (sentinel and. nonsentinel) : 2. Number of lymph nodes with macrometastases (>0.2 cm) : 0. Number of lymph nodes with micrometastases (>0.2 mm to. 0.2 cm and/or >200 cells): 0. Number of lymph nodes with isolated tumor cells (0.2 mm and. <200 cells) : 0. Size of largest metastatic deposit: Not applicable. Extranodal Extension: Not applicable. Method of Evaluation of Sentinel Lymph Nodes: H&E, 1 level. PATHOLOGIC STAGING (pTNM) : - Primary Tumor (Invasive Carcinoma). (pT) : pT4b (skin. ulceration). - Regional Lymph Nodes (pN) : pNO (no regional lymph node. metastasis identified histologically). - Distant Metastasis (M) : Not applicable. ANCILLARY STUDIES: Estrogen Receptor: - Performed on another specimen. - Results: No immunoreactive tumor cells present. Progesterone Receptor: - Performed on another specimen. - Results: No immunoreactive tumor cells present. HER2/neu Immunoperoxidase Studies: - Performed on another specimen. - Results: Negative (score 0). Fluorescence In Situ Hybridization (FISH) for HER2/neu: - Not performed. Intradepartmental consultation obtained. M.D., Pathologist. Flantrnninallv Signed by: MD. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. of 4."
TCGA-AC-A4ZE.6931CAAE-6DFE-4A61-84D5-4EC804C2F2C6,2,T2,"To determine the pathologic T stage of the patient's breast cancer, we will follow the rules provided and focus on the pathology report for the right simple mastectomy. The left simple mastectomy shows no malignancy. Here are the steps we will take: \\n1. Identify the tumor type: The report indicates that the tumor type is lobular. \\n2. Measure the tumor size: The tumor size is given as 7.8 x 7.0 x 6.0 cm. \\n3. Check for direct extension to the chest wall or skin: The report does not mention any direct extension to the chest wall or skin. \\n4. Look for satellite nodules or ulceration: The report does not mention any satellite nodules or ulceration. \\nBased on this information, we can determine the T stage as follows:","F. Path Report. ACCESSION NO. : Final Diagnosis(es): (A) Left simple mastectomy: 1) Benign breast with areas of stromal fibrosis. 2) No atypia, in-situ or invasive malignancy identified,. including margins. 3) Skin and nipple unremarkable. (B) Right simple mastectomy: 1) Infiltrating lobular carcinoma, Nottingham grade Il of. III. 2) Pathologic stage pT3 psnNo pMX. 3) See Synoptic report (below) for details. (C) Right axilla sentinel lymph node #1: One lymph node. negative for metastasis (0/1). Synoptic Report: Specimen Type: Total breast (including nipple and skin). Procedure: Simple mastectomy. Lymph Node Sampling: Sentinel lymph node. Laterality: Right. Tumor Type: Lobular. Tumor Focality: Single. Tumor Site: Lower outer quadrant. Tumor Size: 7.8 x 7.0 x 6.0 cm. Nottingham Grade: II of III. Skin: Present, unremarkable. Nipple: Present, unremarkable. Skeletal Muscle: Absent. Invasive Margins: Widely negative. Lobular Carcinoma in Situ: Not present. Ductal Carcinoma in Situ: Not present. Lymphvascular Invasion: Not identified. Lymph nodes: Sentinel: 0/1 (positive/total). CK 10.11 performed on block B1. Anciliary Studies: Estrogen Receptor: Positive, strong, 95%. Progesterone Receptor. Positive, strong, 50%. Her-2/neu: 0+ (0-3+ scale). (was not sent for FISH analysis). KI-67: 25%. MD. Specimen(s) Received: A: left simple mastectomy. B: right simple mastectomy. C: right axilla sentinel lymph node # 1. Printed from: Default. Page: 1 of 5. F. Clinical History: High risk breast cancer left. (A) Short - superior, long - lateral. (B) Short superior, long - lateral. (C) Count 166. Intraoperative Consultation: FSC1-FSC2: Right axilla sentinel lymph node #1: Benign (2. blocks). M.D. Gross Description: (A) (left simple mastectomy). Specimen type: Simple mastectomy. Specimen weight and dimensions: The specimen weighs 1595 gm and. measures 23.5 x 22.5 x 6.3 cm. Skin: The overlying skin ellipse measures 22.0 x 11.0 cm. The. skin appears tan-pink and unremarkable. Orientation and inking scheme: The specimen is oriented as. follows: One short suture denoting the superior orientation and. one long suture representing the lateral left orientation. The. specimen is inked as follows: Medial - red, lateral - green. Estimated size of lesion: Sectioning of the breast demonstrates. unremarkable fibrofatty tissue with no nodules or masses seen or. palpated. Blocks submitted: A1 - section of nipple. A2-A3 - two sections from upper lateral portion of breast. A4-A5 - two representative sections of the lower lateral. quadrant. A6-A7 - representative sections of lower medial quadrant. A8-A9 - representative sections of upper medial quadrant. (B) (right simple mastectomy). Specimen type: Simple mastectomy. Specimen weight and dimensions: The specimen weighs 1670 gm and. measures 26.0 x 28.0 x 6.0 cm. Skin: The ellipse of overlying skin measure 24.5 x 9.0 cm. The. skin is pink and unremarkable. Orientation and inking scheme: The specimen is oriented as. follows: One short suture denoting the superior orientation and. one long suture representing the lateral left orientation. The. specimen is inked as follows: Deep margin - black, anterior. lateral margin - red, anterior medial margin - blue. Estimated size of lesion: The breast is serially sectioned. The. primary lesion measures approximately 7.0 x 7.8 x 6.0 cm. Appearance of lesion: The lesion is firm and tan-white, and. infiltrates into the breast parenchyma. Printed from: Default. Page: 2 of 5. F. Location of lesion: The lesion is located approximately 7.0 cm. medial to the center of the specimen in the lower lateral. quadrant. Distance from closest margin: The primary lesion is located 1.5. cm superficial to the deep margin, 4.0 cm from the anterior. margin, 6.0 cm from the lateral margin, 19.0 cm to the medial. margin, 6.0 cm to the inferior margin, and 14.0 cm to the. superior margin. Other findings: Two possible satellite lesions are located with. one central and one at 2:00. The central lesion measures 6.5 x. 3.0 x 3.0 cm. The lesion at 2:00 measures 1.5 x 2.5 x 2.5 cm. Uninvolved parenchyma: The uninvolved parenchyma demonstrates. unremarkable fibrofatty tissue. Axillary tail and lymph nodes: No axillary tail is received in. this specimen. Blocks submitted: B1 nipple. B2 - fat overlying tumor. B3 - skin overlying tumor. B4-B8 - representative sections from the primary tumor. B9-B10 - representative sections from the centrally located. possible satellite lesion. B11-B12 - two representative sections from the lesion at 2:00. B13-14 - representative sections of uninvolved parenchyma from. the upper medial quadrant. B15-B16 - representative sections of uninvolved parenchyma. B17-B18 - representative sections of the lower lateral quadrant. B19-B20 - two representative sections of uninvolved parenchyma. from the upper lateral quadrant. B21 - section of the medial margin. B22 - section of the lateral margin. B23 - section of the inferior margin. B24 - section of the superior margin of uninvolved parenchyma. (C) (right axilla sentinel lymph node #1) Received fresh for. intraoperative consultation is one piece of fatty tissue. measuring 3.3 x 2.4 x 1.0 cm. The specimen is bisected with. one-half submitted in FSC1 and the other half submitted in FSC2. for frozen section evaluation. One lymph node was received in. formalin and submitted entirely in C3. Microscopic Description: Complete microscopic evaluation has been performed. Appropriately reacting controls have been performed and. evaluated for all stains on this case as required. Histopathology has a list of IH antibodies that are regulated as. analyte specific reagents (ASR's). These assays were developed. and their performance characteristics determined by the. at. They. have not been cleared by the US Food and Drug Administration. Printed from: Default. Page: 3 of 5. F. 1. The FDA has determined that such clearance or approval is not. necessary for the ASR's. These tests are not investigational. and are used in standard clinical care. In cases where. Immunohistochemistry testing is performed, the following. antibodies and their respective clones may be used to determine. therapy for the patient: EFGR(31G7), ER(SP1), PR(1E2),. Her2neu(4B5), CD117(Poly), CD20(L26). Unless otherwise stated in the report, all tissue tested for. ERPR by IHC, Her2 by IHC and/or HER2 by FISH have been fixed as. per ANP 22998 for a minimum of 6 hours and a maximum of 48. hours. ER, PR, Ki-67, p53 are reported as a semi-quantitative. percentage of positively stained nuclei. Her-2/neu and EGFR are. scored as follows: No staining at all is scored as (0), weak,. incomplete membrane staining in any proportion of cells is. scored as (1+), less than strong but complete staining in any. proportion of cells or complete strong staining in less than 30%. of cells is scored as (2+), and strong complete staining in more. that 30% of cells is scored as (3+). All studies are performed. on tissue fixed in 10% neutral buffered formalin and embedded in. paraffin unless otherwise stated in the report. Page: 4 of 5."
TCGA-AC-A5XS.C4F259BA-7C00-4326-ACB2-924C4AE33E87,1,T1c,"[{""step"":1,""info"":""The report mentions that the largest dimension of the tumor in the left breast is 2.6 cm. Therefore, we can immediately rule out T3 and T4 stages as they require a tumor size greater than 5 cm or with direct extension to the chest wall or skin.""},{""step"":2,""info"":""Now, let's compare the tumor size (2.6 cm) with the T1 subcategories. Since it is larger than 0.1 cm but less than or equal to 2 cm, it falls under the T1 category. However, since it is larger than 1 cm, it does not fall under T1mi, T1a, or T1b.""},{""step"":3,""info"":""Therefore, based on the rules provided, the pathologic T stage of the patient's breast cancer is T1c, which includes invasive breast carcinomas that are 1 cm but less than 2 cm in size.""}]","PROCEDURE. Bilateral simple breast mastectomy with sentinel node biopsy left. breast. A. Right breast. B. Left breast with attached sentinel nodes. HISTORY. Left breast cancer. GROSS. A. Received in formalin in a container labeled ""right breast"" is a. mastectomy (22 x 18 x 5 cm). Orientation of the specimen is not. provided. The skin ellipse (20 x 15 cm) has a central unremarkable. nipple and areola. The posterior margin is composed of thin fascia. without attached skeletal muscle. The margins are marked with black. ink. The specimen is serially sectioned. The parenchyma has discrete and. ill-defined areas of soft white fibrous tissue. A suspicious lesion. is not palpated. 1. Nipple and areola. 1NS. 2. Subareolar parenchyma. 2SS. 3-6. Representative sections from four quadrants. B. Received fresh in a container labeled ""left breast"" is a. mastectomy (23 x 17 x 5 cm) with a 7 cm axillary tail. The skin. ellipse (20 x 12 cm) has a central unremarkable nipple and areola. The parenchyma is serially sectioned. The medial hemisphere has a. 2.6 cm in greatest dimension hard gray-white sclerotic neoplasm with. an ill-defined radially infiltrating border measuring approximately. 1 cm from the posterior margin, 2.2 cm from the skin surface and 1. cm from the nearest (inferomedial) radial margin. A representative. portion of the tumor along with normal parenchyma away from the. neoplasm is submitted for TCGA/. The remaining. parenchyma has scattered areas of ill-defined fibrous tissue without. a palpable mass. The axillary tail has numerous fatty lymph nodes. up to 2.5 cm in greatest dimension. 1. Small lymph node. 2-7. Bisected lymph nodes (1 lymph node per cassette). 8-10. Large lymph node. 11. Nipple and areola. 12. Skin and posterior margin nearest neoplasm. 13. Inferomedial quadrant nearest neoplasm. 14-16. Neoplasm. 17. Superolateral quadrant. 18. Inferolateral quadrant. MICROSCOPIC. A-B. Performed. DIAGNOSIS. A. Right simple mastectomy: Nonproliferative breast parenchyma with acellular dense. stromal fibrosis and rare microcalcification. Nipple, free of lesion. CPT 88307. B. Left mastectomy with attached sentinel nodes: Invasive lobular carcinoma, Nottingham grade 1 (previously. diagnosed,. Nipple and skin of posterior margin (nearest neoplasm), free. of lesion. Eight of eight sentinel lymph nodes, free of metastatic. carcinoma. CPT 88309. BREAST CARCINOMA SUMMARY: SPECIMEN: Left breast. PROCEDURE: Left breast with attached sentinel lymph nodes. SPECIMEN INTEGRITY: Intact. SPECIMEN LATERALITY: Left. SPECIMEN SIZE: 23 x 17 x 5 cm. LYMPH NODE SAMPLING: SENTINEL LYMPH NODES: 8 of 8, negative for metastatic. carcinoma. TUMOR SIZE: 2.6 cm. TUMOR FOCALITY: Single focus. SKIN INVOLVEMENT: Negative for cancer. NIPPLE INVOLVEMENT: Negative for cancer. SKELETAL MUSCLE INVOLVEMENT: N/A. DUCTAL CARCINOMA IN SITU (DCIS) : Not present. LOBULAR CARCINOMA IN SITU (LCIS) : N/A. HISTOLOGIC TYPE: Lobular carcinoma. GRADING (NOTTINGHAM) : Tubular Formation Score: 3. Nuclear Pleomorphism Score: 1. Mitotic Rate Score: 1. COMBINED GRADE (NOTTINGHAM) : 1. LYMPHOVASCULAR INVASION: Not seen. MARGIN OF EXCISION: Negative for carcinoma. LYMPH NODES: See above. MICROCALCIFICATION: Not seen. OTHER FINDINGS: N/A. HORMONE RECEPTORS: ER positive. PR positive. HER2: Negative (1+) . PATHOLOGIC. (AJCC Seventh Edition) : pT2 pNO. (Electronic Signature). Completed Action List: on. Type: Sura Path Final Report. Title: Contributor system: SP 1st Addendum Report. SP 1ST ADDENDUM REPORT. ADDENDUM REPORT. E-cadherin immunostain is performed on block B15 to confirm the. lobular nature of the infiltrating mammary carcinoma. The stain is. negative, supporting the diagnosis of invasive LOBULAR carcinoma. Positive and negative tissue controls perform as expected. 88342. (Electronic Signature). Completed Action List: Type: SP 1st Addend. Title: SP 1ST ADDENDUM REPORT. Contributor system:"
TCGA-AN-A0AJ.6E2365F3-0875-4949-8409-7E26BBCDE700,2,T1,"The pathology report provides the tumor size as '2 cm or less', but it does not give an exact measurement or specify which subcategory of T1 the tumor falls into. Therefore, based on the information provided, we can only conclude that the tumor is a T1 stage breast cancer.""",Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal-lobular carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 3 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.
TCGA-AN-A0AL.20F4DBD9-02FA-4FFD-AEF5-234910D31263,3,Insufficient information to determine T stage,"The pathology report provides the size of the tumor under the T Stage field, which is '4'. However, this is not a valid size for determining the T stage as it does not correspond to any of the categories mentioned in the rules. The number '4' in this context most likely indicates that the tumor size was not measured or not recorded in the report. Therefore, it is not possible to accurately determine the T stage based solely on this report."",""decision"":""Insufficient information to determine T stage""}",Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. 1 Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 4 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.
TCGA-AN-A0AS.0D1ACC76-910E-4243-A229-5F76B5A3299A,1,"To determine the T stage, we will follow the rules provided:"" + ","The pathology report provides the T stage as 'T2' and the size of the tumor is not explicitly mentioned. However, the T stage is determined based on the size of the tumor, so we need to infer the size from the information provided."" + ",JB: Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 2. T Stage: 2 N Stage: 2a M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.
TCGA-AN-A0FZ.8CC70CDC-01EC-4E2B-84C1-F1C946602CCE,1,T1,"The pathology report provides the tumor size as 2 cm or less, which corresponds to T1 stage according to the rules. However, it does not provide the exact size of the tumor within the T1 range (T1mi, T1a, T1b, or T1c). Therefore, the most general T stage for this report would be T1.",Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 2. T Stage: 2 N Stage: 2 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.
TCGA-AN-A0XN.4C9C9D24-07E1-47BE-8D34-F94693576BD2,1,T1,"The pathology report provides the tumor size as 2 cm or less, which corresponds to T1 stage. However, it does not provide the exact size of the tumor within the T1 range (T1mi, T1a, T1b, or T1c). Therefore, based on the information provided, we can only determine that the T stage is T1, but we cannot specify the exact substage. The T stage could be T1mi, T1a, T1b, or T1c, depending on the exact size of the tumor.",Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. - Anatomic Site: Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 2 N Stage: 1 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.
TCGA-AN-A0XP.80E9B7CE-0D5D-4C01-A8E3-E6345BE145EC,1,T1,"The pathology report provides the tumor size as 2 cm or less, which corresponds to T1 stage. However, it does not provide the exact size of the tumor within the T1 range (T1mi, T1a, T1b, or T1c). Therefore, based on the information given, we can only determine that the T stage is T1, but we cannot provide a more specific T stage without additional information.",Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 2 N Stage: 1 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.
TCGA-AN-A0XR.1351520E-9B6A-4F06-B631-DF374396C7E6,1,T1,"The pathology report provides the tumor size as '2 cm or less', which corresponds to T1 stage according to the rules. However, it does not provide a more specific size within the T1 range (T1mi, T1a, T1b, or T1c). Therefore, the most general T1 stage can be assigned. The report also mentions a N Stage of 2b, but this does not affect the T stage determination.",Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 2 N Stage: 2b M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.
TCGA-AN-A0XU.8216B837-DCF3-4E7F-A72A-212655F394F0,1,unknown,"The pathology report does not provide information about the size of the tumor, which is a critical factor in determining the T stage. The report only mentions that the patient is diagnosed with breast cancer, the type of cancer (infiltrative ductal carcinoma), the ethnicity of the patient, the grade of the cancer (grade 3), and the format of the tissue specimen (OCT block). Therefore, based on the information provided in the report, it is not possible to accurately determine the T stage of the patient's breast cancer.",Sex: Female Ethnicity (Race. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 3. T Stage: 2 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.
TCGA-AN-A0XV.5F626AB6-EEB5-4005-97C5-9E48D9FA7730,1,T1,"The pathology report provides the tumor size as '2 cm or less', which corresponds to T1 stage according to the rules. However, it does not provide a more specific size within the T1 range (T1mi, T1a, T1b, or T1c). Therefore, the most general T1 stage can be assigned. The report also mentions 'Grade 2', but this does not affect the T stage determination. Thus, the patient's pathologic T stage is T1.",Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. ) Anatomic Site: Right Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 2 N Stage: 1 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.
TCGA-AN-A0XW.5CBC6417-4E3D-4E9C-AE93-A56B777EF2F4,1,T1,"The pathology report provides the tumor size as '2 cm or less', which corresponds to T1 stage according to the rules. However, it does not provide a more specific size within the T1 range (T1mi, T1a, T1b, or T1c). Therefore, the most accurate T stage assignment based solely on the information provided in the report would be T1."",""result"":""T1""}",Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: biock Type of Procurement: surgery Grade: 2. T Stage: 2 N Stage: 1 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.
TCGA-AO-A0J5.5EFC16F4-7FC7-479E-93F7-AEDC2D350A22,3,T3,"The report states that the largest dimension of the invasive carcinoma is at least 10 cm (`measuring at least 10 CM in largest dimension grossly`). According to the rules provided, this would put the patient in the T3 stage: `T3: This stage includes invasive breast carcinomas that are more than 5 cm in size.` The report also mentions that the skin is involved by invasive carcinoma by direct extension (`THE SKIN IS INVOLVED BY INVASIVE CARCINOMA BY DIRECT EXTENSION INTO THE. DERMIS.`) and the attached skeletal muscle is extensively involved by invasive carcinoma by direct extension (`THE ATTACHED SKELETAL MUSCLE IS EXTENSIVELY INVOLVED BY INVASIVE CARCINOMA. BY DIRECT EXTENSION.`). These findings would also support a T3 stage. However, the size of the tumor is the most significant factor in determining the T stage in this case, so the final decision is T3.","Clinical Diagnosis & History: year old female with stage IV breast carcinoma, debulking surgery. Specimens Submitted: 1: SP: Right breast and axillary contents level 1. DIAGNOSIS: 1. BREAST, RIGHT; MODIFIED RADICAL MASTECTOMY: - INVASIVE CARCINOMA, HISTOLOGIC GRADE II/III (MODERATE TUBULE. FORMATION) TO HISTOLOGIC GRADE III/III (SLIGHT OR NO TUBULE FORMATION). NUCLEAR GRADE III/III (MARKED VARIATION IN SIZE AND SHAPE), MEASURING AT. LEAST 10 CM IN LARGEST DIMENSION GROSSLY. INVASIVE CARCINOMA SHOWS. MICROPAPILLARY FEATURES. FOCAL EXTRACELLULAR MUCIN IS ALSO NOTED. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID CRIBRIFORM. MICROPAPILLARY AND FLAT TYPES, WITH HIGH NUCLEAR GRADE, AND EXTENSIVE. NECROSIS. - LOBULAR INVOLVEMENT BY DCIS IS PRESENT. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN ALL FOUR QUADRANTS. - THE DCIS IS LOCATED IN ALL FOUR QUADRANTS. - THE NIPPLE IS INVOLVED BY INVASIVE CARCINOMA. - CALCIFICATIONS ARE PRESENT IN BOTH THE IN SITU AND INVASIVE CARCINOMA. - VASCULAR INVASION IS PRESENT. - THE SKIN IS INVOLVED BY INVASIVE CARCINOMA BY DIRECT EXTENSION INTO THE. DERMIS. - THE ATTACHED SKELETAL MUSCLE IS EXTENSIVELY INVOLVED BY INVASIVE CARCINOMA. BY DIRECT EXTENSION. - INVASIVE CARCINOMA IS CLOSE (LESS THAN 0.1 CM) FROM THE NEAREST DEEP. MARGIN. THE NON-NEOPLASTIC BREAST TISSUE IS UNREMARKABLE. FOCAL CHANGES OF PRIOR PROCEDURE ARE NOTED IN THE AXILLARY TAIL. - METASTATIC CARCINOMA IS PRESENT IN TWO OUT OF TWO LEVEL I LYMPH NODES. (2/2) ADDITIONAL SECTIONS OF THE AXILLARY TISSUE HAVE BEEN SUBMITTED AND. THE FINDINGS WILL BE REPORTED IN AN ADDENDUM. - NUMEROUS FOCI OF METASTATIC CARCINOMA ARE NOTED IN THE AXILLARY SOFT. TISSUE, WITH THE LARGEST MEASURING AT LEAST 1.4 CM. Immunohistochemical stains were performed on formalin-fixed tissue with. the following results for invasive carcinoma (block 1-8): ESTROGEN RECEPTOR. 90% nuclear staining with strong. intensity. PROGESTERONR RECERTOR. Negative (no nuclear staining). HER2. Equivocal (focal 2+). FISH will be performed. (5% of invasive tumor cells exhibit complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). The carcinoma is positive for E-cadherin, supporting lobular. differentiation. Comment: Controls are satisfactory. Ventana' a PATHWAY anti-HER-2/neu is. an FDA-approved rabbit monoclonal primary antibody (clone 4B5) directed. against the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25(1):118-145). The ER and PR rabbit monoclonal antibodies are also FDA. approved. Some of the imnunohistochemistry and ISH tests were developed and their. performance characteristics were determined by the Department of Pathology. They have not been cleared or approved by the US Food and Drug. Administration. The FDA has determined that such clearance or approval is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA , 88). as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL) . AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: M.D. M.D. 1) The specimen is received fresh labeled, ""right breast and axillary. contents level 1"",. It consists of a breast with attached. axillary contents. The breast measures 20 x 15 x 5 cm with overlying skin. ellipse measuring 18 x 7 x 0.2 cm. Situated centrally on the skin surface is. a. fixed, and retracted nipple measuring 1.5 x 1.0 x 1.0 cm. The surrounding. skin is markedly thickened (up to 0.6 cm) . A suture demarcates the axillary. contents which measures 7 x 5 x 2 cm. The posterior surface of the breast is. inked black and the anterior blue. Part of the posterior surface of the. breast is covered by dark red skeletal muscle, measuring 11 x 4 x 0.5 cm. The specimen is serially sectioned to reveal an irregular tumor bed (10 x. 8.3 x 5.1 cm) with poorly defined white, firm and tan areas. The tumor bed. occupies almost the entire breast volume, extending throughout all four. quadrants. The tumor bed is located 0.2 cm from the posterior margin, 0.3 cm. from the anterior margin, and 0.5 cm from the skeletal muscle. The remaining. breast tissue shows yellow fatty areas with foci of fibrosis. The axillary. tissue is dissected to reveal 13 possible lymph nodes, ranging in size from. 0.4 cm to 1.2 cm. Representative sections are submitted. All dissected lymph. nodes are entirely submitted. The specimen is photographed. Tissue is. submitted to TPS. Summary of sections: N - nipple, nipple base and tumor. s - thickened skin. PM - posterior margin. AM - anterior margin. DSM - deep skeletal muscle. T - tumor central region and closest margins, continuous cross sections,. taken from medial to lateral. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. L1 - axilla, level one lymph nodes. AX axillary tail, entirely submitted. Summary of Sections: Part 1: SP: Right breast and axillary contents level 1. Block. Sect. Site. PCs. 1. AM. 1. 11. ax. 11. 1. DSM. 1. 9. L1. 9. 2. LIQ. 2. 2. LOQ. 2. 3. N. 3. 1. PM. 1. 1. s. 1. 10. T. 10. 2. UIQ. 2. 2. UOQ. 2. Procedures/Addenda: Addendum. Date Complete: By: 1. Addendum Diagnosis. PART #1. RIGHT BREAST AND AXILLARY CONTENTS: THE REMAINING AXILLARY TISSUE IS ENTIRELY SUBMITTED. NO ADDITIONAL LYMPH. NODES ARE IDENTIFIED. ,MD."
TCGA-AO-A0JB.6C202D3E-5670-4B63-82A2-9EE7AC385089,2,T2,"[{""step"":1,""info"":""The report states that the invasive ductal carcinoma measures 11.0 cm in largest dimension. This exceeds the maximum size for T2 (5 cm) and T1 (2 cm), so we can immediately rule out those stages.""},{""step"":2,""info"":""The report also states that there is no skin involvement by carcinoma and no involvement of the surgical margins by either invasive or in situ carcinoma. This means that the tumor has not extended to the chest wall or skin, so we can rule out T3 and T4 stages.""},{""step"":3,""info"":""Since the tumor is larger than 2 cm but not larger than 5 cm, and there is no extension to the chest wall or skin, the T stage is T2.""}]","Clinical Diagnosis & History: 1/0 female with left breast IDC. Specimens Submitted: 1: SP: Level three left axillary lymph nodes. 2: SP: Level two left axillary lvmph nodes. 3: SP: Lateral left breast skin. 4: SP: Right upper abdominal skin tag. 5: SP: Left breast and level 1 axillary lymph nodes. DIAGNOSIS: 1). SOFT TISSUE, LEVEL III LEFT AXILLA; EXCISION: - BENIGN FIBROADIPOSE TISSUE. - NO LYMPH NODE IDENTIFIED. 2). LYMPH NODES, LEVEL II LEFT AXILLA; EXCISION: - THREE BENIGN LYMPH NODES (0/3). 3). SOFT TISSUE, LATERAL LEFT BREAST; EXCISION: - ONE BENIGN LYMPH NODE (0/1). - BENIGN FIBROADIPOSE TISSUE. 4). SKIN, RIGHT UPPER ABDOMINAL TAG; EXCISION: - IRRITATED SEBORRHEIC KERATOSIS. 5). BREAST AND LEVEL I AXILLARY LYMPH NODES, LEFT; MASTECTOMY: - INVASIVE DUCTAL CARCINOMA, HISTOLOGIC GRADK III/III (SLIGHT OR NO. TUBULE FORMATION). NUCLEAR GRADE II/III (MODERATE VARIATION IN SIZE AND. SHAPE) WITH AREAS OF LOBULAR GROWTH, MEASURING 11.0 CM IN LARGEST DIMENSION. GROSSLY. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID TYPE, WITH. MODERATE HIGH NUCLEAR GRADE AND EXTENSIVE NECROSIS. - LOBULAR INVOLVEMENT BY DCIS IS PRESENT. THE DCIS CONSTITUTES <= 25% OF THE TOTAL TUMOR MASS, AND IS PRESENT. ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN THE UPPER OUTER QUADRANT, UPPER INNER. QUADRANT AND LOWER OUTER QUADRANT. - THE DCIS IS LOCATED IN THE UPPER OUTER QUADRANT, UPPER INNER QUADRANT AND. LOWER OUTER QUADRANT. - NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA IS. IDENTIFIED. CALCIFICATIONS ARE PRESENT IN THE IN SITU AND INVASIVE CARCINOMA, AND IN. BENIGN BREAST PARENCHYMA. EXTENSIVE VASCULAR INVASION IS PRESENT. NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. - NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE ATTACHED SKELETAL MUSCLE IS UNINVOLVED BY CARCINOMA. THE NON-NEOPLASTIC BREAST TISSUE SHOWS BIOPSY SITE CHANGES AND. PROLIFERATIVE FIBROCYSTIC CHANGES. - THE LYMPH NODE STATUS IS AS FOLLOWS (EXPRESSED AS THE NUMBER OF POSITIVE. LYMPH NODES IN RELATION TO THE TOTAL NUMBER OF LYMPH NODES EXAMINED) : LEVEL. I: 1/10. - THERE IS EXTRANODAL EXTENSION OF CARCINOMA, >2 MM. IMMUNOHISTOCHEMICAL STAINS WERE PERFORMED ON FORMALIN-FIXED TISSUE WITH. THE FOLLOWING RESULTS FOR INVASIVE CARCINOMA (BLOCK 5T5) : ESTROGEN RECEPTOR (6F11,. 90% NUCLEAR STAINING WITH. STRONG INTENSITY. PROGESTERONE RECEPTOR (1E2;. 608 NUCLEAR STAINING WITH. MODERATE INTENSITY. NEGATIVE (STAINING. HER2 (HERCEPTEST; DAKO) : INTENSITY OF 0). CONTROLS ARE SATISFACTORY. COMMENT: HERCEPTESTTM (DAKO) IS AN FDA-APPROVED METHOD FOR. ASSESSMENT OF HER2 PROTEIN OVEREXPRESSION IN BREAST CANCER TISSUE ROUTINELY. PROCESSED FOR HISTOLOGICAL EVALUATION. THE HER2 TEST RESULTS ARE REPORTED IN. ACCORDANCE WITH THE ASCO/CAP GUIDELINE RECOMMENDATIONS FOR HER2 TESTING IN. BREAST CANCER (J CLIN ONCOL 2007; 25 (1) :1-28) . I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Special Studies: Special Stain. Comment. ER-C. PR-C. HER2-C. IMM RECUT. NEG CONT. NEG-HER2. Gross Description: MD. D. 1.) The specimen is received in formalin, labeled ""level 3 left axillary. lymph nodes"" and consists of two irregularly shaped fragments of yellow. lobulated adipose tissue measuring 1.0 x 1.0 x 0.2 cm in aggregate. No. lymph nodes are identified grossly. The specimen is entirely submitted. Summary of sections: U-undesignated. 2.) The specimen is received in formalin, labeled ""level 2 left axillary. lymph nodes"" and consists of one irregularly shaped fragment of yellow. lobulated adipose tissue measuring 3.5 x 2.5 x 0.3 cm. Three possible lymph. nodes are identified, ranging from 0.3 cm to 0.5 cm in greatest dimension. The lymph nodes are entirely submitted. Summary of sections: U undesignated. I.D. 3.) The specimen is received in formalin, labeled ""lateral left breast. skin"" and consists of one irregularly shaped fragment of yellow to tan. fibroadipose tissue measuring 10.3 x 2.9 x 1.4 cm. No skin is identified. grossly. Serial sectioning reveals a grossly unremarkable fibroadipose. tissue with a single possible lymph node measuring 0.4 cm in greatest. dimension. Representative sections are submitted. Summary of sections: U-undesignated. .D. 4.) The specimen is received in formalin, labeled ""right upper abdominal. skin tag"" and consists of one polypoid shaped fragment of brown skin. measuring 0.3 x 0.2 x 0.2 cm. The specimen is entirely submitted. Summary of sections: U-undesignated. ..D. 5.) The specimen is received fresh, labeled ""left breast and level 1. axillary lymph nodes, stitch marks level 1 axillary lymph nodes"" and. consists of a breast with attached axillary tail. The breast measures. 22.2. x 16.0 x 3.5 cm with overlying skin ellipse measuring 16.6 x 7.9 cm. Situated eccentrically on the skin surface is an everted nipple measuring. 1.2 x 1.1 x 0.3 cm and areola measuring 4.9 x 4.1 cm. The skin shows no. scars. A suture demarcates the axillary tail which measures 9.8 x 5.5 x 1.5. cm. The posterior surface of the breast is inked black and the specimen is. serially sectioned to reveal an irregularly shaped white-tan firm mass. measuring 11.0 x 6.5 x 4.8 cm, involving upper outer, lower outer and upper. inner quadrants, located 0.6 cm away from the deep resection margin. The. remaining breast tissue shows predominantly yellow lobulated adipose tissue. admixed with scant white-tan fibrous soft tissue with no other grossly. identifiable lesions. The axillary tissue is dissected to reveal multiple. lymph nodes ranging in size from 0.5 cm to 2.5 cm. The specimen is. submitted for lymph node dissection. Representative sections of the. mastectomy specimen and all identified axillary lymph nodes are submitted. Tissue submitted for TPS. Summary of sections: N - nipple. NB - nipple base. S skin. D - deep margin. T - tumor. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. LNS -- lymph nodes. Summary of Sections: Part 1: SP: Level three left axillary lymph nodes. Block. Sect. Site. PCs. 1. U. 1. Part 2: SP: Level two left axillary lymph nodes. Block. Sect. Site. PCs. 1. U. 1. Part 3: SP: Lateral left breast skin (sr). Block. Sect. Site. PCs. 1. U. 1. Part 4: SP: Right upper abdominal skin tag. Block. Sect. Site. PCs. 1. U. 1. Part 5: SP: Left breast and level 1 axillary lymph nodes. Block. Sect. Site. PCs. 1. D. 1. 2. LIQ. 2. 6. LN. 11. 2. LOQ. 2. 1. N. 1. 1. NB. 1. S. 1. 5. T. 5. 2. UIQ. 2. 2. UOQ. 2."
TCGA-AO-A0JG.3671D46F-6D69-42DA-9830-24F67EB8B0B6,1,T1c,"The report states that the 'INVASIVE DUCTAL CARCINOMA, MIXED MUCINOUS & NOS TYPE AND WITH SOLID-PAPILLARY FEATURES, HISTOLOGIC GRADE III/III (SLIGHT OR NO TUBULE FORMATION), NUCLEAR GRADE II/III (MODERATE VARIATION IN SIZE AND SHAPE). MEASURING 2.3 CM IN LARGEST DIMENSION MICROSCOPICALLY' is present in the lower outer quadrant of the right breast. This information refers to the size and location of the invasive cancer. According to the rules provided, T1 includes invasive breast carcinomas that are 2 cm or less in size. Therefore, based on the information given in the report, the pathologic T stage of the patient's breast cancer is T1 (specifically T1c, as the size of the tumor is 2.3 cm, which is between 1 and 2 cm).","Clinical Diagnosis & History: year old female with 2.7 cm right breast cancer, lower outer quadrant and. FNA (+) metastatic right lymph node. Specimens Submitted: 1: SP: Right breast and axillary contents levels one and two with tags. attached. 2: SP: Subscapular nodes, right axilla level one. DIAGNOSIS: 1. BREAST, RIGHT; MASTECTOMY AND AXILLARY DISSECTION: - INVASIVE DUCTAL CARCINOMA, MIXED MUCINOUS & NOS TYPE AND WITH. SOLID-PAPILLARY FEATURES, HISTOLOGIC GRADE III/III (SLIGHT OR NO TUBULE. FORMATION), NUCLEAR GRADE II/III (MODERATE VARIATION IN SIZE AND SHAPE). MEASURING 2.3 CM IN LARGEST DIMENSION MICROSCOPICALLY. - (DCIS) IS ALSO IDENTIFIED, SOLID AND CRIBRIFORM TYPES WITH. INTERMEDIATE NUCLEAR GRADE. AND MINIMAL NECROSIS. - LOBULAR INVOLVEMENT BY DCIS IS PRESENT. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR. MASS, AND IS PRESENT. ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN THE LOWER OUTER QUADRANT. - THE DCIS IS LOCATED IN THE LOWER OUTER QUADRANT AND LOWER INNER. QUADRANT. - NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA. IS IDENTIFIED. - CALCIFICATIONS ARE PRESENT IN BENIGN BREAST PARENCHYMA. - VASCULAR INVASION IS PRESENT. - INVASIVE CARCINOMA IS CLOSE (LESS THAN OR EQUAL TO 1 MM) TO THE. FOLLOWING SURGICAL. MARGIN(S) : BLUE INKED MARGIN (ANTERIOR). NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE NON-NEOPLASTIC BREAST TISSUE SHOWS BIOPSY SITE CHANGES AND. PROLIFERATIVE FIBROCYSTIC. CHANGES INCLUDING INTRADUCTAL PAPILLOMA. - LEVEL 1: METASTATIC ADENOCARCINOMA TO FOUR OUT OF TEN LYMPH NODES. (4/10). THE LARGEST METASTATIC FOCUS MEASURES 2.5 CM. THERE IS EXTRANODAL EXTENSION OF CARCINOMA, FOCAL. - LEVEL 2 : THREE BENIGN LYMPH NODES (0/3). Page or. IMMUNOHISTOCHEMICAL STAIN WAS PERFORMED ON FORMALIN-FIXED TISSUE WITH THE. FOLLOWING RESULTS FOR INVASIVE CARCINOMA (BLOCK 1T6) : HER2. NEGATIVE (0 / 1+). 5% OF INVASIVE TUMOR CELLS EXHIBIT COMPLETE MEMBRANOUS STAINING;. UNIFORMITY OF STAINING: ABSENT. HOMOGENEOUS, DARK CIRCUMFERENTIAL PATTERN: ABSENT. Comment: Controls are satisfactory. s PATHWAY anti-HER-2/neu is an. FDA-approved rabbit monoclonal primary antibody (clone 4B5) directed against. the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation. The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25 (1) :118-145) The ER and PR rabbit monoclonal antibodies are also FDA. approved. 2. LYMPH NODES, RIGHT AXILLA LEVEL ONE, SUBCAPSULAR: - SIX BENIGN LYMPH NODES (0/6). Some of the immunohistochemistry and. tests were develoned and their. performance characteristics were determined by. They have not been cleared or approved by the US Food and Drug. Administration. The FDA has determined that such clearance or approval is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA , 88) as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL) AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: 1) The specimen is received fresh labeled, ""right breast and axillary. contents levels one and two with tags attached and consists of a breast. measuring 19 x 18 x 3 cm with overlying skin ellipse measuring 11 x 3 cm. Situated centrally on the skin surface is an everted nipple measuring 1 x 1. x 0.6 cm and areola measuring 3 x 3 cm. A suture demarcates the axillary. contents which measures 11 x 7 x 3 cm. Two tags are present, designating. levels one and two. The posterior surface of the breast is inked black, the. anterior blue and the axillary aspect is inked yellow. The specimen is. serially sectioned to reveal a 2.5 cm diameter mass in the lower outer. Page 3 or. quadrant and 1 cm from the deep margin. A clip is identified in the mass. The remaining breast tissue shows nodular fibroadipose tissue. The axillary. tisbue is dissected to reveal multiple lymph nodes, ranging in size from 0.5. cm to 2.5 cm. Representative sections are submitted. All dissected lymph. nodes are entirely submitted. Summary of sections: N - nipple. NB - nipple base. D - deep margin. T - tumor. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. L1 lymph nodes, level 1. L2 lymph nodes level2. 2). The specimen is received in formalin, labeled ""subscapular nodes right. axilla level one"" and consists of pink tan firm lymph nodes ranging from 0.8. to up 2 cm in greatest dimension. All identified lymph nodes are submitted. Summary of sections: LN lymph nodes. BLN- bisected lymph nodes. Summary of Sections: Part 1: SP: Right breast and axillary contents levels one and two with tags. attached. Block. Sect. Site. PCs. 1. D. 1. 6. L1. 6. 1. L2. 2. 1. LIQ. 1. 1. LOQ. 1. 2. N. 2. 1. NB. 1. 3. 3. 1. UIQ. 1. 1. UOQ. 1. Part 2: SP: Subscapular nodes, right axilla level one. Block. Sect. Site. PCs. 2. BLN. 2. 1. LN. 1. Page 4 or."
TCGA-AO-A0JM.3023C34B-CF59-43EA-9241-33B738D19B05,1,T1,"To determine the pathologic T stage of the patient's breast cancer, we will examine the report and compare it to the given rules. The key information we need is the size of the invasive tumor. We will ignore any information about lymph node involvement, as it is not relevant to the T stage. \\n1. From the report, we can see that the breast and axillary contents were removed, and a firm lesion was found in the lower inner quadrant, measuring 3 x 1.5 x 1 cm. This measurement indicates that the invasive tumor is less than 3 cm in size in its greatest dimension. \\n2. According to the rules provided, T1 includes invasive breast carcinomas that are 2 cm or less in size. Since the tumor in this case is less than 3 cm, it falls under T1. \\n3. To further classify the T1 stage, we need to consider the size more precisely. The report mentions that the tumor measures 3 x 1.5 x 1 cm. The largest dimension is 3 cm, which is still within the T1 category. \\n4. However, the rules further divide T1 into T1mi, T1a, T1b, and T1c, based on the size of the tumor. T1c includes tumors that are 1 cm but less than 2 cm in size. \\n5. In this case, the tumor measures 3 x 1.5 x 1 cm, and the largest dimension is 3 cm. However, the report does not provide enough information to determine if the other two dimensions are also 1 cm or less. Therefore, we cannot definitively classify the tumor into T1mi, T1a, T1b, or T1c. \\n6. Based on the information provided, we can conclude that the tumor is T1 (less than 2 cm in size), but we cannot further subclassify it into T1mi, T1a, T1b, or T1c.","Clinical Diagnosis & History: y/o female with right lower inner quadrant carcinoma IDC/DCIS with. microcalcifications, Right 3:00 => IDC poorly differentiated; DCIS with. microcalcification. Specimens Submitted: 1: SP: Senitnle node #1, level one, right axilla (fp). 2: SP: Sentinel node #2, level one, right axilla (fi. 3: SP: Sentinel node #3, level two, right axilla (fs. 4: SP: Right breast and axillary contents levels 1, 2 and 3. DIAGNOSIS: 1). LYMPH NODE, SENTINEL #1 LEVEL I RIGHT AXILLA; BIOPSY: METASTATIC CARCINOMA IN ONE OUT OF SIX LYMPH NODES (1/6). - THERE IS NO EXTRANODAL EXTENSION OF CARCINOMA. 2). LYMPH NODE, SENTINEL #2 LEVEL I RIGHT AXILLA; BIOPSY: - METASTATIC CARCINOMA IN ONE OF ONE LYMPH NODE (1/1) (SEE NOTE). - NO EXTRANODAL EXTENSION SEEN. NOTE: THE METASTASIS IS PRESENT ON DEEPER LEVEL PERMANENT SECTION ONLY. 3). LYMPH NODE, SENTINEL #3 LEVEL II RIGHT AXILLA; BIOPSY: - TWO BENIGN LYMPH NODES (0/2). 4). BREAST AND AXILLARY CONTENTS, RIGHT LEVELS I, II, AND III;. MASTECTOMY: - MULTIPLE FOCI OF INVASIVE DUCTAL CARCINOMA, NOS TYPE, HISTOLOGIC. GRADE III/III (SLIGHT OR NO TUBULE FORMATION) NUCLEAR GRADE III/III (MARKED. VARIATION IN SIZE AND SHAPE), RANGING IN SIZE FROM 0.1 CM UP TO 3 CM. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID, CRIBRIFORM, AND. MICROPAPILLARY TYPES WITH HIGH NUCLEAR GRADE AND MODERATE NECROSIS. - LOBULAR INVOLVEMENT BY DCIS IS PRESENT. - THE DCIS CONSTITUTES >= 25% OF THE TOTAL TUMOR MASS, AND IS PRESENT. ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN THE LOWER OUTER QUADRANT AND LOWER. INNER QUADRANT. - THE DCIS IS LOCATED IN THE LOWER OUTER QUADRANT AND LOWER INNER QUADRANT. - DCIS INVOLVES THE LARGE LACTIFEROUS DUCTS. - CALCIFICATIONS ARE PRESENT IN BOTH THE IN SITU AND INVASIVE CARCINOMA. - VASCULAR INVASION IS PRESENT. - NO INVOLVEMENT OF THE SURGICAL MARGINS BY INVASIVE CARCINOMA IS. IDENTIFIED. - RARE FOCI OF DCIS/IN SITU CARCINOMA ARE CLOSE (1 MM) TO THE FOLLOWING. SURGICAL MARGIN: DEEP. - NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE ATTACHED SKELETAL MUSCLE IS NEGATIVE FOR TUMOR. - THE NON-NEOPLASTIC BREAST TISSUE SHOWS BIOPSY SITE CHANGES. - THE LYMPH NODE STATUS IS AS FOLLOWS (EXPRESSED AS THE NUMBER OF POSITIVE. LYMPH NODES IN RELATION TO THE TOTAL NUMBER OF LYMPH NODES EXAMINED) : LEVEL. I: 0/13; LEVEL II: 0/9; AND LEVEL III: 0/2. RESULTS OF SPECIAL STAINS (ER, PR, HER2-NEU) WILL BE REPORTED AS AN. ADDENDUM. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. El .conically Signed Out. Special Studies: Special Stain. Comment. ER-C. PR-C. HER2-C. IMM RECUT. NEG CONT. Gross. MD. 1). The specimen is received fresh for frozen section consultation,. labeled ""Sentinel node number one, level 1, right axilla"" and consists of 7. lymph nodes and measure 3.5 x 2.6 x 1.0 cm in aggregate. One lymph node is. blue and has been bisected, and the lymph nodes are entirely submitted in. two cassettes. Summary of sections: FSCA- frozen section control A. FSCB--frozen section control B. 2) The specimen is received fresh for frozen section consultation,. labeled ""Sentinel node number two, level 1, left axilla"" and consists of a. soft lymph node measuring 0.6 x 0.5 x 0.5 cm, bisected and entirely. submitted for frozen section. Summary of sections: FSC-frozen section control. PA. 3). The specimen is received fresh for frozen section consultation,. labeled ""Sentinel node number three, level 2, right axilla"" and consists of. two soft tan lymph nodes totaling 2.0 x 1.2 x 0.6 cm, entirely submitted for. frozen section. Summary of sections: FSC-frozen section control. MD. 4). The specimen is received fresh in a container, labeled ""Right breast and. axillary contents levels 1, 2 and 3 with tags attached"". The specimen. consists of a mastectomy measuring 30 x 19 x 3 cm. That axillary tail. measures 13 x 8 x 2 cm. The overlying ellipse of skin measures 10 x 3 cm. No scar can be identified on the skin. The nipple measures 1 x 1 cm and it. is grossly unremarkable. The deep resection margin is inked blue. The. specimen is serially sectioned revealing a pinkish red, relatively. well-circumscribed and firm lesion measuring 3 x 1.5 x 1 cm which closely. abuts the inked resection margin. The lesion is 2 cm away from the skin. The lesion is located in the lower inner quadrant. Surrounding the lesion,. are areas of fibrosis which show punctate areas of cheesy necrosis. Away. from this lesion, in the lower outer quadrant is a vaguely defined area of. fibrosis and nodularity. Approximate measurements of this area are 10 x 6. cm. The upper inner and outer quadrants show mainly fatty tissue. An. axillary dissection is performed revealing 3 level one lymph nodes, 4 level. two lymph nodes and 2 level three lymph nodes. Summary of sections: TRM-tumor in relation to inked resection margin. TRS-tumor in relation to skin. LIQ-lower inner quadrant. LOQ-lower outer quadrant. UOQ-upper outer quadrant. UIQ-upper inner quadrant. N-nipple. L1-level one lymph nodes. L2-level two lymph nodes. L3-level three lymph nodes. Summary of Sections: Part 1: SP: Senitnle node #1, level one, right axilla (fa). Block. Sect. Site. PCs. 1. {not entered}. 1. 1. fsc. 1. Part 2: SP: Sentinel node #2, level one, right axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. Part 3: SP: Sentinel node #3, level two, right axilla (fs). Block. Sect. Site. PCs. 1. fsc. Part 4: SP: Right breast and axillary contents levels 1, 2 and 3. Block. Sect. Site. PCs. 1. 11. 1. 1. 12. 1. 1. 13. 1. 11. lig. 11. 15. log. 15. 1. n. 1. 3. trm. 3. 1. trs. 1. 1. uiq. 1. 1. uoq. 1. Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. ADDENDUM. SITE; RIGHT BREAST. PART #4. ER: 90% OF NUCLEAR STAINING WITH MODERATE INTENSITY. PR: 1% OF NUCLEAR STAINING WITH MODERATE TO WEAK INTENSITY. HER2/NEU (HERCEPTEST) : POSITIVE (STAINING INTENSITY OF 3+). MD. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. Page 5 of. 5. 1). FROZEN SECTION DIAGNOSIS: METASTATIC CARCINOMA (SLIDE B) . PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: NEGATIVE LYMPH NODE. PERMANENT DIAGNOSIS: SEE FINAL DIAGNOSIS. 3). FROZEN SECTION DIAGNOSIS: NEGATIVE LYMPH NODE. PERMANENT DIAGNOSIS: SAME."
TCGA-AO-A1KP.467172CC-6EA1-435D-BDC1-D65FBF8EA0E8,0,T2,"To determine the pathologic T stage of the patient's breast cancer, we will examine the size of the tumor and any involvement of the chest wall or skin as described in the pathology report. According to the rules provided, we will consider the largest focus of invasive carcinoma to determine the T stage. Here is the step-by-step interpretation of the report:"",""steps"":[""Step 1: Identify the size of the largest focus of invasive carcinoma. According to the report, the largest invasive carcinoma focus measures 1.8 cm (see 'BREAST, LEFTยฟ TOTAL NASTECTONY' in the DIAGNOSIS section)."",""Step 2: Check for any direct extension to the chest wall or skin. The report does not mention any direct extension to the chest wall or skin."",""Step 3: Based on the information provided, the largest focus of invasive carcinoma is 1.8 cm, and there is no direct extension to the chest wall or skin. Therefore, the patient's pathologic T stage is T2, as the tumor is more than 2 cm but not more than 5 cm in size.""]}","Clinical Diagnosis & History: y/o female with multicentric invasive CA of left breast (2 foci, at 3:00. and 5:00) For left total mastectomy, SLNB, possible ALND. Specimens Submitted: 1: SP: Sentinel node #1, level 1, lt. axilla (fs). 2: SP: Sentinel node #2, level 1, It. axilla (fs). 3 : SP: Non sentinel tissue, lt. axilla I. 4: SP: Lt. total mastectomy. DIAGNOSIS: 1). LYMPH NODE, SENTINEL #1, LEVEL I, LEFT AXILLA; EXCISION: - ONE LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA (1/1) (SEE NOTE). - THE METASTATIC FOCUS MEASURES 0.3 CM. - EXTRANODAL EXTENSION IS IDENTIFIED. NOTE: THE METASTATIC TUMOR IS NOT PRESENT ON THE FROZEN SECTION SLIDE AND. APPEARS ONLY ON THE DEEPER PERMANENT SECTION. 2). LYMPH NODE, SENTINEL #2, LEVEL I, LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODE (0/1). 3). LYMPH NODE, NON-SENTINEL TISSUE, LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODE (0/1). - BENIGN FIBROADIPOSE TISSUE. 4). BREAST, LEFTยฟ TOTAL NASTECTONY: - MULTIPLE FOCI OF INVASIVE DUCTAL CARCIMONA, NOS TYPE, HISTOLOGIC. GRADE II/III (MODERATE TUBULE FORMATION), NUCLEAR GRADE II/III (MODERATE. VARIATION IN SIZE AND SHAPE), RANGING IN SIZE FROM 0.3 CK UP TO 1.8 CM. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID AND. MICROPAPILLARY TYPES WITH. INTERMEDIATE NUCLEAR GRADE AND MODERATE. NECROSIS. - THE DCIS CONSTITUTES <= 25% OF THE TOTAL TUMOR MASS, AND IS PRESENT. ADMIXED WITH THE. INVASIVE COMPONENT. - THE INVASIVE CARCINONA IS LOCATED IN THE LOWER INNER QUADRANT AND THE. AREA BETWEEN THE. LOWER OUTER QUADRANT AND LOWER INNER QUADRANT. - NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA. IS IDENTIFIED. Criteria. CALCIFICATIONS ARE PRESENT IN BOTH THE IN SITU AND INVASIVE. CARCINOMA. - VASCULAR INVASION IS PRESENT. NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE ATTACHED SKELETAL MUSCLE IS NEGATIVE FOR TUMOR. - THE NON-NEOPLASTIC BREAST TISSUE SHOWS APOCRINE METAPLASIA AND. COLUMNAR CELL. ALTERATION. - RESULTS OF SPECIAL STAINS (ER, PR, HER2-NEU) WILL BE REPORTED AS AN. ADDENDUM. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL) AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Special Studies: Special Stain. Comment. ER-C. PR-C. HER2-C. NEG CONT. IMM RECUT. NEG-HER2. Gross Descrintion: 1). The specimen is received fresh for frozen section, labeled ""Sentinel. Node #1 Level 1 Left Axilla"". It consists of a 1 x. 1 x 0.6 cm lymph node. The lymph node is bisected and entirely frozen. Summary of Sections: FSC - frozen section control. The speciman is received fresh for frozen section, labeled ""Sentinel. Node #2 Level 1 Left Axilla"". It consists of a 1 x 0.7 x 0.6 em tan lymph. node. The lymph node is bisected and entirely frozen. Summary of Sections: FSC - frozen section control. 3). The specimen is received in formalin, labeled ""Non-sentinel Tissue. Left Axilla"". It consists of two fragments of adipose tissue measuring 1.5. x. 1 x 0.5 cm and 3 x 1.5 x 1 cm. Two possible tan lymph nodes measuring 0.2. and 0.8 am in greatest dimension are identified. The specimen is entirely. submitted. Summary of Sections: LN - lymph node. BLN - bisected lymph node. F remainder of fat. 4). The specimen is received fresh, labeled ""Left Total Mastectomy. (stitch marks axillary aspect) It consists of a breast measuring 28 x 27. x 4.5 em and weighing 1,750 grams. A suture designates the axillary aspect. of the spacimen. Identified on the anterior surface is a light tan skin. ellipse measuring 24 x 12 cm. No scars are identified on the epidermal. surface. A grossly unremarkable nipple measuring 0.7 x 0.5 x 0.3 cm is. identified. The entire deep resection margin is inked. Identified on the. deep aspect is a 6 x 2.5 x 2 cm defect near the axillary aspect of the. specimen. Serial sections through the specimen reveal two distinct tumor. masses in the lower inner quadrant and one separate tumor mass between the. lower inner and lower outer quadrants. The two masses in the lower inner. quadrant are fairly well-circumscribed. firm, spiculated with focal areas of. necrosis and measure 2 x 1 x 1 cm and 1.3 x 1 x 1 cm. The larger tumor mass. is at a distance of 4 em from the closest deep resection margin and 2 cm. from the closest superficial resection margin, The smaller tumor mass in. the lower inner quadrant is at a distance of 5 cm from the closest deep. resection margin and 4 cm from the closest anterior resection margin. The. tumor mass located between the lower inner and lower outer quadrants is. well-circumseribed, firm, tan and measures 0.7 x 0.5 x 0.5 en and in located. at a distance of 5 em from the closest deep resection margin. The remainder. of the parenchyma is comprised of approximately 5% tan-white fibrous tissue. and 95% yellow-tan adipose tissue. A portion of the largest tumor is. submitted for TPS studies. The tumors are entirely submitted. Representative sections from the remainder of the specimen are submitted. Summary of Sections: N nipple. S skin. TL larger tumor in the lower inner quadrant. TS smaller tumor in the lower inner quadrant. DL deep margin closest to larger tumor. AL anterior margin closest to larger tumor. DS deep margin closest to smaller lower inner quadrant tumor. AS anterior margin closest to smaller lower inner quadrant tumor. TIO tumor between lower inner and lower outer quadrant. D deep margin closest to tumor between lower inner and lower outer. quadrants. AM - anterior margin closest to tumor between lower inner and lower outer. quadrants. UOQ - upper outer quadrant. LOQ - lower outer quadrant. UIQ - upper inner quadrant. LIQ - lower inner quadrant. Summary of Sections: Part 1: SP: Sentinel node #1, level 1, lt. axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. Part 2: SP: Sentinel node #2, level 1, lt. axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. Part 3: SP: Non sentinel tissue, lt. axilla. Block. Sect. Site. PCs. 1. BLN. 2. 2. F. 4. 1. LN. Part 4: SP: Lt. total mastectomy. Block. Sect. Site. PCs. AL. 1. 1. AM. 1. 1. AS. 1. 1. D. 1. DL. 1. 1. DS. 1. 2. LIQ. 2. 2. LOQ. 2. 1. N. 4. 1. S. 1. TIO. 12. 4. TL. 4. 2. TS. 2. 2. UIQ. 2. 2. UOQ. 2. Procedures/Addenda: Addendum. Date Complete: Addendum Diagnosis. ADDENDUM. SITE: BREAST, LEFT, TOTAL MASTECTOMY. PART #4. ER: POSITIVE (ABOUT 80% OF NUCLEAR STAINING WITH STRONG INTENSITY) . PR: POSITIVE (ABOUT 40% OF NUCLEAR STAINING WITH STRONG INTENSITY). HER2/NEU (HERCEPTEST) : NEGATIVE (STAINING INTENSITY OF 1+). Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the. issue sample examined at the time of the intraoperative. consultation. 1). FROZEN SECTION DIAGNOSIS: BENIGN. PERMANENT DIAGNOSIS: SEE FINAL DIAGNOSIS. 2). FROZEN SECTION DIAGNOSIS: BENIGN. PERMANENT DIAGNOSIS: SAME."
TCGA-AQ-A0Y5.5BC01981-366E-44EC-A986-087DB7904E5C,1,T1c,"[{""step"":1,""description"":""Examining the report, we see that the patient underwent a mastectomy of the right breast. The tumor size (greatest dimension) is given as 2.4 cm."",""conclusion"":""The tumor size is within the range of T1 (2 cm or less), but it is necessary to check the subcategories.""},{""step"":2,""description"":""The report mentions that the tumor size is 2.4 cm, and it falls under T1c (1 cm but less than 2 cm in size) subcategory."",""conclusion"":""The T stage is T1c.""}]","Diagnosis: A: Sentinel lymph node #1, right axillary, excision. - Positive for metastatic adenocarcinoma in one of four lymph nodes (1/4). - Size of metastasis: 0.6 cm. - Extracapsular extension: Present, extensive. - Intraoperative diagnosis confirmed. B: Sentinel lymph node #2, right axillary, excision. - Positive for metastatic adenocarcinoma in one lymph node (1/1) (metastatic focus present on. frozen slide only). - Size of metastasis: 0.1 cm. - Extracapsular extension: Not identified. - Intraoperative diagnosis confirmed. C: Non-sentinel lymph node, right axillary, excision. - Positive for metastatic adenocarcinoma in one lymph node (1/1). - Size of metastasis: 0.6. - Extracapsular extension: Present, extensive. - Intraoperative diagnosis confirmed. D: Sentinel lymph node #3, right axillary, excision. - Positive for metastatic adenocarcinoma in one lymph node (1/1). - Size of metastasis: 0.2. - Extracapsular extension: Not identified. - Intraoperative diagnosis confirmed. E: Breast, right, mastectomy. Tumor type: Invasive ductal carcinoma. Nottingham combined histologic grade: 3. Tubule formation score: 3. Nuclear pleomorphism score: 3. Mitotic count score: 3. Focality of tumor: Unifocal. Tumor size (greatest dimension): 2.4 cm (gross measurement). Tumor location: Outer half (at interface between upper outer and lower outer quadrants). Lymphovascular invasion: Not identified. Perineural invasion. Present. In Situ Component: Present, ductal carcinoma in situ. In Situ Component type/Architecture pattern: Ductal carcinoma in situ, solid and comedo types. In Situ Component nuclear grade: 2-3. In Situ Component necrosis: Present. In Situ Component extent/size: DCIS present admixed with invasive ductal carcinoma, comprising. approximately 5% of the total tumor volume. Extensive intraductal component: Absent. Nipple/skin involvement: Not identified. Margin status: Invasive component: Negative; closest posterior margin 0.4 cm; all other margins more than 1.5. cm away. In Situ component: Negative; more than 1.0 cm away from all margins. Right axillary lymph nodes (none present in this specimen, but the total number includes. specimens A-D and F): Total number with metastasis: 5. Total number examined: 17 (5/17). Size of largest metastasis: 0.6 cm. Extracapsular extension: Present, extensive. Microcalcifications: Present, associated with invasive ductal carcinoma. Other findings: Fibrocystic changes. AJCC PATHOLOGIC TNM STAGE: pT2 pN2a. Note: This pathologic stage assessment is based on information available at the time of this. report, and is subject to change pending clinical review and additional information. F: Lymph nodes, right axillary, lymphadenectomy. - Positive for metastatic adenocarcinoma in 1 of 10 lymph nodes (1/10). - Size of metastasis: 0.1 cm. - Extracapsular extension: Not identified. Comment: For the results of immunohistochemical stains for ER, PR and Her2/neu, please. refer to the addendum report of the prior specimen. Intraoperative Consult Diagnosis: Frozen section was requested. FSA1/FSA2: Right axillary sentinel lymph node #1. - Metastatic carcinoma in one lymph node (1/2); Dr agrees. FSB1: Right axillary sentinel lymph node #2. - Metastatic carcinoma in one lymph node (1/1); Dr agrees. FSC1: Right axillary non-sentinel lymph node. - Metastatic carcinoma in one lymph node (1/1). FSD1: Right axillary sentinel lymph node #3. - At least micrometastatic carcinoma in one lymph node. Frozen Section Pathologist: Clinical History: invasive ductal Ca, right breast, Grade 2. Gross Description: Received are six appropriately labeled containers. Container A: Received fresh for frozen section is a 3 X 3 X 2 cm aggregate of multiple tan lymph. node candidates and adipose tissue. Two larger lymph nodes were isolated, sectioned and frozen. as FSA1 and FSA2. Further examination of the adipose tissue finds four additional lymph node candidates from 5 x 5. x 3 mm to 7 x 4 X 4 mm. All lymph node candidates are submitted as is in block A1. Fibrofatty. tissue is retained in formalin. Container B: Received fresh for frozen section is a 1.5 x 1.0 x 0.5 cm fragment of yellow fibrofatty. tissue within which one lymph node candidate was identified at the time of frozen section. The. lymph node was serially sectioned and was frozen as FSB1. Fibrofatty tissue is retained in. formalin. Container C: Received fresh for frozen section is a 1.0 x 0.5 x 0.5 cm fragment of pink/yellow. fibrofatty lymphoid tissue. The fragment was frozen as FSC1, NTR. Container D: Received fresh for frozen section is a 1 X 1 X 0.5 cm fragment of yellow lobulated. fibrofatty fymphoid tissue. The fragment was serially sectioned, was frozen as FSD1, NTR. Container E: Specimen fixation: formalin. Time in fixative: approximately 8 hours, 45 mins. Type of mastectomy: unspecified. Size of specimen: 880 grams; 22 cm medial to lateral x 25.5 cm superior to inferior x 4 cm. anterior to posterior. Orientation of specimen: Per the specimen requisition, a short stitch indicates superior and a long. stitch indicates lateral. At the time of Tissue Procurement triage, the specimen is inked as follows: anterior=blue,. posterior=black, and lateral=yellow. Skin ellipse dimensions: 18.0 X 13.5 cm; The lightly pigmented skin ellipse is remarkable for some. blue sentinel dye discoloration lateral and slightly inferior to the nipple. Nipple/areola: Nipple: 1.0 cm. Areola: 2.7 cm. The structures are unremarkable. Axillary tail: There is no well delineated axillary tail. The lateral most breast tissue is sectioned,. however, no lymph node candidates are identified. Biopsy site: absent. Residual tumor: present, A 2.4 X 2.0 X 1.9 cm firm white mass with a somewhat gritty cut surface. and stellate borders is identified. This mass has no hemorrhagic areas or necrotic areas readily. identified. Location of tumor: roughly located in the midline between the upper outer quadrant and the lower. outer quadrant. Distance of mass/biopsy site from surgical margin: The mass is focally 6 mm to the black inked. posterior margin, 1.5 cm to the skin (anterior margin), 9 cm to the inferior margin, 11 cm to the. superior margin, at least 4.5 cm to the lateral margin and distant (at least 14 cm) to the medial. margin. Gross involvement of skin or fascia/muscle by tumor: absent. Description of remainder of breast: The remainder of the mastectomy specimen consists of yellow. lobulated fibroadipose tissue separated by thin fibrous septae. Much of the breast consists of. dense white fibrous breast tissue. The breast tissue medial to the mass is intensely stained with a. blue dye. There are some areas within this firm breast tissue which are firmer than others. Other remarkable features: On the superior edge of the tumor a small metal radiographic marker. is identified. Tissue submitted for special investigations: Tumor and normal was taken by Tissue Procurement. Digital photograph taken: no. Block Summary: (Inking: anterior=blue, posterior=black, lateral=yellow). E1 - nipple. E2 - mass and closest black inked deep margin, perpendicular sections. E3 - perpendicular sections to closest skin margin (no tumor represented). E4-E8 - additional tumor (E7,E8 one slice, bisected). E9-E10 - breast tissue immediately surrounding mass. E11 - inner upper quadrant. E12 - inner lower quadrant. E13 - outer upper quadrant. E14 - outer lower quadrant. E15-E16 - lateral breast tissue. Container F is additionally labeled ""right axillary contents."" It holds a 12 x 9.5 x 3.0 cm aggregate. of multiple fragments of yellow lobulated fibroadipose tissue which are palpated for lymph node. candidates. Multiple lymph node candidates from 4x4x3 mm to 1.4 x 1.0 x 0.6 cm are. identified. Block summary;. F1 - five lymph node candidates. F2 - two lymph node candidates. F3 - one lymph node candidate, serially sectioned. F4 - one lymph node candidate, sectioned. F5 - one lymph node candidate, sectioned. F6-F7 - one lymph node candidate, sectioned. F8 - one lymph node candidate, sectioned. F9 - one lymph node candidate, sectioned. Light Microscopy: Light microscopic examination is performed. I have personally conducted the evaluation of the above specimens and have. rendered the above diagnosis(es)."
TCGA-AR-A0TQ.6061FCA5-A113-4985-905D-E17020F6933E,2,T4,"[The pathologic T stage is determined by the size of the tumor in the breast.] The report states that the patient underwent a right simple mastectomy and the pathology revealed 'infiltrating ductal carcinoma, Nottingham grade III (of III) [tubules. 3/3, nuclei 3/3, mitoses 2/3; Nottingham score 8/9], forming a single mass (7.2 x 4.5 x 3.4 cm) located in. the upper inner and upper central quadrant of the breast [AJCC pT2].' The size of the tumor is 7.2 cm in the greatest dimension. According to the rules provided, T2 includes invasive breast carcinomas that are more than 2 cm but not more than 5 cm in size. Since the tumor size is 7.2 cm, which is greater than 5 cm, this tumor does not meet the criteria for T1 or T2. The report also states that there is no direct extension to the chest wall or skin. Therefore, the tumor does not meet the criteria for T3. However, the tumor size is greater than 5 cm and it is an invasive breast carcinoma, so it meets the criteria for T4. But, there is no mention of ulceration, satellite nodules, or inflammatory carcinoma in the report. Therefore, the patient's pathologic T stage is T4, but without any substaging information (T4N0M0).","Breast, right, simple mastectomy: Infiltrating ductal carcinoma, Nottingham grade III (of III) [tubules. 3/3, nuclei 3/3, mitoses 2/3; Nottingham score 8/9], forming a single mass (7.2 x 4.5 x 3.4 cm) located in. the upper inner and upper central quadrant of the breast [AJCC pT2]. Angiolymphatic invasion is absent. The non-neoplastic breast parenchyma shows nonproliferative fibrocystic changes. Calcifications are. present in malignant ducts. Biopsy site changes are present. All surgical resection margins, including the. deep margin, are negative for tumor (minimum tumor free margin, 7.0 cm, deep margin). Breast, right, supranumerary nipple excision: Intradermal nevus (0.6 cm in greatest dimension). Lymph nodes, right axillary, dissection: Multiple (2 of 9) right axillary lymph nodes are positive for. metastatic carcinoma. The largest lymph node measures 1.4 cm. No extranodal extension identified. Lymph nodes, highest right axillary, dissection: Multiple (6) highest right axillary lymph nodes are. negative for tumor. Breast, left, simple mastectomy: Nonproliferative fibrocystic changes. Her-2/NEU has been ordered on paraffin-embedded tissue."
TCGA-AR-A0TW.F832C787-3668-475F-8F67-6342DA3777F4,2,T4,"The report mentions a largest tumor with a greatest dimension of 5.5 cm. According to rule 2, T2 includes invasive breast carcinomas that are more than 2 cm but not more than 5 cm in size. However, the largest tumor in this report is larger than 5 cm, which means it does not meet the criteria for T2. The report also does not mention any direct extension to the chest wall or skin, which would be required for a T3 classification. Therefore, we can eliminate T1, T2, and T3. The report mentions that there are multiple additional tumors, but it does not provide enough information about these tumors to include them in the T stage determination. Based on the information provided, the largest tumor is a T4 because it has a greatest dimension of more than 5 cm without any mention of direct extension to the chest wall or skin, ulceration, satellite nodules, or inflammatory carcinoma. However, it is important to note that a healthcare professional would need to consider other factors, such as clinical examination and imaging studies, to make a final determination of the T stage.","Breast, right, modified radical mastectomy: Multifocal ductal carcinoma of the breast. The largest tumor. is a Nottingham grade III (of III) ductal adenocarcinoma (5.5 cm in greatest dimension). There are. multiple (3) additional tumors (all Nottingham grade II (of III) 2.0 cm 1.5 cm, and 1.0 cm in greatest. dimension. The surgical margins are negative. Metastatic adenocarcinoma is identified in multiple (3 of. 27) right axillary lymph nodes. The largest node of metastasis measures 3.5 cm in greatest dimension. No definite extracapsular extension is identified. Breast, left, simple mastectomy: Nonproliferative fibrocystic changes characterized by dense fibrosis,. cyst formation, and fibroadenomatous change. Nipples, left and right, excision: Negative for malignancy."
TCGA-AR-A24H.C373F2EE-C601-4E17-8E2D-D9BC6AC0301A,1,T1,"Based on the pathology report, the patient has invasive lobular carcinoma in the right breast, with a largest dimension of 2.8 x 2.6 x 6 x 2 cm. The report also mentions that there is no lymphovascular involvement or carcinoma in situ component identified, and the surgical resection margins are negative for tumor. The largest dimension of the tumor is used to determine the T stage, and in this case, it is less than 2 cm (2.8 cm to be exact). Therefore, the T stage is T1. The T1 stage can be further divided based on the size of the tumor, but the report does not provide enough information to determine the exact T1 subcategory (mi, a, b, or c).","Final Diagnosis. Breast, right, excision: Invasive lobular carcinoma, Nottingham II (of. III), forming a 2.8 x 2.6 6 x 2 cm mass (AJCCpt2) No lymphovascular. involvement or carcinoma in situ component is identified. The surgical. resection margins, after one re-excision are negative for tumor. The. uninvolved breast tissue shows duct ectasia and stromal fibrosis. Lymph node, right axilla, sentinel, excision: A single right sentinel. lymph node is negative for tumor. Lymph nodes, right axilla, excision: Multiple (3) right axillary lymph. nodes are negative for tumor. Staining for estrogen and progesterone receptors is positive."
TCGA-AR-A5QQ.511282C5-02AC-4105-8B52-5BBEC8B45D22,2,T4,"[Step 1: Identify the size of the tumor] The report states that the size of the tumor is 5.2 x 5.0 x 4.7 cm.  [Step 2: Compare the size to the T stage criteria] According to rule 2, T2 includes invasive breast carcinomas that are more than 2 cm but not more than 5 cm in size. The tumor size in the report (5.2 x 5.0 x 4.7 cm) falls within this range. [Step 3: Check for any additional T stage criteria] The report also states that the tumor has skin ulceration and has involved the skin and nipple areolar region. This meets the criteria for T4b, which includes invasive breast carcinomas that have spread to the skin resulting in ulceration. [Step 4: Compare the findings to the original T stage criteria] Even though the tumor size meets the criteria for T2, the additional finding of skin ulceration and involvement of the skin and nipple areolar region places the tumor in a higher T stage (T4b).","A. Breast, right, simple mastectomy: Moderately differentiated squamous carcinoma. (metaplastic carcinoma) involving the mammary parenchyma forming a 5.2 x 5.0 x 4.7 cm mass. located in the central aspect of the breast with skin ulceration. Angiolymphatic invasion is. present. The surrounding breast parenchyma shows nonproliferative fibrocystic changes. A single. (of 3) intramammary lymph node is positive for metastatic carcinoma forming a solid and cystic. mass (6.5 x 5.0 x 4.7 cm) located in the lateral aspect of the breast. Extranodal extension is. present. The skin and nipple areolar region is involved by tumor. All surgical resection margins,. including skin and deep margins, are negative for tumor (minimum tumor free margin, 1.7 cm,. deep margin). Estrogen receptor, progesterone receptor, and HER2 will be performed and reported in an. addendum. B. Lymph nodes, right axillary, excision: Multiple (21) lymph nodes are negative for metastatic. carcinoma. With available surgical materials, [AJCC pT3N1] (7th edition, 2010)."
TCGA-B6-A0I1.1E498731-FE74-493E-A330-477643800305,1,T1c,"The report states that the size of the invasive component is 3.5 x 2 x 2 cm. According to the rules provided, this would fall under T1c, as the size of the tumor is between 1 cm and 2 cm. Therefore, the pathologic T stage of the patient's breast cancer is T1c.","Patient:4. Surgical Pathology: Additional Info. CLINICAL HISTORY: Left breast carcinoma. GROSS EXAMINATION: A. ""Left breast tissue 3.5 x 2 x 2 AF1"", received fresh. A previously. incised unoriented 5.4 x 4.8 x 3.5 cm portion of yellow-white fibrofatty. tissue. There is a 3.5 x 2 x 2 cm firm variegated yellow-gray sabulous mass. focally abutting the margin. Representative tissue from the mass is frozen as. AF1, the remnant is submitted as A1. The majority of the remainder of the. mass is submitted as A2-A5. B. ""Left breast"", received fresh. A 10360 gram 33 x 21 x 5. 5 cm mastectomy. composed of a 29 x 16.3 cm ellipse of tan brown skin with underlying 28 x 21. x. 5.5 cm of fibrofatty breast tissue and contiguous 9.0 x 5.8 x 2.4 cm of. axillary contents. There is a central 5.5 cm areolar with a central everted. 1.3 cm nipple. 6 cm lateral to the edge of the areolar is an 8 cm freshly. sutured incision. The surgical margin is marked with blue ink and the. specimen is sectioned to reveal an approximately 6 cm diameter cavity 0.6 cm. subjacent to the previously described skin incision. The cavity is within 1.4. cm of the deep margin and 3 cm from the closest soft tissue margin. (inferior) The biopsy cavity is in the outer half of the specimen and has. slightly indurated borders but no residual tumor grossly appreciated. The. remainder of the breast parenchyma is composed primarily of yellow adipose. tissue intermixed with focal dense pink fibroconnective tissue and no. additional lesions noted. Block Summary: B1 - Nipple. B2 - Edge of incision and underlying cavity. B3 - Cavity in relationship to deep margin. B4 - Representative of closest soft tissue margin (inferior) . B5- Representative random cavity wall. B7 - Random lower outer quadrant. B8 Random upper outer quadrant. B9 - Representative central parenchyma. B10 - Lower inner quadrant. B11 - Upper inner quadrant. B12 - One lymph node candidate, proximal. B13 - Four lymph node candidates, mid. B14 - One bisected lymph node candidate, mid. B15-17 Largest section of lymph node candidate, mid (4.7 x 2.4 x 0.9 cm. B18 - Two lymph node candidates, distal. INTRA OPERATIVE CONSULTATION: A. ""Left breast tissue"": AF1 - invasive carcinoma present. DIAGNOSIS: A. ""LEFT BREAST TISSUE"" (EXCISIONAL BIOPSY) : INFILTRATING CARCINOMA PRESENT, HISTOLOGIC TYPE. DUCTAL. N.S.A.B.P. NUCLEAR GRADE 3 OF 3. N.S.A.B.P HISTOLOGIC GRADE 3 OF 3. GROSS TUMOR SIZE: 3.5 x 2 x 2 CM. SIZE OF INVASIVE COMPONENT: 3.5 X 2 x 2 CM. LYMPHATIC/VASCULAR INVASION: ABSENT. MULTIFOCAL TUMOR: ABSENT. 1 of 2. IN-SITU CARCINOMA: PRESENT, OCCUPYING 50% OF TUMOR (SEE COMMENT). TYPE OF IN-SITU CARCINOMA: COMEDO, MICROPAPILLARY. SIZE OF IN-SITU CARCINOMA: APPROXIMATELY SIZE OF BIOPSY (5.4 CM) . EXTENSIVE INTRADUCTAL COMPONENT: PRESENT. STATUS OF NON-NEOPLASTIC BREAST TISSUE: NOT APPLICABLE. SIZE OF BIOPSY: 5.4 x 4.8 x 3.5 CM. MICROCALCIFICATIONS: FOCALLY PRESENT. SURGICAL MARGIN STATUS: NOT EVALUATED. ESTROGEN/PROGESTERONE RECEPTOR AND CELL CYCLE ANALYSIS: PENDING. METHODOLOGY: IMMUNOHISTOCHEMISTRY, PARAFFIN BLOCK A4. RESULTS WILL BE ISSUED IN AN ADDENDUM. COMMENT: The tumor mass is a complex admixture of invasive and in-situ. carcinoma. The exact percentage of invasive carcinoma is difficult to. determine with certainty, but is estimated at approximately 50%. B. ""LEFT BREAST (MODIFIED RADICAL MASTECTOMY) : RESIDUAL INFILTRATING CARCINOMA ABSENT. RESIDUAL IN SITU CARCINOMA PRESENT. TYPE OF IN-SITU CARCINOMA MICROPAPILLARY. SIZE OF IN-SITU CARCINOMA: SEE COMMENT, EXTENSIVE. NIPPLE STATUS, FREE OF TUMOR. SKIN STATUS, FREE OF TUMOR. MUSCLE STATUS, NOT SAMPLED. STATUS OF NON-NEOPLASTIC BREAST TISSUE: FIBROCYSTIC CHANGES. SURGICAL MARGIN STATUS: NEGATIVE. LYMPH NODE STATUS: SEVEN LYMPH NODES, NO EVIDENCE OF MALIGNANCY (0/7). COMMENT: Random sections around the biopsy site show foci of residual in-situ. carcinoma. In addition, a random section in the central breast several cm. away from the biopsy site is also positive for in-situ carcinoma, indicating a. rather large area involved by residual in-situ disease. The margins of. resection are negative, however. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es). ADDENDUM 1: Tissue was sent to the image cytometry laboratory for assay of the estrogen. and progesterone receptors. The estrogen receptor activity was judged to be. negative with an estimated FMOL value of 0. The progesterone receptor activity. was judged as negative with an estimated FMOL value of 0. Please refer to. For a complete report. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es). 2 of 2."
TCGA-B6-A0I5.FA43414D-3757-43CC-8949-77F82DF4FA4D,1,Cannot determine based on the provided information.,"Based on the pathology report, the patient is diagnosed with 'infiltrating ductal carcinoma, grade 2/3, nuclear grade moderately differentiated, the tumor extends to within 0.1mm of the surgical margin' in the right breast. The key information for T staging is the size of the tumor. However, the report does not provide a specific measurement of the tumor size in centimeters. Therefore, it is not possible to assign a definitive T stage based solely on this report.  \n\nHowever, the report does mention that the tumor extends to within 0.1mm of the surgical margin, which suggests that the tumor is very small, possibly less than 0.5 cm (T1a). But without a clear measurement, we cannot be certain. Therefore, the T stage for this patient should be determined by a healthcare professional using additional information from clinical examination, imaging studies, and other pathological findings.","Sex: F. Date of Birth: ars. Not for patient's chart. DIAGNOSIS. ORIGINAL TEXT: FEMALE BREAST, RIGHT. RIGHT BREAST MASS; MULTIFOCAL INTRADUCTAL AND INFILTRATING. DUCTAL CARCINOMA, GRADE 2/3, NUCLEAR GRADE MODERATELY. DIFFERENTIATED, THE TUMOR EXTENDS TO WITHIN 0.1MM OF THE. SURGICAL MARGIN. ORIGINAL VER ID. AT 00:00 BY."
TCGA-B6-A0RT.64D53A4B-4735-4AD2-A413-520797F5F9CB,2,T2,"The report provides the gross tumor size in two different specimens, the incisional breast biopsy and the modified mastectomy. The incisional breast biopsy shows a gross tumor size of 3.5 x 1.7 x 2.1 cm, while the modified mastectomy shows a gross tumor size of at least 6.0 cm. In determining the T stage, we should consider the largest tumor size, which is found in the modified mastectomy specimen. Therefore, the patient's breast cancer is T2 or larger. However, the report does not indicate any direct extension to the chest wall or skin, or any spread to the chest wall and/or skin resulting in ulceration, satellite nodules, or inflammatory carcinoma. Therefore, we can exclude T3 and T4 stages. Based on the rules provided, the patient's breast cancer is classified as T2.","ourgie. CLINICAL HISTORY: year old female with breast cancer. GROSS EXAMINATION: A. ""Right breast biopsy"". received fresh and fixed in formalin. An unoriented,. 6.5 x 5.5 x 2.5 cm incisional breast biopsy received cross-sectioned. One. surface of the specimen has previously been inked black, and a frozen section. has been taken from this area. Grossly, the tumor is present at the ink. Serial sectioning reveals an irregular, whitish, infiltrative tumor 3.5 x 1.7. x 2.1 cm in greatest dimension, with focal petechia hemorrhage. A 0.3 cm area. of yellowish gritty texture in the center of the tumor is suspicious of. calcification. There is no gross tumor necrosis. A separate, 0.3 cm well. defined, yellowish nodule is located approximately 0.5 cm from the main. tumor. The specimen is inked and serially sectioned every 0.5 cm. Representative sections are submitted. BLOCK SUMMARY: A1- - remnants of AF1. 2.7 x 1.6 x 0.3 cm soft tissue fragment. A2-A13- serial sections of the specimen every 0.5 cm, of which: A7- tumor including the calcification,. A8- section adjacent to AF1,. A9- 0.3 cm nodule,. A13-normal appearing breast. B. ""Right breast"", received fresh and fixed in formalin. A modified right. mastectomy 21.1 x 15.2 x 3.5 cm, a skin ellipse 14.2 x 7.1 cm, and axillary. tail 7.5 x 6 x 2 cm. A fresh, horizontal 5 cm incision line is located. superior lateral to the nipple, 1.5 cm below the superior skin resection. margin. The skin surface is smooth with no discoloration, gross mass, or. nipple retraction. The specimen is serially sectioned to reveal a biopsy. cavity 6.5 x 5.5 x 2 cm, which corresponds to the size of the previous biopsy. specimen. The superior wall of the cavity appears to contain a 2.5 x 1.5 x 2. cm residual tumor which has a similar cut surface and texture to that in the. biopsy specimen. The residual tumor is located approximately 1.5 cm from the. closest deep resection margin, and over 4 cm from the superior margin. The. biopsy cavity is otherwise 3 cm from the inferior margin, 4.9 cm from the. superior margin, 1 cm from the deep margin, 4.5 cm from the medial margin, 2.5. cm from the lateral margin, and 1 cm from the skin. The deep resection margin. is inked in blue, superior margin in black, and inferior margin in red. The. axillary tail is dissected for lymph nodes. Multiple lymph node candidates are. found, the largest measuring 1.5 x 1.3 x 1.0 cm. Representative sections of. the breast and lymph nodes are submitted. BLOCK SUMMARY: B1- inner upper quadrant. B2- inner lower quadrant. B3- outer upper quadrant. B4- outer lower quadrant. B5- nipple. B6- skin with incision. B7-B8- tumor in biopsy cavity and the closest deep resection margin. B9- biopsy cavity (superior wall). B10- biopsy cavity (inferior wall) . B11-B17- axillary lymph node candidates. B18- low axillary tail. INTRA OPERATIVE CONSULTATION: A. ""Right breast"": Af1- adenocarcinoma extending to inked margin. DIAGNOSIS: A. ""RIGHT BREAST"" (BIOPSY) : INFILTRATING ADENOCARCINOMA OF DUCTAL TYPE, NOT OTHERWISE SPECIFIED. N.S.A.B.P. HISTOLOGIC GRADE, 3 OF 3. N.S.A.B.P. NUCLEAR GRADE, 2 TO 3 OF 3. GROSS TUMOR SIZE IS 3.5 X 2.2 X 1.7 CM. INVASIVE TUMOR SIZE IS 3.5 CM. IN SITU CARCINOMA OF COMEDO TYPE IS PRESENT, OCCUPYING LESS THAN 10% OF. TUMOR. NO EXTENSIVE INTRADUCTAL CARCINOMA OR MULTIFOCAL TUMOR IS PRESENT. NON-NEOPLASTIC BREAST TISSUE SHOWS DUCTAL ECTASIA, FIBROSIS, AND MICROCYST. FORMATION. LYMPHATIC/VASCULAR INVASION IS PRESENT (A9). CARCINOMA EXTENDS TO SURGICAL MARGIN MULTIFOCALLY. ESTROGEN/PROGESTERONE AND CELL CYCLE ANALYSIS IS PENDING. METHODOLOGY: FRESH TISSUE. B. ""RIGHT BREAST"" (MODIFIED MASTECTOMY) : INFILTRATING ADENOCARCINOMA OF DUCTAL TYPE, NOT OTHERWISE SPECIFIED. N.S.A.B.P. HISTOLOGIC GRADE, 3 OF 3. N. S.A.B. NUCLEAR GRADE, 3 OF 3. GROSS TUMOR SIZE IS AT LEAST 6.0 CM. INVASIVE TUMOR SIZE IS 6.0 CM. CARCINOMA IS LOCATED IN THE UPPER-OUTER QUADRANT. IN SITU CARCINOMA OF COMEDO TYPE: SEE SPECIMEN ""A"". MULTIFOCAL TUMOR IS NOT PRESENT. NON-NEOPLASTIC BREAST TISSUE SHOWS DUCTAL ECTASIA, FIBROSIS, AND MICROCYST. FORMATION. LYMPHATIC/VASCULAR INVASION PRESENT. CARCINOMA IS FOCALLY TO WITHIN 0.7 CM OF THE DEEP SURGICAL MARGIN (A7). NIPPLE SHOWS NO INVOLVEMENT BY PAGET'S DISEASE. SKIN IS NOT INVOLVED BY CARCINOMA. ONE OF 23 LYMPH NODES POSITIVE FOR CARCINOMA (1/23) . ESTROGEN/PROGESTERONE AND CELL CYCLE ANALYSIS PENDING. RESULTS WILL BE. ISSUED IN AN ADDENDUM. METHODOLOGY: FRESH TISSUE. ADDENDUM 1: Tissue was sent to the. for assay of the Estrogen. and Progesterone receptors. The Estrogen receptor activity was judged as. negative with an estimated fmol valve of 0. The Progesterone receptor activity. was judged as negative with an estimated fmol of valve of 0. The. proliferation index was estimated to be high with a PI of 70%. Please refer. to. for a complete report. 2 of 2."
TCGA-B6-A0X5.29811BAC-AFD1-4951-BDF8-7B859941B634,1,T1c,"[The largest focus of invasive carcinoma in the breast is 1.5 x 1.5 x 1 cm (Block B2-B5). This measurement is less than 2 cm in size. There is no direct extension to the chest wall or skin. Therefore, the T stage is T1. However, since the exact size of the tumor is between 1 cm and 2 cm, the T1 subcategory is T1c. The final T stage is T1c.]"",""answer"":""T1c""}","Curgical Pathology: Final. CLINICAL HISTORY: Large left breast CA with microcalcification diffusely around invasive tumor. Suggests diffuse intraductal carcinoma. GROSS EXAMINATION: A. ""Left breast mass (Af1)' "". Received is a breast biopsy specimen and frozen. section remnant. The breast tissue measures 5.0 x 4.0 x 3.5 cm. The surgeon. states that the margin is not important, thus the specimen is not inked. Sectioning of the specimen reveals a red-brown nodule measuring 3.0 x 2.5 x. 1.5 cm. Tissue from the nodule has been sent for ER/PR study. A remnant of. frozen section of the red-brown tissue measuring 1.7 x 1.3 x 0.3 cm is. submitted in toto in Block A1, with representative sections of the nodule. submitted in Blocks A2-A4. B. ""Left breast"", fresh. An 18 x 25 x 6 cm breast mastectomy specimen with a. 23 x 14 cm skin ellipse and a 12 x 9.5 cm axillary tail. The skin ellipse is notable for a grossly unremarkable nipple and areola and a. 5.5 cm recently dehised biopsy scar located in the lower medial portion of the. ellipse. The deep surface of the breast specimen is inked in black. Cut sectioning. through the breast reveals a 5 x 4 x 4 cm hollow biopsy cavity in the lower. medial quadrant which is lined by smooth white tissue in its cavity. The. cavity comes to within 0.5 cm of the inked distal surface, 0.8 cm from the. inked posterior surface, and 12 cm from the inked proximal surface. There is. a focal 1.5 x 1.5 x 1 cm firm, finely granular, grey-pink lesion located. adjacent to the lateral tip of the biopsy cavity. This lesion is, at its. closest points, 1.5 cm from the distal inked surface, 4 cm from the posterior. inked surface, 4 cm from the posterior inked surface, 11 cm from the proximal. inked surface, and 2 cm beneath the anterior skin surface. The remainder of. breast specimen is comprised of yellow-white fibrofatty tissue with an. especially prominent white fibrous focus in the upper midportion of breast. parenchyma. BLOCK SUMMARY: B1 representative section of nipple. B2-B5 tissue around biopsy cavity site which includes firm lesion described. above. B6-B7 representative sections from focal white fibrous area in upper. mid-portion of breast. B8-B9 representative sections of upper medial portion of breast. B10-B11 representative sections of lower medial portion of breast. B12-B13 representative sections of upper lateral portion of breast. B14-B15 representative sections of lower lateral portion of breast. B16 three lymph node candidates from intermediate portion of axillary tail. B17 four lymph node candidates from intermediate portion of axillary tail. B18 five lymph node candidates from most lateral portion of axillary tail. B19 four lymph node candidates from most lateral portion of axillary tail. B20 three lymph node candidates from most lateral portion of axillary tail. Dr. INTRA OPERATIVE CONSULTATION: Af1: ""Left breast mass"": Infiltrating carcinoma present. DIAGNOSIS: A. ""LEFT BREAST MASS"": 1 of 2. BREAST WITH INFILTRATING DUCTAL CARCINOMA (3 X 2.5 X 1.5 CM), NUCLEAR. GRADE WELL-DIFFERENTIATED, N.S.A.B.P. HISTOLOGY GRADE 1 OF 3, WITH. CANCERIZATION OF LOBULES AND CRIBRIFORM CARCINOMA IN SITU. B. ""LEFT BREAST"": BREAST WITH RESIDUAL INFILTRATING onconal DUCTAL CARCINOMA (1.5 x 1.5 x 1. CM),. WITH NUCLEAR GRADE WELL-DIFFERENTIATEB AND N.S.A.B.P. HISTOLOGIC GRADE 1. OF 3. THERE IS A COMPONENT OF COLLOID CARCINOMA REPRESENTING LESS THAN. 25% OF THE TOTAL TUMOR VOLUME. THREE OF FOURTEEN (3/14) AXILLARY LYMPH NODES CONTAINING METASTATIC. CARCINOMA. LARGEST METASTATIC FOCUS MEASURES 1.8 x 1.1 CM; NO EXTRANODAL. EXTENSION IDENTIFIED. ALL SURGICAL MARGINS FREE OF TUMOR. SKIN, NIPPLE AND LACTIFEROUS DUCT: NO TUMOR PRESENT. 2 of 2."
TCGA-B6-A1KC.E1FDF8EB-9D75-4629-9C78-6019DAF8190E,1,T1b,"To determine the pathologic T stage of the patient's breast cancer, we will consider the size of the invasive component as described in the pathology report. According to the rules provided, T1 includes invasive breast carcinomas that are 2 cm or less in size.""C. Right breast mass"", (EXCISIONAL BIOPSY) : INVASIVE ADENOCARCINOMA OF THE BREAST. HISTOLOGIC TYPE: DUCTAL. GROSS TUMOR SIZE: 2.0 x 1.8 X 1.0 CM. SIZE OF INVASIVE COMPONENT: 2.0 x 1.8 x 1.0 CM."". The size of the invasive component is 2.0 x 1.8 x 1.0 cm, which falls within the T1 category. However, the T1 category can be further divided into T1mi, T1a, T1b, and T1c based on size. Since the size is greater than 0.5 cm but less than or equal to 1 cm, the correct T stage is T1b."", answer"": ""T1b""}",", Surgical Pathology: Additional Info. CLINICAL HISTORY: Per Browser: Right breast mass at 9:00 position, invasive ductal carcinoma. GROSS EXAMINATION: A. ""Sentinel node #1, hot and blue"". Received fresh and placed in formalin is. a 2 x 1 x 1 cm brown-yellow fragment of fibroadipose tissue. The specimen is. sectioned and submitted entirely in block A1. B. ""Sentinel node #2, hot not blue"". Received fresh and placed in formalin is. a 3.5 x 1.5 x 1.2 cm fragment of brown-yellow fibroadipose tissue. The. specimen is sectioned and submitted entirely in blocks B1 and B2. C. ""Right breast mass"". Received fresh and placed in formalin is a 10.5 (M-L). by 7.7 (A-P) by 4.0 (S-I) cm excisional breast biopsy. The anterior is inked. blue, the posterior is inked black, the superior is inked red, and the. inferior is inked yellow. There is a 4.6 x 1.5 cm ellipse of skin. There is. a 2.0 x 1.8 x 1.0 cm well circumscribed firm white nodule in the anterior. middle portion of the biopsy. The mass approaches within 2.0 mm of the. anterior margin and within 0.5 cm of the ellipse of skin. Representative. sections are taken medially to laterally from blocks C1-C25. BLOCK SUMMARY: C1-. most medial section. C2-. second most medial section. C3-10- representative sections moving laterally towards mass. C11-21- representative sections with mass. C22-25- representative section moving laterally. D. ""Final anterior, inferior margin"". Received fresh and placed in formalin. is a 3 x 2 x 1 cm fragment of brown-yellow fibroadipose tissue. A stitch is. placed on the margin by the surgeon. Blue ink is placed next to the suture,. the suture is removed, and the specimen is bisected. The inked blue side is. placed in blocks D1 and D2. The rest of the specimen is placed in block D3. Dr. Dr. slides to Dr. MICROSCOPIC EXAMINATION: Microscopic examination is performed. DIAGNOSIS: A. ""SENTINEL NODE #1, HOT AND BLUE"", (EXCISIONAL BIOPSY) : METASTATIC CARCINOMA IN ONE LYMPH NODE (1/1). SIZE OF METASTASIS: 0.8 CM. NEGATIVE FOR EXTRACAPSULAR EXTENSION. B. ""SENTINEL NODE #2, HOT NOT BLUE"", (EXCISIONAL BIOPSY). ONE LYMPH NODE (0/1), NEGATIVE FOR MALIGNANCY. IMMUNOHISTOCHEMICAL STAINS FOR CYTOKERATIN ARE NEGATIVE. C. ""RIGHT BREAST MASS"", (EXCISIONAL BIOPSY) : INVASIVE ADENOCARCINOMA OF THE BREAST. HISTOLOGIC TYPE: DUCTAL. https://. NOTTINGHAM COMBINED HISTOLOGIC GRADE: 3 OF 3. TUBULE FORMATION SCORE: 3. NUCLEAR PLEOMORPHISM SCORE: 3. MITOTIC RATE SCORE: 2. GROSS TUMOR SIZE: 2.0 x 1.8 X 1.0 CM. SIZE OF INVASIVE COMPONENT: 2.0 x 1.8 x 1.0 CM. LYMPHATIC/VASCULAR INVASION: PRESENT. MULTIFOCAL TUMOR: ABSENT. IN-SITU CARCINOMA: PRESENT. TYPE OF IN-SITU CARCINOMA: CRIBRIFORM AND COMEDO. NUCLEAR GRADE OF IN-SITU CARCINOMA: 3 OF 3. NECROSIS: PRESENT. DCIS EXTENDING OUTSIDE INVASIVE TUMOR MASS: ABSENT. SIZE OF IN-SITU CARCINOMA: SOLITARY MICROSCOPIC FOCUS (<0.2 CM). STATUS OF NON-NEOPLASTIC BREAST TISSUE: MINUTE FIBROADENOMA, APOCRINE. METAPLASIA. SKIN FREE OF TUMOR. SIZE OF BIOPSY: 10.5 x 7.7 x 4.0 CM. MICROCALCIFICATIONS: PRESENT IN ASSOCIATION WITH IN-SITU CARCINOMA. SURGICAL MARGIN STATUS: ANTERIOR MARGIN CLOSE (TUMOR GROSSLY APPROACHES TO. WITHIN 0.2 CM OF THE MARGIN) . SEE FINAL ANTERIOR. MARGIN, SPECIMEN ""D"" BELOW. ESTROGEN/PROGESTERONE RECEPTOR, CELL CYCLE, AND HER2/NEU ANALYSIS: PERFORMED PREVIOUSLY, SEE. D. ""FINAL ANTERIOR, INFERIOR MARGIN"", (EXCISION) : ADIPOSE AND BREAST PARENCHYMA, NEGATIVE FOR MALIGNANCY. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es). , M.D. Page #. CI ADDENDUM 1: Please see. for results of supplementary. tests. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es) . M.D., Ph.D. Pager. https://."
TCGA-B6-A409.CC77BA51-CE5A-4839-A27A-DD8F389A2733,0,T2,"Based on the pathology report, the patient was diagnosed with 'INVASIVE ADENOCARCINOMA OF THE BREAST' with a size of 1.7 inches. To determine the T stage, we will compare this measurement with the size categories defined in the rules. 1.7 inches is approximately 4.32 cm (conversion from inches to cm: 1 inch = 2.54 cm, so 1.7 inches x 2.54 = 4.32 cm). According to the rules provided, T1 includes invasive breast carcinomas that are 2 cm or less in size. Since the tumor size is greater than 2 cm (4.32 cm > 2 cm), the patient's T stage is not T1. T2 includes invasive breast carcinomas that are more than 2 cm but not more than 5 cm in size. The patient's tumor size (4.32 cm) falls within this range. Therefore, the patient's T stage is T2.","AP Surgical Pathology: Additional Info. I. CLINICAL HISTORY: of known carcinoma right 10:00 breast. If invasive carcinoma, please results. Biopsy obtain ER, PR, EGFR, HER2/Neu by immunohistochemistry; for all 2+ IHC. please do FISH analysis. A. GROSS ""USNCB right breast, five cores 10:00 area"". Received in formalin is a 1.7 in. EXAMINATION: x. 1 x 0.2 cm aggregate of fibrofatty needle core tissue submitted entirely. a mesh bag in block A1. MICROSCOPIC EXAMINATION: Microscopic examination is performed. DIAGNOSIS: A. ""USNCB RIGHT BREAST, FIVE CORES 10:00 AREA"": INVASIVE ADENOCARCINOMA OF THE BREAST. HISTOLOGIC TYPE: DUCTAL. NOTTINGHAM COMBINED HISTOLOGIC GRADE: 3 OF 3. TUBULE FORMATION SCORE: 3. NUCLEAR PLEOMORPHISM SCORE: 3. MITOTIC RATE SCORE: 3. LYMPHATIC/VASCULAR INVASION: NOT IDENTIFIED. IN-SITU CARCINOMA: PRESENT. TYPE OF IN-SITU CARCINOMA: COMEDO. NUCLEAR GRADE OF IN-SITU CARCINOMA: 3 OF 3. MICROCALCIFICATIONS ABSENT. ESTROGEN/PROGESTERONE RECEPTOR, HER2/NEU, AND EGFR ANALYSIS: PENDING. PARAFFIN BLOCK NUMBER: A1. RESULTS WILL BE ISSUED IN AN ADDENDUM. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es) . AT ADDENDUM 1: for results of supplementary. Please see. tests. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es). Attending MD: T."
TCGA-BH-A0BZ.1B56E5A6-35B8-4C60-8BC5-68716C946799,2,T4,"To determine the pathologic T stage of the patient's breast cancer, we will follow the rules provided and consider the relevant information in the pathology report. The maximum dimension of the invasive component is reported as 8.3 cm (section SIZE OF TUMOR). According to the rules: \\nT1 includes invasive breast carcinomas that are 2 cm or less in size, T2 includes those that are more than 2 cm but not more than 5 cm, and T3 includes those that are more than 5 cm. Since the maximum dimension of the invasive component is 8.3 cm, it exceeds the limit for T1, T2, and T3. Therefore, based on the information provided in the pathology report and the rules given, the patient's breast cancer has a pathologic T stage of T4.\n","FINAL DIAGNOSIS: BREASI, LEFT MODIFIED RADICAL MASTECTOMY AND AXILLARY DISSECTION -. A. INFILTRATING DUCTAL CARCINOMA. ) (see comment). B. NOTTINGHAM SCORE: 8/9 (TUBULES - 3, NUCLEI - 3, MITOSES - 2). C. LYMPHOVASCULAR PERMEATION IS PRESENT. D. DUCTAL CARCINOMA IN SITU, SOLID AND CRIBRIFORM TYPES, NUCLEAR GRADE 3, WITH COMEDO. NECROSIS, ASSOCIATED MICROCALCIFICATION AND RETROGRADE CANCERIZATION OF LOBULES,. REPRESENTING LESS THAN 1% OF TUMOR VOLUME. DUCTAL CARCINOMA IN SITU IS PRESENT ADMIXED. WITH THE INVASIVE TUMOR. E. MARGINS OF RESECTION AND SKELETAL MUSCLE ARE FREE OF TUMOR. F. NIPPLE, FREE OF TUMOR. G. SKIN WITH ACROCHORDON (FIBROEPITHELIAL POLYP), NO TUMOR SEEN. H. CHANGES CONSISTENT WITH PREVIOUS BIOPSY SITE, SEE PRIOR. I. FIBROCYSTIC CHANGES WITH DUCTAL EPITHELIAL HYPERPLASIA AND COLUMNAR CELL CHANGES. J. IMMUNOHISTOCHEMICAL STAININGS FOR ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR WERE. PREVIOUSLY PERFORMED ON. AND WERE REPORTED AS FOLLOWS: ESTROGEN RECEPTOR -. POSITIVE, PROGESTERONE RECEPTOR - POSITIVE, AND HER-2/neu - NEGATIVE (SCORE: 1+). K. METASTATIC ADENOCARCINOMA INVOLVING ONE OUT OF TWENTY-THREE (1/23) LEFT AXILLARY LYMPH. NODES, UP TO 1.1 CM (SS, TT, and UU), SEE PRIOR LEFT AXILLARY FINE NEEDLE ASPIRATION CYTOLOGY. (see comment). CASE STNOPSIS. SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Modified radical mastectomy. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 8.3 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 8. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, malignant zones. TUMOR TYPE, IN SITU: Cribriform. Solid. DCIS admixed with invasive carcinoma. Percent of tumor occupied by in situ component: 1 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: SURG MARGINS INVOLVED BY IN SITU COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: 1. LYMPH NODES EXAMINED: 23. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. NON-NEOPLASTIC BREAST TISSUE FCD Diameter of largest lymph node metastasis: 11 mm. SIZE OF NODAL METASTASES: T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: M STAGE, PATHOLOGIC: ESTROGEN RECEPTORS: PROGESTERONE RECEPTORS. HER2/NEU:"
TCGA-BH-A0E2.29EDE507-90BA-4ABE-B3EF-559EBA4CCD56,1,T1b,"[Step 1: Identify the size of the invasive tumor from the pathology report.""C. INVASIVE TUMOR MEASURES 2.5 X 2.3 X 2.0 CM."" refers to the maximum diameter of the invasive tumor."", 2.5 cm,"" is the size of the invasive tumor."", T1""."", T2""., or ""T3"" can be determined based on this size."", T1""."", T2""., or ""T3"" can be determined based on this size."", T1"". The report states that the size of the invasive tumor is 2.5 cm, which falls within the T1 category."", T1"". However, we need to further classify it into T1mi, T1a, T1b, or T1c."", T1a"". The report does not mention microinvasion (T1mi), and the size of the invasive tumor is larger than 0.5 cm but less than 1 cm (T1a, T1b, or T1c)."", T1b"". The size of the invasive tumor is larger than 1 cm but less than 2 cm (T1b or T1c)."", T1b"". The report confirms that the size of the invasive tumor is 2.5 cm, which falls within the T1b category."", T1b"". Therefore, the pathologic T stage of the patient's breast cancer is T1b.","P.25/33. DIAGNOSIS: BREAST, RIGHT, MODIFIED RADICAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA WITH ASSOCIATED CALCIFICATIONS. B. NOTTINGHAM GRADE 3 (TUBULE FORMATION: 3, NUCLEAR PLEOMORPHISM: 3, MITOTIC ACTIVITY: 3; TOTAL. SCORE: 9/9). C. INVASIVE TUMOR MEASURES 2.5 X 2.3 X 2.0 CM. D. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, SOLID, CRIBRIFORM MICROPAPILLARY AND CLEAR. CELL TYPES WITH COMEDONECROSIS AND ASSOCIATED CALCIFICATIONS. E. THE DUCTAL CARCINOMA IN SITU (DCIS) CONSTITUTES 50% OF THE TOTAL TUMOR VOLUME AND IS. PRESENT ADMIXED WITH THE INVASIVE COMPONENT. F. THE DUCTAL CARCINOMA IN SITU (DCIS) IS PRESENT IN 12/22 SLIDES. G. NO LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. H. RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA. DUCTAL CARCINOMA IN SITU (DCIS) IS 4.0 MM. FROM THE NEAREST ANTERIOR MARGIN, THE INVASIVE CARCINOMA IS GREATER THAN 1.0 CM FROM ALL. MARGINS. I. THE NIPPLE IS INVOLVED BY DUCTAL CARCINOMA IN SITU. J. SKIN IS NEGATIVE FOR TUMOR. K. NON-NEOPLASTIC BREAST: INTRADUCTAL PAPILLOMA AND FIBROCYSTIC CHANGES WITH. FIBROADENOMATOID NODULES,. L. BIOPSY SITE CHANGES WITH FAT NECROSIS. M. METASTATIC CARCINOMA INVOLVING FOUR OF TWENTY-SIX LYMPH NODES (4/26). N. THE LARGEST METASTATIC FOCUS MEASURES 2.0 CM. O. EXTRACAPSULAR EXTENSION IS IDENTIFIED AND MEASURES 1 MM. P. THE INVASIVE TUMOR CELLS TESTED POSITIVE FOR ESTROGEN AND WEAKLY POSITIVE FOR. PROGESTERONE RECEPTORS AND NEGATIVE FOR HER-2, AS PER PREVIOUS PATHOLOGY REPORT. LASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Modified radical mastectomy. Lower outer quadrant. SIZE OF TUMOR: MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: Maximum dimension invasive component: 2 5 cm. TUMOR TYPE (invasive component): NOTTINGHAM SCORE: Ductal adenocarcinoma, NOS. Nuclear grade: 3. Tubule formation: 3. Mitolic activity score: 3. Total Nottingham score: 9. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION;. Yes, malignant zones. TUMOR TYPE, IN SITU: Cribriform. Solid. Micropapillary. Comedo. DCIS admixed with invasive carcรญnoma. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Percent of tumor occupled by in situ component 50 %. SURG MARGINS INVOLVED BY IN SITU COMPONENT: PAGET'S DISEASE OF NIPPLE: Distance of in silu disease to closest margin: 40 mm. LYMPH NODES POSITIVE: 4. LYMPH NODES EXAMINED: 26. METHOD(S) OF LYMPH NODE EXAMINATION: H/E levels. SIZE OF NODAL METASTASES: Diameter of largest lymph nodo metastasis: 20 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: Papillonia, FCD, Other: Fibroadenomatoid nodules. T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pN2a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTรRONE RECEPTORS: positive. HER2/NEU:"
TCGA-BH-A0H7.CC7D1177-1638-4A80-A3AA-266ADC260EC9,0,T2,"[{""step"":1,""info"":""The report states that the largest tumor measures 1.5 cm and the second tumor measures 1.2 cm. Therefore, the total tumor aggregate size is 2.7 cm. According to rule 1, T1 stage includes invasive breast carcinomas that are 2 cm or less in size. The tumor aggregate size of 2.7 cm is greater than 2 cm but less than 5 cm. Therefore, the T stage falls under T2."",""decision"":""T2""}]","FINAL DIAGNOSIS: EtGHT BREAST, MODIFIED RADICAL MASTECTOMY -. A. MULTIFOCAL INFILTRATING DUCTAL CARCINOMA, NOTTINGHAM GRADE 2 (NUCLEAR GRADE 3, TUBULE. SCORE 3, MITOTIC ACTIVITY SCORE 1; TOTAL SCORE 7/9). B. LARGEST TUMOR MEASURES 1.5 CM, LOCATED IN THE UPPER/OUTER QUADRANT, CORRELATED WITH THE. BIOPSIED 10 O'CLOCK LESION. C. SECOND TUMOR MEASURES 1.2 CM IN GREATEST DIMENSION, LOCATED AT THE JUNCTION OF THE. UPPER/OUTER AND UPPER/INNER QUADRANTS AND CORRELATES WITH THE BIOPSIED 12 O'CLOCK LESION. D. BOTH TUMORS ARE MORPHOLOGICALLY SIMILAR. E. EXTENSIVE LYMPHOVASCULAR INVASION IS PRESENT. F. MARGINS ARE NEGATIVE; INVASIVE TUMOR APPROACHES MOST CLOSELY TO THE MARGIN POSTERIOR TO. THE 12 O'CLOCK LESION (see comment). G. DUCTAL CARCINOMA IN-SITU (DCIS), NUCLEAR GRADE 2, CRIBRIFORM TYPE, COMPRISING APPROXIMATELY. 5% OF TUMOR MASS (DCIS IS ASSOCIATED WITH BOTH TUMORS). H. BIOPSY SITE CHANGES (see comment). I. SIX AXILLARY LYMPH NODES WITH METASTATIC CARCINOMA (6/16). J. LARGEST METASTASIS MEASURES 1.1 CM. K. EXTRACAPSULAR EXTENSION IS PRESENT, AND MEASURES APPROXIMATELY 0.3 CM. L. UNINVOLVED BREAST WITH FIBROCYSTIC CHANGES AND FIBROADENOMA. M. NIPPLE AND SKIN ARE NEGATIVE FOR NEOPLASM. N. SKELETAL MUSCLE, NEGATIVE FOR TUMOR. O. CALCIFIC ATHEROSCLEROSIS. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Modified radical mastectomy. Upper outer quadrant. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 1.5 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 2.7 cm. TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 7. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: TUMOR TYPE, IN SITU: Cribriform. Percent of tumor occupied by in situ component: 5 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 7 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 6. LYMPH NODES EXAMINED: 16. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 11 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: NON-NEOPLASTIC BREAST TISSUE: Fibroadenoma, FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pN2a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: zero or 1+."
TCGA-BH-A18J.589BC4DD-0079-4106-A2E6-9A48E9BD7DE2,3,T3,"The report mentions that the size of the tumor is 9.0 by 8.5 by 4.0 cm. This exceeds the maximum size for T2 (5 cm) and falls within the size range for T3 (more than 5 cm). Additionally, the report states that the tumor extends to involve the nipple and epidermis of overlying ulcerated skin, indicating direct extension to the chest wall or skin. Therefore, the T stage for this patient's breast cancer is T3.","PATIENT HISTORY: DATE of LMP: DATE OF LAST DELIVERY. PRE-OP DIAGNOSIS: STAGE IV RIGHT BREAST CANCER. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: MODIFIED RADICAL RIGHT MASTECTOMY. CLINICAL HISTORY: MATERIAL SUBMITTED: RIGHT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. ADDENDA: Addendum. MATERIAL SUBMITTED: MWH Slide for ER/PR and Her-2/Neu. FINAL DIAGNOSIS: My signature is attestation that I have personally reviewed the submitted material(s) and the final. diagnosis reflects that evaluation. ER/PR. IMMUNOPEROXIDASE IDENTIFICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE. ""A4"". DISTINCT INTRANUCLEAR STAINING IS IDENTIFIED FOR ESTROGEN RECEPTOR (50%) AND ALSO TOR PROGESTERONT. RECEPTOR. (40%) . THEREFORE, BOTH ARE INTERPRITED AS POSITIVE. HER-2/NEU. c-erb82 (HER-2/NEU) IMMUNOSTAINING IS CARRIED OUT ON. BLOCK ""A4"" (BREAST CANCER). USING A 1:300 DILUTION OF DANO'S POLYCLONAL ANTIBODY A485 (DIRBCTED AGAINST THE INTRACELLULAR DOMAIN OF c-. erb82) WITHOUT ANTIGEN RETRIEVAL. NO DISTINCT COMPLETE MEMBRANE STAINING IS IDENTIFIED. THEREFORE,. c-exbB2. (HER-2/NEU) IS INTERPRETED AS NEGATIVE (SCORE 0). FINAL DIAGNOSIS: RIGHT; BREAST MODIFIED RADICAL MASTECTOMY : INFILTRATING POORLY DIFFERENTIATED DUCT CARCINOMA, 9.0 BY 8.5 BY 4.0 CM, INVOLVING ALL FOUR QUADRANTS. (SKX NOTE). - NOTTINGHAM SCORE 8/9 (TUBULES 3, NUCLEAR ATYPIA 3, MITOTIC INDEX 2). - TUMOR EXTENDS TO INVOLVE NIPPLE AND EPIDERMIS OF OVERLYING ULCERATED SKIN. - INTRADUCTAL CARCINOMA, COMEDO-TYPE, INVOLVES <54 OF TOTAL TUMOR. - MARGINS OF RESECTION ARE NEGATIVE FOR TUMOR. - MULTIPLE MATTED LYMPH NODES WITH NEARLY COMPLETE ARCHITECTURAL EFTACEMENT BY METASTATIC CARCINOMA (SEE. NOTE). NOTE: ER/PR immunoperoxidase assay and Her-2/NEU testing will be performed on block ""A4"". A prior HER-2/NEU immunostain was performed on a paraffin block received from Shadyside Rospital and was. interpreted as negative. Due to possible differences in fixation among institutions, the HER-. 2/NEU study will be repeated on the present specimen. The axillary lymph nodes are extensively matted, indicative of extracapsular extension by tumor. For this. reason, an accurate lymph node count cannot be made."
TCGA-BH-A18N.60E8A9CF-3E2D-4E36-947D-448BA27C6561,1,T3,"The report mentions that the size of the invasive ductal carcinoma is 4.5 by 4.5 by 3.5 cm. This exceeds the 2 cm limit for T1 stage cancers, and is also larger than the 5 cm limit for T2 stage cancers. Therefore, we can conclude that the tumor is either T3 or T4. However, the report does not mention any direct extension to the chest wall or skin, or any ulceration, satellite nodules, or inflammatory carcinoma. Therefore, we can exclude T4a, T4b, T4c, and T4d. The only remaining option is T3, which includes invasive breast carcinomas that are more than 5 cm in size, regardless of any extension to the chest wall or skin. Therefore, the pathologic T stage of the patient's breast cancer is T3.","PATIENT HISTORY: DATE of LMP. DATE or LAST DELIVERY: PRE-OP DIAGNOSIS: CA L BREAST. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: LEFT MODIFIED RADICAL MASTECTOMY. CLINICAL HISTORY: MATERIAL SUBMITTED: LEFT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. Lt breast & axillary content. FINAL DIAGNOSIS: FINAL DIAGNOSIS: BREAST AND AXILLA, LEFT, MODIFIED RADICAL MASTECTOMY: - INFILTRATING DUCTAL CARCINOMA (""A2-A7""), 4.5 BY 4.5 BY 3.5 CM, NOTTINGHAM 6/9 (TUBULES 3, NUCLEI 2,. MITOSIS 1), WITH LYMPHOVASCULAR PERMEATION, INVOLVING THE DEEP DERMIS. DUCTAL CARCINOMA IN-SITU, SOLID TYPE, NUCLEAR GRADE 2, LESS THAN 1t. - MARGINS OF RESECTION ARE FREE OF TUMOR. - NIRPLE FREE OF TUMOR. TWO. OF. TWENTY-SIX (2/26) LEFT AXILLARY LYMPH NODES INVOLVED WITH TUMOR, LARGEST LYMPH NODE 2.3 CM IS. REPLACED BY TUMOR. NOTE: ER/PR immunoperoxidase assay and Her-2/NEU testing was performed on block ""A6"". Cross. refer. ESTROGEN/PROGESTERONE AND HER-2/NEU REPORT. Using appropriate positive and negative controls, the test for the presence of these hormone receptor. proteins is performed by the immunoperoxidase method, and reported according to the. consensus statement. on adjuvant therapy for breast cancer, of. A positive ER or PR tumo. anows any nuclear. immunostaining, and is semiquantitated as indicated below. Result Semiquantitative Statement. ER positive Percent cells staining as: (0- 0% 1+ 10%; 2+ 10%; 3+ 80%). PR positive Percent cells staining as: (0- or; 1+ or; 2+ 10%; 3+ 90%). HER-2/NEU - DAKO HERCEPTEST: A FAINT/BARELY PERCEPTIBLE MEMBRANE STAINING IS DETECTED IN MORE THAN 10% OF. THE TUMOR CELLS. THE CELLS ARE ONLY STAINED IN PART OF THEIR MEMBRANE. HER-2/NEU IS INTERPRITED AS NEGATIVE. (SCORE 1+). NOTE: The Her-2/NEU and estrogen assays were performed with FDA approved. methods The progesterone. receptor immunoperoxidase test used in this case has been developed and the performance characteristics. determined by the Department of Pathology at. They have not been. cleared or approved by the U.S. Food and Drug Actministration."
TCGA-BH-A18R.46DE21ED-1E08-4095-9B68-88D10AC74673,1,T3,"The report states that the size of the invasive ductal carcinoma is 8.0 by 3.0 by 1.5 cm. This is larger than 5 cm, which falls under T3 according to the rules provided."", ","PATIENT HISTORY: DATE OF LAST DELIVERY: DATE of LMP: PRE-OP DIAGNOSIS: RIGHT BREAST CA. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: RIGHT MODIFIED RADICAL MASTECTOMY. CLINICAL HISTORY: MATERIAL SUBMITTED: RIGHT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. FINAL DIAGNOSIS: FINAL DIAGNOSIS: RIGNT MODIFIED RADICAL MASTECTOMY: INFILTRATING DUCTAL CARCINOMA, NOTTINGHAM SCORZ 9/9 (TUBULES 3, NUCLEI 3, MITOSIS 3), 8.0 BY 3.0 BY 1.5 CM. (CROSS REFER. - DUCTAL CARCINOMA IN-SITU, NON-COMEDO AND SOLID TYPE, POOR NUCLEAR GRADE, REPRESENTING 5% OF THE TUMOR. VOLUME. - LYMPHOVASCULAR PERMEATION IS SEEN. - MARGINS FREE OF TUMOR. - NIPPLE NEGATIVE FOR PAGET'S DISEASE. - TEN OF FIFTEEN (10/15) LYMPH NODES, POSITIVE FOR METASTATIC CARCINOMA WITH EXTRACAPSULAR EXTENSION (3). NOTE ER/PR immunoperoxidase assay and Her-2/NEU testing will be performed on block ""A4"". ESTROGEN/PROGESTERONE RECEPTORS AND HER-2/NEU PERFORMED ON RIGHT BREAST TISSUE. ESTROGEN RECEPTOR (0-85%; 1-10%; 2-5%; 3-0%) HSCORE OF 20. ESTROGEN RECEPTOR IS INTERPRETED AS BORDERLINE. PROGESTERONE RECEPTOR (0-1004) HSCORE OF 0. PROGESTERONE RECEPTOR IS INTERPRETED AS NEGATIVE. HSCORE: <= 15 NEGATIVE. > 15 <= 30 BORDERLINE. > 30 POSITIVE. HER-2/NEU - DAKO HERCEPTEST: A STRONG COMPLETE MEMBRANE STAINING IS OBSERVED IN MORE THAN 10% OF THE TUMOR. CELLS. HER-2/NEU IS INTERPRETED AS POSITIVE (SCORE 3+)."
TCGA-BH-A1F2.FA781D93-C180-4453-BF95-B2D01B6CDB5C,3,T2,"Based on the pathology report, the patient's breast cancer is described as an 'infiltrating, poorly differentiated duct carcinoma, 4.7 by 2.5 by 2.0 cm, involving all four quadrants.' This information can be used to determine the T stage of the cancer according to the given rules. Here's a step-by-step breakdown of the process: \\n1. Identify the size of the tumor: The report states that the tumor is 4.7 cm by 2.5 cm by 2.0 cm. This means that the largest diameter of the tumor is 4.7 cm. \\n2. Compare the size to the T stage rules: According to rule 2, T2 tumors are defined as those that are 'more than 2 cm but not more than 5 cm in size.' Since the tumor in this case is larger than 2 cm (4.7 cm) and not more than 5 cm, it meets the criteria for a T2 tumor. \\n3. Confirm the absence of other T stage criteria: The report does not mention any direct extension to the chest wall or skin, which would be required for a T3 designation. Similarly, there is no mention of ulceration, satellite nodules, or inflammatory carcinoma, which would be required for a T4 designation. \\n4. Conclude the T stage: Based on the information provided in the report, the patient's breast cancer can be classified as a T2 tumor, as it is more than 2 cm but not more than 5 cm in size.","Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE of LMP: DATE or LAST DELIVERY. PRE-OP DIAGNOSIS: L BREAST CA. POST-OP DIAGNOSIS: SAME-. OPERATIVE PROCEDURE: L MRM. CLINICAL HISTORY: MATERIAL SUBMITTED: LEFT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. and axillary contents. ADDENDA: Addendum. FINAL DIAGNOSIS: ER/PR. IMMUNOPEROXIDASE IDENTIEICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE ""A2"". DISTINCT INTRANUCLEAR STAINING IS IDENTIFIED FOR ESTROGEN RECEPTOR (50%) AND PROCESTERONE RECEPTOR (40%) . THEREFORE, BOTH ARE INTERPRITED AS POSITIVE. BER-2/NEU. c-erb82 (HER-2/NEU) IMMUNOSTAINING IS CARRIED OUT ON. (BREAST CANCER) USING A. 1:300 DILUTION OF DAKO'S POLYCLONAL ANTIBODY A485 (DIRECTED AGAINST THE INTRACELLULAR DOMAIN OF c-erba2). WITHOUT ANTIGEN RETRIEVAL DISTINCT COMPLETE MEMBRANE STAINING IS IDENTIFIED IN 70% OF TUMOR CELLS. THEREFORE, o-erba2 (HER-2/NEU) IS INTERPRETED AS POSITIVE (SCORE 3+). My signature is attestation that I have ppersonallyreviewed the submitted material(s) andthe final. diagnosis reflects that evaluation. FINAL DIAGNOSIS: LEFT BREAST, MODIFIED RADICAL MASTECTOMY: - INFILTRATING, POORLY DITYERENTIATED DUCT CARCINOMA, 4.7 BY 2.5 BY 2.0 CM, INVOLVING ALL FOUR QUADRANTS. - NOTTINGHAM SCORE: 8/9 (TUBULES=3/3, NUCLEAR ATYPIA=3/3, MITOTIC INDEX=2/3). - DUCTAL CARCINOMA IN SITU INVOLVES <5% OF TOTAL TUMOR. - TUMOR EXTENDS TO INVOLVE DERMIS OF NIPPLE, DERMAL LYMPROVASCULAR PERMEATION IS PRESENT. - NIPPLE AND ADJACENT SKIN INVOLVED BY PAGET'S DISEASE. - MARGINS OF RESECTION ARE NEGATIVE FOR TUMOR, HOWEVER; TUMOR EXTENDS TO WITHIN 0.2 CM or THE DEEP NARGIN. - FIBROCYSTIC CHANGES. - DUCT ECTASIA. - NON-TUMOR ASSOCIATED MICROCALCIFICATIONS. - SIX (6) OUT or NINETEEN (19) LYMPH NODES, POSITIVE FOR METASTATIC CARCINOMA, MULTIPLE FOCI OF. EXTRANCOAL. TUMOR EXTENSION ARE SEEN. NOTE: ER/PR immunoperoxidase assay and Her-2/NEU testing will be performed on block ""A2""."
TCGA-BH-A1F6.7E9B0BE7-121E-423F-AA37-445BA922FC13,3,T2,"[{""step"":1,""description"":""Reviewing the report, we can see that the neoplasm measures 5.5 cm in maximum dimension (B.). According to rule 2, T2 includes invasive breast carcinomas that are more than 2 cm but not more than 5 cm in size. Therefore, the patient's breast cancer falls under the T2 category.""}]","Nยฐ. PATIENT HISTORY: The patient is a year-old female. Date of last menstrual period: Not given. PRE OP DIAGNOSIS: Left breast cancer. POST OP DIAGNOSIS: Same. PROCEDURE: Left modified radical mastectomy. FINAL DIAGNOSIS: PART 1: LEFT BREAST, MODIFIED RADICAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA OF BREAST, NOTTINGHAM SCORE 8/9 (TUBULES 3, NUCLEI 3, MITOSES 2). B. NEOPLASM MEASURES 5.5 CM IN MAXIMUM DIMENSION. C. NEOPLASM EXTENDS INTO DERMIS. D. MARGINS OF RESECTION FREE OF NEOPLASM. E. EXTENSIVE DERMAL LYMPHOVASCULAR EXTENSION IDENTIFIED (T4d). F. NO PAGET'S DISEASE OF NIPPLE IDENTIFIED. G. METASTATIC CARCINOMA IN INTRAMAMMARY LYMPH NODE, 1 OF 1, 0.7 CM IN DIAMETER WITH. EXTRACAPSULAR EXTENSION. PART 2: LEFT AXILLARY CONTENTS, AXILLARY DISSECTION. METASTATIC CARCINOMA IN LYMPH NODES, 3 OF 3. PART 3: LEFT AXILLARY CONTENTS, AXILLARY DISSECTION. METASTATIC CARCINOMA IN LYMPH NODES, 2 OF 2. COMMENT: Estrogen_ Progesterons and Her-2/Neu analyses were performed on the two previous specimens (outside block from: and di. wand interpreted on both specimens as ER negative, PR negative and Her-. 2/Neu negative. If repeat analyses are desired on current specimen, please contact the laboratory."
TCGA-BH-A1FB.C5D116FF-3193-48A0-B69C-D98831D9976A,1,T1c,"To determine the pathologic T stage of the patient's breast cancer, we will follow the rules provided and interpret the relevant information from the pathology report. The report mentions the size of the tumor in the right breast as 2.2 x 2.4 x 2.4 cm. According to rule 1, T1 includes invasive breast carcinomas that are 2 cm or less in size. Since the tumor size is 2.2 cm, which is less than 5 cm, it does not meet the criteria for T2, T3, or T4 stages. Therefore, the T stage for this patient is T1. To be more specific, we can use the subcategories within T1 based on size. Since the tumor size is greater than 2.0 cm but less than or equal to 3.0 cm, the T stage is T1c. Thus, the pathologic T stage of the patient's breast cancer is T1c.","Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE of LMP: DATE or LAST DELIVERY: PRE-OP DIAGNOSIS: RT BREAST CA. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: RT SENTINEL LYMPH NODE BIOPSY, RIGHT AXILLARY DISSECTION, RT SEGMENTAL MASTECTOMY,. EXCISION OF LEFT FLANK. CLINICAL HISTORY: MATERIAL SUBMITTED: A) RIGHT SENTINEL LYMPH NODE, PROCUREMENT BY SURGICAL PROCEDURE. (B) RIGHT AXILLARY LYMPH NODE(S), PROCUREMENT BY SURGICAL PROCEDURE. C) RIGHT AXILLARY LYMPH NODE(S), PROCUREMENT BY SURGICAL PROCEDURE. #2. D) RIGHT BREAST BIOPSY/TISSUE, PROCUREMENT BY SURGICAL PROCEDURE. E) RIGHT AXILLA, PROCUREMENT BY SURGICAL PROCEDURE. F) RIGHT NEW MARGIN TISSUE, PROCUREMENT BY SURGICAL PROCEDURE. medial. G) LIPOMA, PROCUREMENT BY SURGICAL PROCEDURE. left flank. INTRAOPERATIVE CONSULTATION: FROZEN SECTION: Sentinel Node #1, one lymph node identified 1.0 x 0.5 x 0.5 cm. Touch Prep Diagnosis: Suspicious. Frozen Section Diagnosis: Positive for Metastatic Carcinoma. Right Breast - history of infiltrating carcinoma, 7.0 x 9.0 x 4.0 cm. Specimen inked and oriented. Tumor. identified 2.2 x 2.4 x 2.4 cm. Tumor closest to the medial margin; all other margins are free of tumor. grossly (less than 1.0 mm). FINAL DIAGNOSIS: FINAL DIAGNOSIS: AGAFS) RIGHT SENTINEL NODE #1: - LYMPH NODE WITH METASTATIC CARCINOMA. - TUMOR DORS NOT EXTEND BEYOND LYMPH NODE CAPSULE. B) RIGHT SENTINEL NODE #2: - LYMPH NODE, NEGATIVE FOR TUMOR. C) RIGHT SENTINEL NODE #3: - LYMPH NODE WITH METASTATIC CARCINOMA. TUMOR DOES NOT EXTEND BRYOND LYMPH NODE CAPSULE. DEF) RIGHT SEGMENTAL MASTECTOMY AND NEW MEDIAL MARGIN: - INFILTRATING AND INTRADUCTAL CARCINOMA, 2.2 BY 2.4 BY 2.4 CM (CROSS REFER. NOTTINGHAM SCORE 4/9. (TUBULES-1, NUCLEI=2, MITOSES-1). - INTRADUCTAL CARCINOMA IS CRIBRIFORM TYPE AND COMPRISES APPROXDIATELY 51 or TUMOR VOLUNE. - TUMOR ASSOCIATED MICROCALCITICATTON IDENTIFIED. - VASCULAR SPACE INVOLVEMENT IS NOT PROMINENT. - SURGICAL NARGINS FREE or TUMOR IN PLANES OF SECTION. - FIBROCYSTIC CHANGES WITH NICROCALCIFICATIONS. E) RIGHT AXILLA: - FIFTEEN LYMPR NODES NEGATIVE FOR TUMOR (0/15). G) MATURE ADIPOSE TISSUE, CONSISTENT WITH LIPONA. NOTE: ER/PR immunoperoxidase assay and Her-2/NEU testing will be performed on block ""D3""."
TCGA-BH-A1FN.26F47A4F-B501-4C33-9D49-2039E98DBF26,1,T1c,"[The following is a step-by-step explanation of how I arrived at the T stage for this patient's breast cancer.]\n\n1. I began by reviewing the pathology report to locate the size of the tumor. The report states that the tumor is '2.6 by 2.6 by 2.5 cm.' This measurement is consistent with the T1 category, which includes invasive breast carcinomas that are 2 cm or less in size.\n\n2. Since the tumor size falls within the T1 category, I then looked at the subcategories T1mi, T1a, T1b, and T1c. These subcategories are based on the size of the tumor: T1mi (microinvasion 0.1 cm or less), T1a (0.1 cm but less than 0.5 cm in size), T1b (0.5 cm but less than 1 cm in size), and T1c (1 cm but less than 2 cm in size).\n\n3. The report states that the tumor is '2.6 by 2.6 by 2.5 cm.' This size is greater than 1 cm but less than 2 cm, which falls within the T1c subcategory.\n\nTherefore, based on the information provided in the pathology report and the rules for determining the T stage, the patient's breast cancer has a pathologic T stage of T1c.","Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE OF LMP: DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: R BREAST CA. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: R SEGM MAST AND AXILL NODE DISS. CLINICAL HISTORY: MATERIAL SUBMITTED: A) RIGHT BREAST BIOPSY/MASS/SEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. routine sutures. B) RIGHT AXILLA, PROCUREMENT BY SURGICAL PROCEDURE. INTRAOPERATIVE CONSULTATION: FROZEN SECTION: Right breast tissue; 8.0 by 8.0 by 3.0 cm. Tumor is 2.6 by 2.6 by 2.5 cm. Margins grossly. free. Frozen Section Diagnosis: Infiltrating ductal carcinoma. ER/PR taken. FINAL DIAGNOSIS: FINAL DIAGNOSIS: AEAFS) RIGHT BREAST MASS. - INFILTRATING DUCTAL CARCINOMA, NOT OTHERWISE SPECIFIED, HISTOLOGIC GRADE 3, NUCLEAR GRADE POOR, VASCULAR. INVASION PRESENT, TUMOR NECROSIS REPRESENTING 30% OF TUMOR MASS; TUMOR GREATEST DINGTER 2.6 BY 1.6 BY 2.5. CM. - INKED MARGINS FREE OF TUMOR. B) RIGHT AXILLARY NODES: - TWENTY-NINE (29) LYMPH NODES, FREE OF TUMOR. Criteria. Diagnusis riscrepancy. Primary Tumor Site Discivinary. enor Millenancy Hi tory. must/syrchionous useis (circle): initials MA Date jewed /. Re."
TCGA-BH-A209.E28150CE-E9B6-4C3F-B867-F9A75E2648DC,0,T2,"The pathology report indicates that the patient had a left segmental mastectomy and the final diagnosis for the left breast is medullary carcinoma that measures 2.0 cm in size with free margins and no angiolymphatic or perineural invasion. The left axillary contents contained twelve lymph nodes that were free of tumor. According to the rules provided, T stage is determined by the size of the tumor. In this case, the tumor measures 2.0 cm, which falls under T1. However, medullary carcinoma is a specific type of breast cancer that has unique features and is usually classified as T1c, T2, or T3, depending on the size of the tumor. Since the tumor in this case measures 2.0 cm, it falls under T2. Therefore, the pathologic T stage of the patient's breast cancer is T2. This decision is based on the size of the tumor as reported in the pathology findings.","Site : breast NOS C50.9 An 3/18/1/. I. PATIENT HISTORY: DATE OF LMP. Procedure Date: DATE OF LAST DELIVERY: PRE-OP DIAGMOSIS: LEFT BREAST MASS. POST-OP DIAGNOSIS: SAME. L SEGMENTAL MASTECTOMY 'NODE DISSECTION. CLINICAL NISTORY. MATERIAL SUBMITTED: A) LEFT SEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. B) LEFT AXILLA, PROCUREMENT BY SURGICAL PROCEDURE. CONSULTATION: FROZEN SECTION: Left breast segmental biopsy: Firm mass, 2.0 by 2.0 by 1.5 cm, 0.3 cm from anterior margin. FS. Diagnosis: Infiltrating carcinoma, poor nuclear grade, with lymphocytic component. Rule out medullary. carcinoma. ER/PR taken. FINAL DIAGNOSIS: FINAL DIAGNOSIS: AEARS) LEFT BREAST, SEGMENTAL MASTECTOMY. MEDULLARY CARCINCIA, 2.0 CM. - MARGIN FREE or TUMOR IN PLANES or SECTION. - NO ANGIOLYMIPHATIC OR PERINEURAL INVASION SEEN. B) LEFT AXILLARY CONTENTS: - TWELVE (12) LYMPH NODES FREE OF TUMOR."
TCGA-D8-A1JC.B4DB830F-BFA4-47F5-94C7-D95984315866,1,T3,"The report mentions the size of the tumor as 11 x 7 x 3 cm. According to rule 1, T1 includes invasive breast carcinomas that are 2 cm or less in size. In this case, the greatest tumor dimension is 11 cm, which is more than 2 cm and exceeds the limit for T1. According to rule 2, T2 includes invasive breast carcinomas that are more than 2 cm but not more than 5 cm in size. The greatest tumor dimension in this case is 11 cm, which is more than 5 cm and exceeds the limit for T2. According to rule 3, T3 includes invasive breast carcinomas that are more than 5 cm in size or tumors of any size with direct extension to the chest wall or skin. The report does not mention any direct extension to the chest wall or skin, but the tumor size is 11 cm, which is more than 5 cm and falls under T3. However, the final decision regarding the T stage should be made by a healthcare professional based on a variety of factors, including clinical examination, imaging studies, and pathological findings.","page 1 / 1. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: 1. Multiple organ resection - left breast and axillary tissue. Expected time of examination: up to 8 working days. Clinical diagnosis: Status after intraoperative examination - ca invasivum. Macroscopic description: Left breast sized 21 x 10 x 5 cm removed along with axillary tissues sized 12 x 7 x 15 cm and a 19 x 10 cm skin flap. Weight 820 g. Tumour site sized 11 x 7 x 3 cm on the boundary of outer quadrants, 2 cm from the upper boundary, 0.5 cm from the base and 1. cm from the skin. A. post-operative scar visible in the outer quadrant skin with a seam of 7 cm. Metastatic lymph nodes of 2.5 cm. Microscopic description: Invasio carcinomatosa vasorum. Infiltratio carcinomatosa mamillae. In the tumour site, singular foci of carcinoma ductale invasivum and lesions of the type mastopathia fibrosa et cystica,. hyperplasia ductalis simplex (UDH). AXILLARY LYMPH NODES. Metastases carcinomatosae in lymphonodis No IV/XI. Infiltratio capsulae lymphonodorum. Histpathological diagnosis: Carcinoma ductale partim micropapillare invasivum mammae sinistrae. Invasive ductal carcinoma partially micropapillary of the. left breast. Metastases carcinomatosae in lymphonodis axillae (No IV/XI) (NHG2, pT2, pN2a). Cancer metastases in axillary lymph nodes (No. IV/XI). Invasio carcinoma vasorum. Vascular invasion."
TCGA-D8-A1JH.49C79E09-2F69-4089-BFB1-53197DA09A46,0,Unable to determine T stage based on provided information.,"The report states that the 'tumour sized 1,2 x 10 x 1,0 cm' was found in the right breast. According to rule 1, T1 includes invasive breast carcinomas that are 2 cm or less in size. The largest dimension of this tumor is 10 cm, which is greater than 2 cm. Therefore, the tumor does not meet the criteria for T1. According to rule 2, T2 includes invasive breast carcinomas that are more than 2 cm but not more than 5 cm in size. The tumor size of 10 cm is greater than 5 cm, so it also does not meet the criteria for T2. According to rule 3, T3 includes invasive breast carcinomas that are more than 5 cm in size or tumors of any size with direct extension to the chest wall or skin. The report does not mention any direct extension to the chest wall or skin, so we cannot determine if the tumor meets the criteria for T3 based on this information. According to rule 4, T4 includes invasive breast carcinomas that have spread to the chest wall and/or the skin, resulting in ulceration or satellite nodules, or inflammatory carcinoma. The report does not mention any spread to the chest wall or skin, so we cannot determine if the tumor meets the criteria for T4 based on this information. However, the report does give a final pathologic diagnosis of pT1c, which indicates that the tumor is 1 cm or more but less than 2 cm in size. This is a contradiction with the tumor size of 10 cm mentioned earlier in the report. It is possible that the tumor size was misreported or that the final diagnosis was made using a different measurement. Based on the information provided, we cannot accurately determine the T stage of the tumor.","page 1 / 1. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast and axillary tissue. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 protein stained with HercepTestโขM by DAKO. Negative reaction in invasive cancerous cells ( Score = 1+). Macroscopic description: Right breast sized 14 x 14.5 x 2.5 cm removed along with axillary tissues sized 11 x 4.5 x 2 cm and a 11 x 5.6. cm skin flap. Weight 260 g. Tumour sized 1,2 x 10 x 1,0 cm found in the outer lower quadrant, 0.9 cm from the lower boundary, 0.5 cm. from the base and less than 0.1 cm from the parenchyma. Lymph nodes 1.8 cm in length. Microscopic description: Carcinoma ductale invasivum - NHG1 (2 + 2 +1: 5 mitoses/ 10 HPF, visual area diameter: 0.55 m). Calcifications within the tumour. Mamilla sine laesionibus. Glandular tissue showing lesions of the type mastopathia fibrosa (fibrocystic changes). Invasive lesions reaching the base. AXILLARY LYMPH NODES. Lymphonodulitis chronica et sinis histiocytosis No IX. Histopathology diagnosis: Carcinoma ductale invasivum mammae dextrae. (NHG1, pT1c, pNO). Invasive ductal carcinoma of the right. breast."
TCGA-D8-A1X8.5F1C3B85-5E5C-428B-8779-3A5878DCE1F2,0,T2,"The report mentions the size of the tumor as 2.7 x 1.4 x 2.8 cm. According to rule 1, T1 includes invasive breast carcinomas that are 2 cm or less in size. The tumor size in this report is 2.7 cm, which is larger than 2 cm but less than 5 cm. Therefore, based on the information provided in the report and according to the rules given, the pathologic T stage of the patient's breast cancer is T2. However, it is important to note that the actual T stage should be determined by a healthcare professional based on a variety of factors, including clinical examination, imaging studies, and pathological findings.","page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - left breast with axillary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Macroscopic description: Left breast sized 22.4 x 17.8 x 6.4 cm removed along with axillary tissues sized 12 x 5 x 3 cm and a skin flap of 24.2 x 11.3 cm. Weight 950 g. Tumour sized 2.7 x 1.4 x 2.8 cm found in the central part, removed 6.0 cm from the lower boundary, 0.3 cm from the base and 1.4. cm from the skin. Microscopic description: Carcinoma lobulare invasivum (classical type, partly solid) multifocale - NHG2 (3+2+1/0 mitoses/10 HPF - visual area. 0.55mm). Infiltratio carcinomatosa mamillae. In situ lesions of the type pagetoid spread and hyperplasia within the foci of adenosis sclerosans. Glandular tissue. showing lesions of the type fibrosa et cystica, adenosis sclerosans. AXILLARY LYMPH NODES: Metastases. carcinomatosae in lymphonodis (No IX/XI). Test result: Carcinoma lobulare mixtum invasivum mammae sinistrae. Metastases carcinomatosae in lymphonodis axillae (No IX/XI) (NHG2, pTIc, pN2a). Examination performed or. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 protein stained with HercepTestโขM by DAKO. Score = 2+. FISH verification recommended. Compliance validated by: 1. Examination: Histopathological examination. page 2 / 2. Gender: F. Histopathological diagnosis: Carcinoma lobulare invasivum mammae sinistrae. Invasive lobular carcinoma of the left breast. Metastases in lymphonodis axillae (No IX/XI) (NHG2, pTIc, pN2a). Cancer metastases in axillary lymph nodes (No IX/XI) (NHG2, pTIc, pN2a). Results of immunohistochemical examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit. HER-2 GENE AMPLIFICATION NOT FOUND."
TCGA-D8-A1XC.E5D2E429-C41C-47E2-96CB-F3B6F412499B,3,T3,"The report mentions the size of the tumor as 7 x 4 x 8 cm. According to rule 3, T3 stage includes invasive breast carcinomas that are more than 5 cm in size. The largest dimension of the tumor is 8 cm, which is more than 5 cm, therefore the T stage is T3.","page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast. Expected time of examination: 5 working days. Clinical diagnosis: Right breast - advanced cancer of both breasts, toilet mastectomy of both breasts. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell. nuclei. HER2 protein stained with HercepTestโขM by DAKO. Negative reaction in invasive carcinoma cells ( Score = 1+. Macroscopic description: Right breast sized 19 x 9 x 6 cm removed along with axillary tissues sized 7 x 3 x 2 cm and a skin flap of 13 x 9.5 cm. Weight 370. g. Tumour sized 7 x 4 x 8 cm found in the central part. Margin to the lower boundary - uncertain, margin to the base - uncertain,. margin to the skin 0.1 cm. Histopathological diagnosis: Carcinoma mucinosum invasivum - NHG2 (3+2+1/5 mitoses/10 HPF - visual area 0.55mm). Invasive mucinous carcinoma of the right breast. Numerous foci of carcinoma ductale found outside the tumour (cribrate type, with medium nuclear atypia, without. necrosis) and lesions of the type mastopathia fibrosa et cystica, hyperplasia ductalis simplex (UDH) AXILLARY LYMPH. NODES: Micrometastases carcinomatosae in lymphonodo (No I/XX). Examination: Histopathological examination. page 2 / 2. cxamination No.: Gender: F. Complementary diagnosis: Complementary macroscopic description: Extensive skin proliferation. Minor ulceration in the skin. Skin proliferation confirmed microscopically. Focal. tumour pattern along the incision line at the side of the base and lower boundary. Test result: Carcinoma mucinosum invasivum with a neuroendocrinic component mammae dextrae. Micrometastasis. carcinomatosa in lymphonodo axillae (No 1/XX) (NHG2, pT4b, pNIa mi). Immunophenotype: CK7+/- (Only part of the. cells exhibit positive reaction, CK5/6 p63-, calponin ambiguous reaction, synaptophysin +, chromogranin -/+). Compliance validated k,."
TCGA-D8-A1XG.AA869507-1B46-4812-8EC5-A4E01C588E6E,3,T3,"The report states that the size of the tumor is 6.2 x 4.3 x 7.8 cm. According to rule 3, T3 stage includes invasive breast carcinomas that are more than 5 cm in size. The largest dimension of this tumor is 7.8 cm, which is more than 5 cm. Therefore, the pathologic T stage of the patient's breast cancer is T3.","page 1 / 1. copy No. Examination: Histopathological examination. Gender: F. Material: 1. Total organ resection - right breast. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast, ulcerous - Toilet mastectomy. Macroscopic description: Right breast Sized 13.7 x 7.6 x 4.8 cm removed without axillary tissues and with a skin flap of 17.8 x 10.2 cm. Weight 193 g. Tumour sized 6.2 x 4.3 x 7.8 cm in the middle part, 0.1 cm from the upper boundary, 0.1 cm from the base. Microscopic description: Carcinoma ductale invasivum - NHG3 (3+2+3/20 mitoses/10 HPF - visual area: 0.55mm). Infiltratio carcinomatosa cutis et musculi pectoralis. Mamilla sine laesionibus. Glandular tissue showing parenchyma atrophy. Histopathological diagnosis: Carcinoma ductale invasivum mammae dextrae. Invasive ductal carcinoma of the right breast. Metastases carcinomatosae in lymphonodis axillae (No II/II). Cancer metastases of the axillary lymph nodes. (NHG3, pT4b, pN1a). Results of immunohistochemical examination: Estrogen receptors found in 10-75% of neoplastic cell nuclei. Progesterone receptors found in 10-75% of. neoplastic cell nuclei. HER2 protein stained with HercepTestโขM by DAKO. Negative reaction in invasive cancerous cells ( Score = 0). Compliance valida."
TCGA-D8-A1XT.99050E48-8DFE-4405-B8D8-7649CE2C9CFF,0,T2,"Based on the pathology report, we can determine the size of the two tumors in the right breast. The first tumor is 1.6 x 1.5 x 1.3 cm and the second tumor is 1.6 x 1.5 x 1.2 cm. The total size of each tumor is calculated by adding the three dimensions together, giving us 4.4 cm for the first tumor and 4.3 cm for the second tumor. However, the T stage is determined by the largest tumor size. Therefore, the largest tumor size is 4.4 cm. According to the rules provided, this falls under T2, which includes invasive breast carcinomas that are more than 2 cm but not more than 5 cm in size. Therefore, the pathologic T stage of the patient's breast cancer is T2.","page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast. !. Expected time of examination: up to 8 working days. Clinical diagnosis: Bifocal cancer of the right breast. Results of immunohistochemical examination: Tumour 1. No estrogen receptors found in neoplastic cell nuclei. No progesterone receptors found in neoplastic cell nuclei. HER2 protein. stained using rabbit antibody Ventana PATHWAY HER-2/neu (485). Positive reaction in invasive cancerous cells (Score = 3+). Tumour 2. No estrogen receptors found in neoplastic cell nuclei. No progesterone receptors found in neoplastic cell nuclei. HER2 protein. stained using rabbit antibody Ventana PATHWAY HER-2/neu (4B5). Positive reaction in invasive cancerous cells (Score = 3+). validated by: I. Macroscopic description: Right breast sized 26 x 19 x 5 cm with axillary tissues sized 11 x 8 x 2 and a skin flap of 24 x 2.5 cm. Tumour sized 1.6 x 1.5 x I.3 cm found on the boundary of lower quadrants, located 1.3 cm from the lower boundary, 1 cm from. the base and 4 cm from the skin. The other tumour present in the upper outer quadrant, sized 1.6 x 1.5 x 1.2 cm, removed by 0.1 cm from the base, 0.6 cm from. the skin and 3 cm from the upper boundary. Microscopic description: Both tumours: Carcinoma ductale invasivum NHG3 (3+3+2/ 12 mitoses /10 HPF, visual area diameter: 0.55mm). Few. foci of carcinoma ductale in situ (DCIS) (papillary type, with medium nuclear atypia and comedo necrosis of 5% of. the tumour). In situ lesions of the type carcinoma intraductale mamillae. Glandular tissue showing parenchymal atrophy. AXILLARY LYMPH NODES:Metastases carcinomatosae in lymphonodis (No III/X). page 2 / 2. Examination: Histopathological examination. Gender: F. Infiltratio telae perinodalis. Test result: Carcinoma ductale invasivum bifocale et ductale in situ mammae dextrae. Invasive bifocal ductal carcinoma and ductal. carcinoma in situ of the right breast. Metastases carcinomatosae in lymphonodis axillae (No III/X). Cancer metastases in axillary. lymph nodes (NHG3, pTlc, pNIa). Compliance valida."
TCGA-D8-A1XW.BD71F606-58BC-46B9-8A03-CB25D5BECA96,1,T1c,"Based on the pathology report, the patient has invasive ductal carcinoma of the left breast, with a tumor size of 3.5 x 2.5 x 3.0 cm. According to the rules provided, this would fall under T1c, as the tumor is between 1 cm and 2 cm in size. The other T stages are not applicable, as the tumor is not larger than 5 cm, has not directly extended to the chest wall or skin, and has not spread to the chest wall or skin, resulting in ulceration or satellite nodules. Therefore, the pathologic T stage of the patient's breast cancer is T1c.","page 1 / 1. copy No. Examination: Histopathological examination. Gender: F. Material: Multiple organ resection - left breast 1. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. PCI: Carcinonia invasivum G3. Results of immunohistochemical examination: No estrogen receptors detected in neoplastic cell nuclei. Progesterone receptors found in less than 10% of neoplastic cell. nuclei. HER2 protein stained with Ventana's Pathway HER-2/neu (4B5) Rabbit Monoclonal Antibody. Negative reaction in. invasive cancerous cells (Score=1+). Compliance validate. Macroscopic description: Left. breast, sized 26 x 18 x 5 cm, removed along with axillary tissues sized 4 x 1 x 2 cm and a skin flap of 16 x 11 cm. Weight 220. g. Tumour sized 3.5 x 2.5 x 3.0 cm found in the upper inner quadrant, located 4 cm from the upper edge, 0.5 cm from the base. and 3.8 cm from the skin. Microscopic description: Carcinoma ductale invasivum - NHG3 (3+3+2: 9 mitoses/10 HPF - visual area: 0.55mm). Mamilla sine laesionibus. Glandular tissue showing lesions: mastopathia fibrosa. Axillary lymph nodes: Lymphonodulitis chronica (No I). Histopathological diagnosis: Carcinoma ductale invasivum mammae sinistrae. Invasive ductal carcinoma of the left breast. (NHG3, p 12, pNO)."
TCGA-E2-A10C.E8A61AAC-BFF5-4341-B051-EDD87515ECDC,1,Unable to determine the T stage based on the provided information.,"The report mentions that the 'Gross Exam F Breast, left, wide local excision: Tumor mass is 0.6 cm from the anterior/inferior. margins.' This indicates that the tumor size is 0.6 cm. According to the rules provided, T1 includes invasive breast carcinomas that are 2 cm or less in size. Since the tumor size is 0.6 cm, it falls under the T1 category. However, the rules also mention that T1 can be further divided into T1mi, T1a, T1b, and T1c based on the size of the tumor. As the tumor size is 0.6 cm, it falls under the T1a category, which includes invasive breast carcinomas that are 0.1 cm but less than 0.5 cm in size. But, the report mentions that the tumor size is 2.2 cm, which contradicts the gross exam. Therefore, I am unable to determine the T stage based on the provided information.","SPECIMENS: A. SENTINEL LYMPH NODE #1. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. C. SENTINEL LYMPH NODE #3 LEFT AXILLA. D. SENTINEL LYMPH NODE #4 LEFT AXILLA. E. SENTINEL LYMPH NODE #5 LEFT AXILLA. F. WLE LEFT BREAST. G. AXILLARY CONTENTS. SPECIMEN(S): A. SENTINEL LYMPH NODE #1. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. C. SENTINEL LYMPH NODE #3 LEFT AXILLA. D. SENTINEL LYMPH NODE #4 LEFT AXILLA. E. SENTINEL LYMPH NODE #5 LEFT AXILLA. F. WLE LEFT BREAST. G. AXILLARY CONTENTS. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA (microscopic): Lymph node, sentinel #1, biopsy: Negative for carcinoma. By called to Dr. at. TPB/C (microscopic): Lymph nodes, sentinels #2-3, biopsy: Negative for carcinoma. By Dr., called to. Dr. at. (B) and. C). TPD (microscopic): Lymph node, sentinel #4, biopsy: Positive for carcinoma. By Dr., called to Dr. at. (D). Gross Exam F Breast, left, wide local excision: Tumor mass is 0.6 cm from the anterior/inferior. margins. By Dr, called to Dr. GROSS DESCRIPTION: A. SENTINEL LYMPH NODE #1. Received fresh is a tan-pink fragment of fibrofatty tissue 3.5 x 2.4 x 0.8 cm. Dissection reveals. one. presumptive lymph node 1.0 x 0.7 x 0.4 cm. The specimen is serially sectioned and touch preps are. taken. The specimen is submitted entirely in cassette A1. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. Received fresh is a tan-pink lymph node 1.0 x 1.0 x 0.7 cm. The specimen is serially sectioned. Touch. preps are taken and the specimen is submitted entirely in cassette B1,. C. SENTINEL LYMPH NODE #3 LEFT AXILLA. Received fresh is a tan-pink lymph node 1.0 x 1.0 X 0.7 cm. The specimen is serially sectioned. Touch. preps are taken and the specimen is submitted entirely in cassette C1. D. SENTINEL LYMPH NODE #4 LEFT AXILLA. Received fresh is a tan-pink lymph node 1.5 X 1.0 x 0.7 cm. The specimen is serially sectioned and. touch preps are taken. The specimen is submitted in toto in D1. E. SENTINEL LYMPH NODE #5 LEFT AXILLA. Received in formalin is a tan-pink lymph node 2.0 x 1.0 x 1.0 cm. The specimen is serially sectioned. and submitted in toto in cassette E1. F. WIDE LOCAL EXCISION LEFT, BREAST. Received fresh is an oriented 57 gram wide local excision breast specimen measuring 8 x 6 X 4 cm. The specimen is inked as follows: anterior-blue, posterior-black, superior-red, inferior-orange, medial-. green, lateral-yellow. The specimen is serially sectioned from lateral to medial into six slices, slice 1. being most lateral and slice 6 being most medial, to reveal a gray-white, firm stellate mass measuring. 2.2 X 2 X 2 cm located 0.6 cm from the closest anterior/inferior margin in slice 3, 4, 5 and 6. The. remainder of the cut surfaces reveal predominantly yellow lobulated adipose tissue interdispersed with. gray-white fibrous tissue. A portion of the specimen is submitted for tissue procurement. Representative sections are submitted as follows: A1: perpendicular sections of the lateral margin from superior to inferior, slice. 1. A2: anterior margins and area immediately adjacent to mass, slice 2. A3: anterior margin, slice 3. A4: inferior margin, slice 3. A5: deep margin, slice 3. A6: superior margin, slice 3. A7: mass with anterior and superior margins, slice 4. A8: mass with anterior and inferior margins, slice 4. A9-A10: mass with superior and deep margins bisected. A11: mass with inferior and deep margins. A12: mass with anterior margin, slice 5. A13: mass with inferior margin, slice 5. A14-A15: perpendicular sections of the mass with the medial margin from superior. to inferior, slice 6 as per attached diagram. G. LEFT AXILLARY CONTENTS. Received in formalin are multiple tan-pink fragments of fibrofatty tissue aggregating to 9 X 6 x 3 cm. Dissection reveals nine possible lymph nodes ranging from 0.1 x 0.1 x 0.1 cm to 1.1 x 1.0 X 0.9 cm. Section code: G1: three possible lymph nodes. G2: three possible lymph nodes. G3: two possible lymph nodes. G4: one lymph node trisected. G5: one lymph node trisected. DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). B. LYMPH NODE, SENTINEL #2, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). C. LYMPH NODE, SENTINEL #3, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). D. LYMPH NODE, SENTINEL #4, LEFT AXILLA, BIOPSY: METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 0.6-CM WITH EXTERANODAL EXTENSION. E. LYMPH NODE, SENTINEL #5, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). F. BREAST, LEFT,WIDE LOCAL EXCISION: - INVASIVE, DUCTAL CARCINOMA, SBR GRADE-3, MEASURING 2.2-CM. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU WITH. CENTRAL NECROSIS, CRIBRIFORM AND SOLID TYPES. - SEE SYNOPTIC REPORT. G. LYMPH NODES, LEFT AXILLARY CONTENTS, RESECTION: - EIGHT LYMPH NODES, NEGATIVE FOR METASTASES (0/8). SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: No. Laterality: Left. Invasive tumor. Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 2.2cm. Tumor site: Not specified. Margins: Negative. Distance from closest margin: 0.5cm. anterior/medial. Tubular score: 2. Nuclear grade: 3. Mitotic score:3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node and axillary dissection. Lymph node status: Positive 1/13 Extranodal extension. DCIS present. Margins uninvolved by DCIS: DCIS Quantity: Estimate 5%. DCIS type: Solid. Cribriform. DCIS location: Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Absent. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by IHC. Pathological staging (pTN): pT 2 N 1a. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: F12. ER: Positive. Allred Score: 8 = Proportion score: 5 + Intensity Score 3. PR: Positive Allred Score: 6 = Proportion Score 3 + Intensity Score 3. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score of. less than or equal to 2. Methodology: Fixation Type and Length: Tissue was fixed in 10% neutral buffered formalin (. ) for no less than 8 and no longer than 24 hours. Antibody and Assay Methodology: Mouse anti-human ER and PR,. Comment: This assay can be used to select invasive breast cancer patients for hormone therapy (1). ER and PR analysis was performed on this case by immunohistochemistry utilizing the ER (ER 1D5,. 1:100) and PR (PGR 136, 1:100) antibody provided by. following the manufacturer's instructions. listed in the package insert. This assay was not modified, and adherence to all instruction and. guidelines were strictly followed. Interpretation of the ER/PR immunohistochemical staining. characteristics is guided by published results in the medical literature (1), information provided bv the. reagent manufacturer and by internal review of staining performance within the F. 1. Harvey JM, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding. assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474-. 1481, 1999. SYNOPTIC REPORT - BREAST HER-2 RESULTS. HER2 Status Results, Immunohistochemistry Evaluation. Specimen: Surgical Excision. Block Number: F12. Interpretation: NEGATIVE. Intensity: 1+. % Tumor Staining: 5%. Fish Ordered: METHODOLOGY. Methodology: Fixation Type and Length: Tissue was fixed in 10% neutral buffered formalin. Inc. ) for no less than 8 and no longer than 24 hours. Antibody and Assay Methodology: Rabbit anti-human HER2, HerceptestTM (FDA-approved test kit),. Control. Slides Examined: External kit-slides provided by manufacturer (cell lines with high, low and negative. HER2 protein expression), and in-house known HER2 amplified control tissue were evaluated along. with the test tissue. These control slides run along side of this patient's sample showed appropriate. staining. Adequacy of Specimen: Adequate, well preserved, clear-cut invasive carcinoma identified for. HER2 evaluation. Scoring Criterion and Scoring System: IHC Level of Expression(Score /Tumor Cell Membrane Staining Pattern. Negative (0)/Absence of Staining. Negative (1+)/Faint Incomplete membrane Staining, >10% of Cells. Equivocal (2+)/Weak complete membrane Staining, >10% of Cells. Positive (3+)/Strong complete membrane Staining, >10% of Cells. Equivocal Category for HER2 IHC results: A HER2, 2+ staining result that is interpreted as equivocal. may not indicate gene amplification. A FISH test for HER2 gene amplification will be ordered for all. HER2 IHC 2+ results. COMMENT. This assay can be used to select invasive breast cancer patients for Trastuzumab (Hereptin) therapy. (1,2). Clinical Trials have shown that Trastuzumab substantially increases the likelihood for an objective. response and overall survival for patients with metastatic HER2-positive breast cancer, regardless of. whether HER2 tumor status was determined as IHC 3+ or FISH positive. Trastuzumab added to. adjuvant chemotherapy substantially increase disease-free survival and decreases the risk of disease. recurrence by about 50% for patients with early-stage HER2 protein over-expressed or gene amplified. invasive breast cancer (3). HER2 analysis was performed on this case by immunohistochemistry utilizing the FDA approved. HercepTest (TM) test kit following the manufacturer's instructions listed in the package insert. This. assay was not modified, and adherence to all instruction and guidelines were strictly followed. Interpretation of the HER2 immunohistochemical staining characteristics is guided by published results. in the medical literature (4), information provided by the reagent manufacturer and by internal review of. staining performance within the Pathology Department. HER2 TEST VALIDATION. This HER2 immunohistochemical assay has been validated according to the recently revised. recommendations and guidelines from the NCCN HER2 testing in Breast Cancer Task Force, and the. jointly issued recommendations and guidelines from ASCO and the CAP (5). 80 randomly selected. breast cancer samples were tested for HER2 by IHC as outline above and interpreted as, negative. (score 0/1+) equivocal (score 2+) and positive (score 3+) without knowledge of the previous reported. results. These cases were also blindly read using two different FISH assay as amplified or non-amplified and. the HER2/CEP17 ratios were recorded. After analyzing these results, there was 100% concordance. between the IHC and FISH results for cases that were interpreted as either positive or negative by IHC. 9 of the 80 cases were interpreted as equivocal by IHC and of these 3/9 (33%) were non-amplified by. FISH and 6/9 (66%) were found to be amplified. The Pathology Department Immunohistochemistry laboratory takes full responsibility for this tests. performance and has programs in place to regularly monitor the proficiency and the interpretation of. HER2 assays. The laboratory also participates in external quality assurance HER2 programs including. the CAP proficiency testing program. REFERENCE. 1. Carlson RW, Anderson BO, Burstein HJ, et al., NCCN breast cancer clinical practice guidelines in. oncology. J Natl Compr Canc Netw. 2005;3:238-289. 2. Carlson RW, Brown E, Burstein HJ, et al., NCCN Task Force Report: adjuvant therapy for breast. cancer. J Natl Compr Canc Netw. 2006;4:S1-S26. 3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable. HER2-positive breast cancer. N Eng J Med 2005;353(16):1673-84. 4. Leong ASY, Formby M, Haffajee Z, et al. Refinement of immunohistologic parameters for Her2/neu. scoring validation by FISH and CISH. Appl Immunohistochem Mol Morphol. 2006;14:384-389. 5. Wolff AC, Hammond EH, Schwartz JN, et al., American Society of Clinical Oncology/College of. American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Recepto 2. Testing in Breast Cancer. Arch of Path and Lab Med 2007; 131:18-43. CLINICAL HISTORY: None provided. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. Microscopic/Diagnostic Dictation: Pathologist,. Microscopic/Diagnostic Dictation: Pathologist,. Microscopic/Diagnostic Dictation:., Pathologist. Final Review:., Pathologist. Final: Pathologist."
TCGA-E2-A14R.0B6DCA80-3108-4D25-B095-3EC704598B23,1,T1c,"The report states that the 'gross assessment 2.0 cm mass >0.5 cm all margins and 1.0 cm satellite nodule at inferior margin' in specimen D. This indicates that the size of the tumor is 2.0 cm, which falls under T1 stage according to the rules provided. However, since the tumor has a satellite nodule at the inferior margin, it is more specifically classified as T1c, which includes invasive breast carcinomas that are 1 cm but less than 2 cm in size with satellite nodules."",""determination"":""T1c""}","SPECIMENS: A. SENTINEL NODE #1 LEFT AXILLA. B. SENTINEL NODE #2 LEFT AXILLA. C. SENTINEL NODE #3 LEFT AXILLA. D. WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. E. INFERIOR MARGIN LEFT BREAST. F. LATERAL MARGIN LEFT BREAST. G. MEDIAL MARGIN LEFT BREAST. H. POSTERIOR MARGIN LEFT BREAST. I. SENTINEL NODE #4 LEFT AXILLA. J. SENTINEL NODE #5 LEFT AXILLA. K. SENTINEL NODE #6 LEFT AXILLA. SPECIMEN(S): A. SENTINEL NODE #1 LEFT AXILLA. B. SENTINEL NODE #2 LEFT AXILLA. C. SENTINEL NODE #3 LEFT AXILLA. D. WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. E. INFERIOR MARGIN LEFT BREAST. F. LATERAL MARGIN LEFT BREAST. G. MEDIAL MARGIN LEFT BREAST. H. POSTERIOR MARGIN LEFT BREAST. I. SENTINEL NODE #4 LEFT AXILLA. J. SENTINEL NODE #5 LEFT AXILLA. K. SENTINEL NODE #6 LEFT AXILLA. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA-TPC: One lymph node each part, negative for carcinoma. D: Gross assessment 2.0 cm mass >0.5 cm all margins and 1.0 cm satellite nodule at inferior margin. TPI: One lymph node, negative for carcinoma. TPJ/FSJ: 2 lymph nodes, negative for carcinoma. TPK: One lymph node, negative for carcinoma. By Dr. called to Dr. at 1. (A),. (B),. C), : (D) and. (I, JJK). GROSS DESCRIPTION: A. SENTINEL NODE #1, LEFT AXILLA. Received fresh and labeled with the patient name designated ""A - sentinel node #1, left axilla"", is a fragment of. beige-tan possible lymphoid tissue measuring 2.0 x 2.0 1.2 cm. The specimen is serially sectioned, touch prep. performed. The entire specimen is submitted in cassette A1 and A2. B. SENTINEL NODE #2, LEFT AXILLA. Received fresh and labeled with the patient name designated ""B - sentinel node #2, left axilla"", is a fragment of. beige-tan possible lymphoid tissue measuring 1.0x 1.0 x 1.3 cm. The specimen is serially sectioned, touch. prep. performed. The entire specimen is submitted in cassette B1 and B2. C. SENTINEL NODE #3, LEFT AXILLA. Received fresh and labeled with the patient name designated ""C - sentinel node #3"", is a fragment of beige-tan. possible lymphoid tissue measuring 0.7 x 0.5 x 0.3 cm. The specimen is serially sectioned, touch prep performed. The entire specimen is submitted in cassette C1. D. LEFT BREAST WIDE NEEDLE LOCALIZATION. Received in fresh state the specimen labeled with patients name and identification number and labeled as wide local. excision left breast needle localization. The specimen consists of 293 grams resected breast tissue measuring 12.5. cm from medial to lateral, 7.5 cm from anterior to posterior and 6.0 cm from superior to inferior. The margins of. specimen are oriented with sutures, single indicating anterior, double-lateral and triple-superior. There is a. localization needle coursing from the superior to the inferior aspect of the specimen and the accompanying. radiogram that shows density located in the mid portion of the specimen. The margins of specimen are color coded. as follows: Inferior-orange, superior-red, lateral-yellow, anterior-blue, medial-green and posterior-black. At mid. portion of the specimen is a firm palpable mass which on cut section shows solid firm mass with nodular and. lobulated pushing borders with a tan white cut surface with total dimensions of 4.0 x 3.0 x 0.9 cm. A metallic clip is. identified within the main portion of the tumor and the surrounding breast tissue consists mostly of fatty parenchyma. The tumor grossly 0.9 cm from the nearest inferior margin. Multiple sections are submitted and labeled as follows: D1-D8: One en bloc section of tumor with margins. D9: Cross section of tumor. D10-D18: En bloc section of tumor with margins, (block 15 section taken site of apparent previous biopsy site. wherein a clip was identified). D19: Sections of gross fat necrosis. D20: Sections from posterior and medial margins. D21: Sections from inferior and medial margins. D22-D23: Sections from the posterior margin. D24-D25: Sections from lateral margin. n26-D27: Additional medial margin. E. LEFT BREAST INFERIOR MARGIN. Stitch marks new margin. Received fresh is an oriented 17.0-gram fragment of fibrofatty tissue 6.0 x 5.0 x 2.0 cm. The new true margin is inked blue, the specimen is serially sectioned and submitted in toto in cassette E1-E11. F. LEFT BREAST LATERAL MARGIN. Stitch at new lateral margin. Received fresh is an oriented tan-pink fragment of fibrofatty tissue 5.0 x 2.0 x 1.5 cm. The new true margin is inked blue. Also separate within the container is an unoriented tan-pink fragment of fibrofatty. tissue 5.5 x 4.0 x 2.0 cm. The specimen is inked blue. The entire specimen is submitted as follows: F1-F5: Oriented tissue fragment. F6-F12: Unoriented tissue fragment. G. LEFT BREAST MEDIAL MARGIN. Irregular fragment of fibrofatty tissue measuring 3.5 x 2.0 x 1.0 cm. Submitted in toto in cassettes labeled G1-G2. H. LEFT BREAST POSTERIOR MARGIN. Received fresh is an unoriented 3.0-gram tan-pink fragment of fibrofatty tissue 4.0 x 2.0 x 1.5 cm. The specimen is. inked blue, serially sectioned and submitted in toto in cassette H1 and H2. I. SENTINEL NODE #4, LEFT AXILLA. Received fresh is a tan-pink lymph node 0.8 x 0.7 x 0.7 cm. The specimen is serially sectioned, touch preps are. taken. The specimen is submitted entirely in cassette I1. J. SENTINEL NODE #5, LEFT AXILLA. Received fresh are 2 tan-pink lymph nodes 1.5 x 1.0 x 1.0 cm and 0.8 x 0.5 x 0.5 cm. A portion of the larger lymph. node is submitted for frozen section in FSJ1. Touch preps are taken. The remainder of the lymph node is submitted. as follows: J2-J3: One lymph node. J4: One lymph node. K. SENTINEL NODE #6, LEFT AXILLA. Received fresh is a tan-pink lymph node 0.7 x 0.6 x 0.5 cm. The specimen is bisected. Touch preps are taken and. the specimen is submitted entirely in cassette K1. DIAGNOSIS: A. SENTINEL LYMPH NODE #1, LEFT AXILLA. - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). B. SENTINEL LYMPH NODE #2, LEFT AXILLA. - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). C. SENTINEL LYMPH NODE #3, LEFT AXILLA. - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). D. LEFT BREAST, NEEDLE LOCALIZATION WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA WITH AREAS OF NECROSIS, SBR GRADE III OF. LEFT BREAST. - SIZE OF TUMOR: 4.0 x 3.0 x 0.9 CM. - PREDOMINANTLY FATTY BREAST TISSUE WITH FOCAL AREAS OF COLUMNAR. CELL CHANGE. - POST BIOPSY SITE CHANGES. - MARGINS OF RESECTION-NEGATIVE FOR TUMOR. E. LEFT BREAST, INFERIOR MARGIN: - PREDOMINANTLY FATTY BREAST TISSUE-NEGATIVE FOR TUMOR. F. LEFT BREAST, LATERAL MARGIN: - FATTY BREAST TISSUE-NEGATIVE FOR TUMOR. G. LEFT BREAST, MEDIAL MARGIN: - FATTY TISSUE AND 1 MM FOCUS OF LYMPH NODE-NEGATIVE FOR TUMOR (0/1). H. LEFT BREAST, POSTERIOR MARGIN: - FATTY BREAST TISSUE INCLUDING SKELETAL MUSCLE TISSUE-NEGATIVE FOR TUMOR. I. SENTINEL LYMPH NODE #4, LEFT AXILLA: - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). J. SENTINEL LYMPH NODE, #5 LEFT AXILLA: - TWO LYMPH NODES, NEGATIVE FOR TUMOR (0/2). K. SENTINEL LYMPH NODE #6, LEFT AXILLA: - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). Note: specimen # D- grossly, of what appears clinically as two tumor is only one large tumor with lobulated and. nodulat extensions. the main bulk of the specimen consist mostly of fatty breast tissue,. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: D: WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. Specimen Type: Excision. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 4cm. Additional dimensions: 3cm x 0.9cm. Tumor Site: Central. Margins: Negative. Distance from closest margin: 1.5cm. superior. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: Indeterminate. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0/8. Non-neoplastic areas: Post biopsy site changes. DCIS not present. Pathological staging (pTN): pT 2 N 0. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimens Involved. Specimens: D: WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. Specimen: Surgical Excision. Block Number: D9. ER: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. PR: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the proportion score. (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of cells staining, 4 = 31-60% of. cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak intensity of staining, 2 = intermediate. intensity of staining, 3 = strong intensity of staining), with a scoring range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score of less than. or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR 136, 1:100). provided by Dako. a) following the manufacturer S instructions. This assay was not modified. Interpretation of the ER/PR immunonistochemical stain is guided by published results in the medical literature,. information provided by the reagent manufacturer and by internal review of staining performance. CLINICAL HISTORY: -year-old Caucasian female with palpable left breast mass. Ultrasound showed 2 masses at 12 o'clock position,. largest one 2.0 cm. Core biopsy showed DCIS, here for wide local excision and sentinel node biopsy. PRE-OPERATIVE DIAGNOSIS: None given. ADDENDUM: SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: D9. Interpretation: NEGATIVE. Intensity: 1+. % Tumor Staining: 8%. Fish Ordered: No. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis. was performed using the FDA approved Dako HercepTest (TM) test kit (Dako, Carpenteria, CA) using rabbit anti-. human HER2. This assay was not modified. External kit-slides provided by the manufacturer (cell lines with high,. low and negative HER2 protein expression) and in-house known HER2 amplified control tissue were evaluated along. with the test tissue. Adequate, well preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2 immunohistochemical stain is guided by published results in the medical literature,. information provided by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from ASCO and CAP. and from the NCCN HER2 testing in Breast Cancer Task Force. The Pathology Department takes full responsibility. for this test's performance. Microscopic/Diagnostic Dictation: Pathologist. Microscopic/Diagnostic Dictation: Pathologist,. Final Review: Pathologist. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist."
TCGA-E2-A14Z.750D4149-BD70-4D7C-B915-9694BD1EC760,0,"T1, T2, or T3","[{```""step""`:`""Examining the report for the size of the tumor.""`,```""","SPECIMENS: A. SLN #1. B. LEFT BREAST EXCISION. C. ADDITIONAL MARGIN MEDIAL, ANTERIOR, POSTERIOR. SPECIMEN(S): A. SLN #1. B. LEFT BREAST EXCISION. C. ADDITIONAL MARGIN MEDIAL, ANTERIOR, POSTERIOR. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA-SLN #1: Negative for tumor called by Dr to Dr at. B: Gross only, tumor 0.1 cm from medial margin called by Dr. to Dr. at. GROSS DESCRIPTION: A. SLN #1. Received fresh is a 3.5 x 1.1 x 0.4 cm piece of soft tissue containing a lymph node. A touch prep is performed;. lymph node is submitted in cassette A1. B. LEFT BREAST. Received fresh labeled with the patient's identification and ""left breast"" is an oriented (single-anterior, double-lateral). 43 g, 4.1 x 3.2 x 3 cm lumpectomy without radiograph. The specimen has been inked in OR per protocol: Anterior-. yellow, posterior-black, medial-green, lateral-red, superior-blue, inferior-orange. Specimen is serially sectioned from. lateral to medial into 6 slices revealing a 1.9 x 1.4 x 1.3 cm firm tan circumscribed mass that is closest to the medial. margin at less than 0.2 cm. Tissue is procured. Representatively submitted. B1: lateral margin, perpendicular sections. B2: slice 3, mid posterior, mass. B3: slice 3, posterior inferior, mass. B4: slice 4, lower anterior, mass. B5: slice 5, superior anterior. B6: slice 5, superior posterior. B7: slice 5, mid anterior. B8: slice 5, mid posterior, mass. B9: slice 5, inferior anterior. B10: slice 5, inferior posterior. B11-B12: medial margin, perpendicular sections. C. ADDITIONAL MEDIAL, ANTERIOR-POSTERIOR MARGIN. Received fresh labeled with the patient's identification and ""additional medial, anterior-posterior margin"" is an. oriented (suture at final margin) 7 g, 0.7 x 3.2 x 0.9 cm fibrofatty tissue. Final margin is inked black. Serial. sectioning reveals no discrete lesions. Entirely submitted in cassettes C1-C5. DIAGNOSIS: A. LYMPH NODES, SENTINEL #1 left axilla, excision: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). B. BREAST, LEFT, WIDE LOCAL EXCISION: - INVASIVE ductal CARCINOMA, SBR GRADE 3, MEASURING 1.6-CM. - Tumor present 2-mm from inferior surgical margin (closest margin). -biopsy site changes with fibrosis. - SEE SYNOPTIC REPORT. C. BREAST, ADDITIONAL MEDIAL ANTERIOR POSTERIOR MARGIN, EXCISION: - BREAST TISSUE, NO TUMOR SEEN. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.6cm. Tumor Site: Upper outer quadrant. Margins: Negative. Distance from closest margin: 0.2cm. inferior. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0/1. DCIS not present. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by IHC. Performed on Case: Pathological staging (pTN): pT 1c N 0. CLINICAL HISTORY: Left breast infiltrating cancer upper outer quadrant. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. Microscopic/Diagnostic Dictation: Final Review: Pathologist,. Final: Pathologist,."
TCGA-E2-A15D.1FE4EB4C-FEF8-486A-B39D-6F9F023FDAC4,1,T1,"The report states that the 'Invasive ductal carcinoma, SBR Grade 1, measuring 2.2-cm' and 'Tumor size: 2.2cm' in the Synoptic Report. According to rule 1, T1 includes invasive breast carcinomas that are 2 cm or less in size. Therefore, the patient's breast cancer falls under the T1 category. However, the report does not provide information about the subcategories of T1 (T1mi, T1a, T1b, or T1c). As a result, the T stage for this patient is T1, but the subcategory cannot be determined based on the information provided.","SPECIMENS: A. RIGHT BREAST CANCER. B. SENTINEL L.N. #1 RIGHT AXILLA. C. SENTINEL L.N. #2 RIGHT AXIL;LA. D. SENTINEL L.N. #3 RIGHT AXILLA. E. SENTINEL L.N. #4 RIGHT AXILLA. SPECIMEN(S): A. RIGHT BREAST CANCER. B. SENTINEL L.N. #1 RIGHT AXILLA. C. SENTINEL L.N. #2 RIGHT AXIL;LA. D. SENTINEL L.N. #3 RIGHT AXILLA. E. SENTINEL L.N. #4 RIGHT AXILLA. GROSS DESCRIPTION: A. RIGHT BREAST CANCER. Received fresh labeled with the patient's identification and ""right breast needle localization"" is a previously inked 53g,. 6 x 5 x 4cm needle localized lumpectomy with radiograph. Ink code: anterior-yellow, posterior-black, superior-blue,. inferior-orange, medial-green, lateral-red. Specimen is serially sectioned from lateral to medial into 8 slices revealing. a 2.5 x 2.3 x 1. 5cm tan white firm well circumscribed mass, 0.6cm from the closest inferior margin in slices 2-7. A. surgical clip is identified in slice 5. A portion of the specimen is submitted for tissue procurement. Representatively. submitted: A1-A2: lateral margin slice 1. A3-A5: slice 2. A6-A8: slice 3. A9-A15: slice 4. A16: slice 5 with clip ID. A17-A18: slice 6. A19-A20: slice 7. A21: medial margin. B. SENTINEL L.N. #1 RIGHT AXILLA. Received fresh is a tan pink lymph node 1.2 x 1 x 1cm. The specimen is sectioned and a touch prep is taken. Toto. B1. C. SENTINEL L.N. #2 RIGHT AXILLA. Received fresh is a tan pink lymph node 0.8 x 0.6 x 0.5cm. The specimen is bisected and a touch prep is taken. Toto. C1. D. SENTINEL L.N. #3 RIGHT AXILLA. Received fresh is a tan pink lymph node 1.2 x 1 x 0.8cm. The specimen is bisected and a touch prep is taken. Toto. D1. E. SENTINEL L.N. #4 RIGHT AXILLA. Received fresh is a tan pink lymph node 1.4 x 1 x 0.6cm. The specimen is bisected and a touch prep is taken. Toto. E1. DIAGNOSIS: A. BREAST, RIGHT, WIDE LOCAL EXCISION: INVASIVE DUCTAL CARCINOMA, SBR GRADE 1, MEASURING 2.2-CM. INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, CRIBRIFORM TYPE WITH CENTRAL. NECROSIS. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. DCIS PRESENT WITHIN 0.15-CM FROM INFERIOR SURGICAL RESECTION MARGIN. - BIOPSY SITE CHANGES WITH FIBROSIS AND GRANULATION TISSUE. - SEE SYNOPTIC REPORT. B. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). C. LYMPH NODE, SENTINEL #2, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). D. LYMPH NODE, SENTINEL #3, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). E. LYMPH NODE, SENTINEL #4, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Yes For mass. Laterality: ( Right. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 2.2cm. Tumor Site: Not specified. Margins: Negative. Distance from closest margin: 0.4cm. inferior. Tubular Score: 2. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 1. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0 / 4. DCIS present. Margins uninvolved by DCIS 0.15-cm from inferior. DCIS Quantity Estimate 30%. DCIS Type: Cribriform. DCIS Location: Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Present. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT 2N0. CLINICAL HISTORY: None provided. PRE-OPERATIVE DIAGNOSIS: Right breast cancer. INTRAOPERATIVE CONSULTATION: A. GROSS CY^MINATION: Right breast-mass is 2.5cm and 0.6cm from the closest inferior margin. Diagnosis called. to Dr. at. by Dr. TPB-TPC-TPD-TPE SLN #1-4: Negative for carcinoma. Diagnosis called to Dr. at. by Dr. ADDENDUM: ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 17. CLINICAL EXPERIENCE: Patients with a recurrence score of: 17 in the clinical validation study had an average. rate of Distant Recurrence at 10 years of 11%. ER Score: 9.8 Positive. PR Score: 8.4 Positive. Her2 Score: 9.5 Negative. Interpretation: ER. Negative < 6.5 Positive >= 6.5. PR. Negative < 5.5 Positive >= 5.5. Her2 Negative <10.7 Positive >=11.5 Equivocal = 10.7 - 11.4. See separate. report for further information. Microscopic/Diagnostic Dictation: Pathologist,. Final Review: Pathologiet. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist,."
TCGA-E2-A1LE.42E3E8C1-D18A-4457-B2F0-FE49F4C027D7,1,Either T1c or T2,"The report states that the largest tumor size is 3.6 cm (B3-B9) and it is an invasive ductal carcinoma. This exceeds the T1 category (T1 includes tumors up to 2 cm) and is not quite T2 (T2 includes tumors between 2 and 5 cm). Therefore, the T stage cannot be determined without additional information about the tumor size. However, based on the information provided, the T stage would be either T1c (if the tumor is exactly 3 cm) or T2 (if the tumor is larger than 3 cm but not more than 5 cm). The report also mentions 'extensive lymphovascular invasion' but this does not affect the T stage, it is used to determine the N stage.","SPECIMENS: A. NON-SENTINEL NODES RIGHT AXILLA Path Site-breast, upperimen. B. RIGHT BREAST. SPECIMEN(S): A. NON-SENTINEL NODES RIGHT AXILLA. B. RIGHT BREAST. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA: Lymph nodes, right axillary non-sentinel, biopsy: Two lymph nodes positive for carcinoma on. tough prep. By Dr. called to Dr. GROSS DESCRIPTION: A. NON-SENTINEL NODES RIGHT AXILLA. Received fresh and labeled with the patient name designated ""A - non-sentinel nodes right axilla"", are 2. portions of fibroadipose tissue demonstrating 2 presumptive palpable lymph nodes; one lymph node. measures 3.5 x 1.2 x 0.8 cm, the second measures 2.0 x 1.2 x 0.7 cm. Both nodes are bisected. Touch prep performed. One lymph node is submitted in cassette A1 and the second is submitted in. cassette A2. B. RIGHT BREAST. Received fresh and labeled with the patient name designated ""B - right breast"", is a resected. mastectomy specimen weighing 1,383 grams and measuring 29.5 x 22.0 x 4.0 cm. The attached. axillary tail measures 13.0 x 7.2 x 1.5 cm. A suture indicates the axillary region. The posterior margin. is inked black. The white-beige ellipse of overlying skin measures 21.8 x 11.0. The light beige areola. measures 3.5 cm in diameter. The inverted nipple measures 1.0 cm in diameter. The surface of the. skin is dense and wrinkled. The specimen is serially sectioned from medial to lateral. Cut section. shows two firm beige distinct lesions; the larger lesion is located in the lower inner quadrant in the. subareolar region and measures 3.6 x 2.2 x 1.5 cm located 4.4 cm from the smaller lesion. The smaller. lesion is firm present in the upper inner quadrant measuring 1.0 x 0.9 x 0.8 cm. The larger lesion is 5.1. cm from the deep margin. The smaller lesion approaches the deep margin at a distance of 2.0 cm. The. remainder of the specimen shows dark yellow lobulated adipose tissue. Many firm lymph nodes are. demonstrated in the axillary tail ranging in size from 0.5 x 0.5 x 0.4 cm up to 2.5 x 2.0 x 1.0 cm. A. portion of the specimen is submitted for tissue procurement. Representative sections are submitted as. follows: B1-B2: The smaller lesion submitted entirely with overlying deep margin. B3-B9: Sections from the larger lesion. B10: Margin overlying the larger lesion. B11-B13: Sections of nipple. B14: Section of skin adjacent to nipple. B15: Additional section of skin. B16-B17: Representative sections upper outer quadrant. B18-B19: Representative sections lower outer quadrant. B20: Additional section upper inner quadrant. B21-B22: One bisected lymph node. B23: One-half of one bisected lymph node. B24: One bisected lymph node. B25: Three possible lymph nodes. B26: Three possible lymph nodes. B27: Four possible lymph nodes. B28: Four possible lymph nodes. B29: Four possible lymph nodes. B30: One lymph node. B31: One lymph node. B32: One lymph node. DIAGNOSIS: A. LYMPH NODE, NON-SENTINEL, RIGHT AXILLA, BIOPSY: METASTATIC CARCINOMA TO TWO OF TWO LYMPH NODES (2/2),. MEASURING 2-CM, WITH EXTRANODAL EXTENSION. B. BREAST, RIGHT, MASTECTOMY AND AXILLARY NODE DISSECTION: - MULTIFOCAL, INVASIVE, DUCTAL CARCINOMA, SBR GRADE 3, LARGEST. MEASURING 3.6-CM, PRESENT IN THE LOWER INNER AND UPPER INNER. QUADRANTS AND INVOLVES NIPPLE AND ADJACENT SKIN. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - EXTENSIVE LYMPHOVASCULAR INVASION IDENTIFIED. - METASTATIC CARCINOMA TO TWENTY FIVE OF TWENTY SIX LYMPH. NODES (25/26), LARGEST MEASURING 2.1-CM, WITH EXTENSIVE. EXTRANODAL EXTENSION. - SEE SYNOPTIC REPORT AND SEE NOTE. NOTE: Breast biomarkers have been ordered and addendum report to follow. SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: No. Laterality: Right. Invasive Tumor: Present. Multifocality: Yes. Tumor size: 3.6cm. Tumor Site: Upper inner quadrant. Lower inner quadrant and nipple and adjacent skin. Margins: Negative. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: Present. Extent: extensive. Lobular neoplasia: None. Lymph nodes: Axillary dissection. Lymph node status: Positive 27/28 Extranodal extension. DCIS not present. ER/PR/HER2 Results. ER: Pending. PR: Pending. HER2: Pending. Pathological staging (pTN): pT 2 N 3a. CLINICAL HISTORY: A -year-old Caucasian female post menopausal abnormal mammogram. Biopsy showed an. adenocarcinoma, ER/PR-, Her2+, 2 masses at right breast seen. One at 12 o'clock position subareolar,. 2nd mass at 1 o'clock posterior to 1st mass (3.0 cm). PRE-OPERATIVE DIAGNOSIS: Infiltrating adenocarcinoma. ADDENDUM: SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: B4. ER: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. PR: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer S instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: B4. Interpretation: POSITIVE. Intensity: 3+. % Tumor Staining: 90%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved. HercepTest (TM) test kit. using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate, well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. Pathology. Department takes full responsibility for this test's performance. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologis'."
TCGA-E2-A2P6.E6A21CE6-841D-4D9B-A563-80B9BAF6E682,1,T3,"[{""step"":1,""info"":""The report states that the largest focus of the invasive lobular carcinoma is 3.5 cm. This exceeds the maximum size for T1 (2 cm) and T2 (5 cm), so we can eliminate T1 and T2.""},{""step"":2,""info"":""The report also states that the invasive carcinoma is present at the superior margin and within 0.1 cm of the inferior margin. This indicates that the tumor involves the margin of the wide local excision, which is consistent with T3 or T4.""},{""step"":3,""info"":""However, the report does not mention any direct extension to the chest wall or skin, or any ulceration, satellite nodules, or inflammatory carcinoma. This rules out T3 (tumor size > 5 cm with or without chest wall/skin involvement) and T4 (tumor with chest wall/skin involvement or inflammatory carcinoma).""},{""step"":4,""info"":""Therefore, based on the information provided in the report and the rules, the pathologic T stage of the patient's breast cancer is T1 (since it is less than 2 cm in size), but this is incorrect because the report states that the largest focus is 3.5 cm. It is likely that the pathologic T stage should be T3 (since it involves the margin of the wide local excision), but this cannot be confirmed without additional information about the chest wall/skin involvement.""}]","SPECIMENS: A. WIDE LOCAL EXCISION LEFT BREAST. B. SENTINEL LYMPH NODE #1 LEFT AXILLA. C. SENTINEL LYMPH NODE #2 LEFT AXILLA. D. SENTINEL LYMPH NODE #3 LEFT AXILLA. E. SENTINEL LYMPH NODE #4 LEFT AXILLA. F. SENTINEL LYMPH NODE #5 LEFT AXILLA. SPECIMEN(S): A. WIDE LOCAL EXCISION LEFT BREAST. B. SENTINEL LYMPH NODE #1 LEFT AXILLA. C. SENTINEL LYMPH NODE #2 LEFT AXILLA. D. SENTINEL LYMPH NODE #3 LEFT AXILLA. E. SENTINEL LYMPH NODE #4 LEFT AXILLA. F. SENTINEL LYMPH NODE #5 LEFT AXILLA. DIAGNOSIS: A. BREAST, LEFT, WIDE LOCAL EXCISION: - MULTIFOCAL INVASIVE LOBULAR CARCINOMA, NOTTINGHAM GRADE 2. - LARGEST FOCUS IS 3.5 CM. INVASIVE CARCINOMA IS PRESENT AT THE SUPERIOR MARGIN. AND IS WITHIN 0.1 CM OF THE INFERIOR MARGIN. - LOBULAR CARCINOMA IN SITU (LCIS). NOTE: Several foci of invasive carcinoma are seen, spanning throughout a 6.4 cm lumpectomy. B. SENTINEL LYMPH NODE 1, LEFT AXILLA, BIOPSY: - METASTATIC CARCINOMA (1.9 CM IN SIZE) IN ONE LYMPH NODE. WITH FOCAL EXTRANODAL EXTENSION (1/1). C. SENTINEL LYMPH NODE 2, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR CARCINOMA (0/1). D. SENTINEL LYMPH NODE 3, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR CARCINOMA (0/1). E. SENTINEL LYMPH NODE 4, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR CARCINOMA (0/1). F. SENTINEL LYMPH NODE 5, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR CARCINOMA (0/1). SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive lobular carcinoma 8520/3. Tumor size: 3.5cm. Tumor Site: Upper outer quadrant. Margins: Involved at. superior. Extent:: 0.2 cm. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: LCIS. Lymph nodes: Sentinel lymph node. Lymph node status: Positive 1/5 Extranodal extension. Non-neoplastic areas: columnar cell change. DCIS not present. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT 2 N 1. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. GROSS DESCRIPTION: A. WIDE LOCAL EXCISION LEFT BREAST. Received fresh labeled with the patient's identification and designated ""left breast wide local excision"" is. an oriented, previously inked, 55 g, 6.4 x 5.5 x 3.3 cm lumpectomy. The single suture designates. anterior, double-lateral, triple-superior. Ink code: Anterior-yellow, posterior-green, medial-black, lateral-. red, superior-blue, inferior-orange. The specimen is serially sectioned from posterior to anterior into 5. slices revealing a 2.5 x 2.1 x 1.9 cm, ill-defined firm pale tan mass, located 0.6 cm from the lateral. margin. The remainder of the specimen shows focal areas of white dense fibrous parenchyma. Tissue. is procured. The specimen is representatively submitted: A1-A2: Representative section posterior margin (green ink). A3: Slice 2, inferior/lateral. A4-A5: Slice 2, lateral/medial, respectively. A6-A11: Slice 3, entirely submitted, A7 demonstrating mass and nearest the lateral margin. A12-A13: Slice 4, mass, lateral margin. A14-A15: Slice 4, medial/inferior, respectively. A16: Slice 4, superior. A17-A18: Representative perpendicular sections anterior margin. B. SENTINEL LYMPH NODE #1 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node #1 left. axilla"" is a yellow-tan lymph node measuring 1.9 x 1.7 x 1.5 cm. The specimen is sectioned, entirely. submitted, B1. C. SENTINEL LYMPH NODE #2 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node #2 left. axilla"" is a yellow-tan lymph node measuring 2.4 x 0.8 x 0.4 cm. The specimen is sectioned, entirely. submitted, C1. D. SENTINEL LYMPH NODE #3 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node #3 left. axilla"" is a tan lymph node measuring 1.6 x 1 x 0.5 cm. The specimen is sectioned, entirely submitted,. D1. E. SENTINEL LYMPH NODE #4 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node #4 left. axilla"" is a yellow-tan lymph node measuring 1.5 x 1.1 x 0.3 cm. The specimen is sectioned, entirely. submitted, E1. F. SENTINEL LYMPH NODE #5 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node #5 left. axilla"" is a tan lymph node measuring 0.8 x 0.5 X 0.2 cm. Entirely submitted, F1. CLINICAL HISTORY: 1.5-2 cm invasive cancer upper outer quadrant left breast. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. FROZEN SECTION INTRAOPERATIVE REPORT: Part A: Breast, left, wide local excision, gross examination: 2.4 cm tumor mass located approximately. 0.6 cm to the lateral margin, gross examination only. Diagnosis called at. by Dr. Microscopic/Diagnostic Dictation: Patnologist,. Final Review: Pathologist,. Final: Pathologist,."
TCGA-E9-A1NG.73953A70-DAC0-443A-AC04-28BDA8D5F673,1,T1,"Based on the pathology report provided, we can determine the patient's T stage as follows:""T1""""T1"" refers to invasive breast carcinomas that are 2 cm or less in size. The report states that the tumor size is 3.2 x 3.2 x 3.2 cm, which is clearly larger than 2 cm. However, the rules state that the T stage should be determined by a healthcare professional based on a variety of factors, including clinical examination, imaging studies, and pathological findings. It is possible that the actual tumor size was measured differently or that other factors were taken into account. Therefore, we cannot make a definitive conclusion based solely on the information provided in the report. However, if we were to base the T stage on the tumor size alone, it would be classified as T2 or higher. But, since the report mentions that the specimen type is mastectomy, it is possible that the tumor was removed in its entirety, and therefore the T stage could be T1. But, without further information, we cannot make a definitive conclusion.","the. the. BREAST TISSUE CHECKLIST. Specimen type: Mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 3.2 X 3.2 x 3.2 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 0/5 positive for metastasis (Regional 0/5). Right,Jupper. Extracapsular invasion of the lymph nodes: Not specified. outer. Margins: Not specified. quadrant. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None."
TCGA-EW-A1P1.AE0C51EF-017E-4F53-968C-804110F9A7E6,1,T1c,"The pathology report states that the 'Size of Invasive Component: 2.3 cm in greatest dimensions.' This meets the criteria for T1 stage, but is greater than 2 cm, so it does not meet the criteria for T1mi, T1a, or T1b. Therefore, the T stage is T1c. However, the report also states 'Tumor Summary: Specimen Type Lumpectomy. Lymph Node Sampling: Axillary dissection. Specimen Size (for excisions less than total mastectomy): 6 cm in greatest dimensions.' This suggests that the tumor may be larger than 2.3 cm, but the report does not specify the size of the entire tumor, only the invasive component. Based on the information provided, the T stage is T1c.","F. Pathologic Interpretation: A. Sentinel node #1 (. right FS: - Metastatic carcinoma into one lymph node (1/1). B. Sentinel node #2 I. ) FS: - Metastatic carcinoma into theree out of four lymph nodes (3/4). C. Sentinel node #3 (. FS: - One benign lymph node (0/1). D. Right breast lumpectomy, long - lateral, short - superior: - In situ and invasive carcinoma. - The entire tumor mass measures 2.3 cm in greatest dimensions. - The invasive component represents the majority of the tumor mass and is of Nottingham grade of 3 +3 +3=9/9. - Foci of vascular invasion are noted. - The in-situ component is of ductal type, high nuclear grade with central necrosis and calcifications (comedocarcindma). - All margins of resection appear free of invasive and intraductal carcinoma. - The closest margins of resection are the medial and anterior at 4 mm from the tumor. - The non-neoplastic breast tissue shows fibroproliferative disease, radial scar, atypical ductal hyperplasia and changes consistent. with previous biopsy site. D. Right axillary content: - Metastatic carcinoma into six out of twenty-thre lymph nodes (6/23). E. Level 3 (right) permanent: - Metastatic carcinoma into one out of three lymph nodes (1/3). Tumor Summary: Specimen Type Lumpectomy. Lymph Node Sampling: Axillary dissection. Specimen Size (for excisions less than total mastectomy): 6 cm in greatest dimensions. Laterality: Right. Tumor Site: Not specified. Size of Invasive Component: 2.3 cm in greatest dimensions. Histologic Type: Ductal. Histologic Grade (any grading system may be used; mitotic count is also required independent of the grading system): 3 +3 +3=9/9. Total Nottingham Score:9/9. Margins: Free. Pathologic Staging (pTNM). pT 2, N3, MX. SURGICAL PATHOL Report. NOTE: IDS-ER. Some PgR immunokissochemical 636-PR, A4RS-HER2. antibodies H-II=EGFR. are analyte All immunohistochemical specific reagents (ASRs) stains validated are used by with our formalin laborasory. or molecular These ASRs fixed. are paraffis clinically embedded useful indicators tissue. Derection that do not is by require Envision FDA Method. approval. the These results ciones are read are used: by a. pathologist as positive or negative. As the attending pathologist, / attest that I: (i) Examined the relevant preparation(s). for the specimen(s); and (ii) Rendered the diagnosis(es). Intraoperative Consultation. A. Sentinel node #1 (. right FS: Metastatic adenocarcinoma to one lymph node (1/1). B. Sentinel node #2 (. ) FS: Metastatic adenocarcinoma to three of four lymph nodes (3/4). C. Sentinel node #3 (. 1 FS: One lymph node, no tumor seen (0/1). 1 MD. Clinical History: None provided. Operation Performed. Right breast lumpectomy with sentinei node blopsy, possible axiliary node dissection; possible left breast reduction. Pre Operative Diagnosis: Breast cancer. Specimen(s) Received: A: Sentinel node #1. 1) right FS. B: Sentinel node #2 (. ) FS. C: Sentinel node #3 (. FS. D: Right breast lumpectomy, long - lateral, short - superior. E: Right axillary content. F: Level 3 (right) permanent. Gross Description: A. Received fresh is an irregular fragment of fibroadipose tissue, measuring 2.3 x 1.2 x 0.7 cm. One lymph node is ill-. defined. The lymph node is submitted in toto in one cassette for frozen section. B. Received fresh is an irregular fragment of fibroadipose tissue, measuring 3.2 x 1.7 x 0.9 cm. Four lymph nodes are. grossly identified. The lymph nodes are submitted in toto as follows: 1. One lymph node for frozen. 2. Lymph node for frozen section. C. Received fresh is an irregular fragment of fibroadipose tissue, measuring 1.9 x 1.1 x 0.7 cm. One lymph node is grossly. identified. The lymph node is submitted in toto in one cassette for frozen section. D. Received in formalin is a lumpectomy specimen measuring 6 cm from medial to lateral, 5.4 cm from superior to inferior. and 4.4 cm from anterior to posterior. The specimen has an ellipse of skin in the anterior surface measuring 3.8 x 0.9 cm. The specimen is labelled as follows: long stitch lateral; short stitch superior. The margin is inked as follows: Anterior. yellow, posterior black, superior blue, inferior green, medial red, lateral orange. Upon sectioning ill-defined fiem white and. SURGICAL PATHOL Report. tan mass is identified measuring 2.3 x 2 x 1.5 cm. The mass is 1 cm from the lateral margin up to 1.6 cm from. the. superior margin, 0.5 cm from the inferior margin, 0.5 cm from the posterior margin, 0.4 cm from the medial. margin and 0.4. cm from the anterior margin from the skin. Other areas of the mastectomy specimen show unremarkable ibroadipose. tissue. Representative sections are submitted as follows: 1. Lateral margin. 2. Superior margin. 3. Anterior margin and skin in relation with the tumor. 4. Medial margin in relation with the tumor. 5. Posterior margin in relation with the tumor. 6. Inferior margin in relation with the tumor. 7-8. Other areas of the mass. E. Received in formalin are multiple irregular fragments of fibroadipose tissue measuring 9 x 7.5 x 2.2 cm in aggregate. Five-. possible lymph nodes are identified. The lymph nodes are submitted in toto-. as follows: 1-2. One lymph node bisected per cassette. 3-4. Lymph node bisected per cassette. 5-6. Three lymph nodes bisected per c assette. 7-8. Four lymph nodes per cassette. F. Received in formalin are four irregular fragments of soft tan brown and yellow tissue measuring 1 x 0.5 x 0.4 cm in. aggregate. Submitted in toto in one cassette."
TCGA-EW-A423.0BB6CAC8-CE26-461F-A9FE-46E28E96A368,1,T1,"The report states that the 'Size of Largest Invasive Carcinoma: Greatest dimension of largest focus of invasion: 2 cm.' This is the key piece of information we need to determine the T stage. According to the rules provided, a tumor that is 2 cm or less in size falls under the T1 category. Therefore, the patient's pathologic T stage is T1.","Laboratory. Collected: xx. F. Received: xx. Reported: xx. Pathologic Interpretation: A. LEFT BREAST NEEDLE LOCALIZATION LUMPECTOMY: INVASIVE LOBULAR CARCINOMA with pleomorphic features, Nottingham grade 2 (3+2+2=7), measuring. 2. cm. PLEOMORPHIC LOBULAR CARCINOMA IN SITU is present. Prior biopsy site present. The invasive carcinoma is 0.1 cm from inferior and lateral margins (green, orange). B. HOT SPOT #1, AXILLAI, CT-xxx: One lymph node, negative for carcinoma (0/1). C. HOT SPOT #1, AXILLAI CT -xxx: One lymph node, negative for carcinoma (0/1). Note: Receptor studies and keratin stains to follow. See Tumor Summary. Surgical Pathology Cancer Case Summary. Procedure: Excision with wire-guided localization. Lymph Node Sampling: Sentinel lymph nodes. Specimen Integrity: Single intact specimen (margins can be evaluated). Specimen Size (for excisions less than total mastectomy): Greatest dimension: 5 cm. Additional dimensions: 4.5 x 3.5 cm. Specimen Laterality: Left. Tumor Size: Size of Largest Invasive Carcinoma: Greatest dimension of largest focus of invasion: 2 cm. Tumor Focality: Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of Tumor: Skin: Skin is not present. Skeletal Muscle: No skeletal muscle present. Ductal Carcinoma in Situ (DCIS): No DCIS is present. Lobular Carcinoma in Situ (LCIS): Present (pleomorphic type). Histologic Type of Invasive Carcinoma: Invasive lobular carcinoma (pleomorphic type). Histologic Grade: Nottingham Histologic Score: Glandular (Acinar)/Tubular Differentiation. Score 3: < 10% of tumor area forming glandular/tubular structures. Nuclear Pleomorphism. Score 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate. variability in both size and shape. Mitotic Count: Score 2. Overall Grade: Grade 2. Margins: Margins uninvolved by invasive carcinoma. Distance from closest margin: 1 mm. Distance from superior margin: > 5 mm. Distance from inferior margin: 1 mm. Distance from anterior margin: > 5 mm. Distance from posterior margin: > 5 mm. Distance from medial margin: 4 mm. Distance from lateral margin: 1 mm. Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy: In the Breast: No known presurgical therapy. Lymph-Vascular Invasion: Not identified. Lymph Nodes: Number of sentinel lymph nodes examined: 2. Total number of lymph nodes examined (sentinel and nonsentinel): 2. Number of lymph nodes with macrometastases (> 0.2 cm): 0. Number of lymph nodes with micrometastases (> 0.2 mm to 0.2 cm and/or > 200 cells): 0. Number of lymph nodes with isolated tumor cells (s 0.2 mm and S 200 cells): 0. Method of Evaluation of Sentinel Lymph Nodes: Hematoxylin and eosin (H&E), one level. Pathologic Staging (pTNM): Primary Tumor (pT): pT2: Tumor > 20 mm but 50 mm in greatest dimension. Regional Lymph Nodes (pN): pNO: No regional lymph node metastasis identified histologically. Distant Metastasis (pM): Not applicable. Ancillary Studies (performed on another specimen: xxxx): Estrogen Receptor: POSITIVE (> 50%). Progesterone Receptor: NEGATIVE (less than 1% immunoreactive cells present). HER2/neu Immunoperoxidase Studies: NEGATIVE (CISH: NOT AMPLIFIED). NOTE: Some immunohistochemical antibodies are analyte specific reagents (ASRs) validated by our laboratory (Her 2, Parvo, H. pylori, HBcore). These ASRs are clinically. useful indicators that do not require FDA approval. These clones are used: ID5=ER, PgR 636=PR, A485=HER2, H-11=EGFR, CCH2/DDG9=CMV, F39.4 1=AR and HPV. ISH. Allimmunohistochemical stains are used with formalin or molecular fixed, paraffin embedded tissue. Detection is by LSAB. The results are read by a pathologist as positive. or negative. Procedures/Addenda. Addendum. Date Complete: xx. Addendum Diagnosis. A. LEFT BREAST NEEDLE LOCALIZATION LUMPECTOMY: Immunohistochemical studies were performed on formalin fixed tissue with the following results for [invasive. carcinoma/DCIS/metastatic carcinoma] (block xx): Estrogen receptor. POSITIVE ( > 90%). Progesterone receptor. PgR 636. POSITIVE (1-10%). HER-2/neu (c-erb-B2). NEGATIVE 0. B. HOT SPOT #1, AXILLA I, CT-xx: Immunohistochemical studies were performed on formalin fixed tissue with the following results for metastatic. carcinoma (block B): Keratin: NEGATIVE (see note). Note: A single cell that appears to be keratin positive is present in the subcapsular space. However, the nuclear size. and morphology of this cell is different than the primary tumor cells. Selected slides were reviewed with Dr. XX and. concurs with the diagnosis. C. HOT SPOT #1, AXILLAI CT -xx: Immunohistochemical studies were performed on formalin fixed tissue with the following results for metastatic. carcinoma (C): Keratin: NEGATIVE. Interpretation Guidelines: For hormone receptor immunohistochemical analysis, the percent of immunoreactive. nuclei in the invasive or in-situ carcinoma is assessed manually by light microscopic examination and reported as. follows: Positive: greater than or equal to 1 percent of nuclei immunoreactive. Negative: less than 1 percent of nuclei immunoreactive. Non-neoplastic mammary epithelial cells are immunoreactive for estrogen and progesterone receptors (internal. control). For HER2/neu immunohistochemical analysis, the cell membrane staining is assessed manually by light microscopic. examination. Cytoplasmic immunoreactivity alone is scored as a negative result. Reference #1: XX. Reference #2: XX. Clinical History: Infiltrating lobular cancer in left breast. Please evaluate margins of lumpectomy. If sentinel nodes are negative, do. immunohistochemistry. Specimen(s) Received/Processing Information: Fee Codes: A: Left breast lumpectomy, 1 suture superficial margin, 2 suture medial, 3 suture. inferior H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1,. H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, Estrogen Receptor (ER) x 1,. Progesterone Receptor x 1, CERbB2, HER2/neu x 1. B: Hot spot #1, axilla I, CT-356 H&E, Initial x 1, unstained x 1, unstained x 1, unstained x. 1, unstained x 1, Desmin 33 x 1. C: Hot spot #1, axilla I CT -473 H&E, Initial x 1, unstained x 1, unstained x 1, unstained x. 1, unstained x 1, Cytokeratin Cocktail (KER) x 1. Gross Description: A. Received fresh and labeled ""Left breast lumpectomy"" is a yellow-tan irregular-shaped lumpectomy,. measuring 5.0 x 4.5 x 3.5 cm and weighing 35.0 grams. The specimen is inked as follows: superior. margin. inked blue, inferior margin inked green, medial margin inked red, lateral margin inked orange,. anterior/superficial margin inked yellow and deep margin inked black. Sections reveal an ill-defined area with. firm to hard consistency, 2.0 x 2.0 x 1.5 cm. This area is located toward the medial to posterior resection. margin at 0.2 to 0.3 cm from the deep resection margin (nearest), 0.3 cm from the inferior resection margin,. 3.0 cm from lateral resection margin, 2.0 cm from the superior resection margin, 1.0 cm from the superficial. resection margin. The remainder of the specimen is homogeneous, yellow-tan, grossly unremarkable. adipose tissue. No other suspicious lesions are present. The specimen is submitted in nine cassettes, as. follows: Cassette #1-3: Tissue with clip in toto. Cassette #4: Perpendicular section superior margin. Cassette #5: Perpendicular section inferior margin. Cassette #6: Perpendicular section medial margin. Cassette #7: Perpendicular section lateral margin. Cassette #8: Perpendicular section superficial margin. Cassette #9: Perpendicular section deep margin. B. Received in formalin and labeled ""Hot spot #1, axilla I, ct xx"" is a yellow-tan irregular-shaped soft tissue. fragment, 3.5 x 3.0 x 1.0 cm. Sections reveal one lymph node, 1.5 x 1.0 x 1.0 cm. The lymph node is bisected and. submitted in toto in one. cassette. C. Received in formalin and labeled ""Hot spot #1, axilla I, ct xx"" is a yellow-tan irregular-shaped soft tissue. fragment, 2.8 x 2.0 x 1.0 cm. Sections reveal one lymph node, 1.5 x 1.0 x 1.0 cm. the lymph node is bisected and. submitted in toto in one cassette."
TCGA-JL-A3YW.476488A9-3708-4B11-854A-C91B583C7804,1,T1c,"Based on the pathology report, the patient has been diagnosed with Infiltrating Lobular Carcinoma grade II, which is a type of invasive breast carcinoma. The report mentions that the tumor size is not explicitly stated in centimeters. However, it does mention that the tumor nuclei constitute approximately 70% of the total nuclei. This suggests that the tumor is likely to be larger than 1 cm but less than 2 cm in size. Therefore, based on the rules provided, the patient's pathologic T stage would be T1c, which includes invasive breast carcinomas that are 1 cm but less than 2 cm in size.","1. LAS NO : CLINICAL INFORMATONICOMMENTS: FEMALE YEARS. Loc: METRICS CANCER PR. PATIENT CODF. CONSULTANT: Histopathology Blopay Smatt. Specimen: Two blocks representing left breast tissue are received. Clinical Note: Carcinoma left breast. Microscopic Features: One of the block reveals breast tissue infiltrated by รกcellular neoplastic lesion composed. of. intermediate size tumor cells exhibiting moderate nuclear pieomorphism with eosinophilic. cytoplasm. Mitotic figures are also identified. The surrounding stroma exhibits moderate. chronic inflammation, Focal necrosis (< than 5%) is noted. The other block reveals benign breast tissue. Conclusion: Two blocks representing left breast tissue received for 2nd opinion :-. Infiltrating Lobular Carcinoma grade Il (Tubule formation 2/3, Nuclear pleomorphism 2/3,. Mitoses 2/3, Total = (6/9), according to Modified Bloom and Richardson's grading system. Tumour nuclei constitute approximately 70% of the total nuclei. Dr."
TCGA-UL-AAZ6.1AD1E3C4-0D7C-447B-B330-0245F9159FCC,1,T1,[{,"SPECIMEN(S) RECEIVED. A: RIGHT TOTAL MASTECTOMY. B: SENTINEL LYMPH NODE #1 HOT. C: SENTINEL LYMPH NODE #2 HOT. D: SENTINEL LYMPH NODE #3 HOT. FINAL DIAGNOSIS. A. RIGHT TOTAL MASTECTOMY: SYNOPTIC REPORT. MICROSCOPIC: HISTOLOGIC TYPE: INVASIVE DUCTAL CARCINOMA. SIZE OF INVASIVE COMPONENT: 3.4 x 3.0 x 2.5 cm. TUMOR FOCALITY: SINGLE FOCUS OF INVASION. MACRO/MICRO EXTENT OF INVASIVE TUMOR. SKIN. TUMOR DOES NOT INVADE DERMIS/ EPIDERMIS. NIPPLE. DCIS DOES NOT INVOLVE THE NIPPLE EPIDERMIS. SKELETAL MUSCLE. SKELETAL MUSCLE IS PRESENT AND IS FREE OF CARCINOMA. DUCTAL CARCINOMA-IN-SITU (DCIS): DCIS IS PRESENT. EXTENSIVE INTRADUCTAL COMPONENT (EIC) NEGATIVE. LOBULAR CARCINOMA-IN-SITU (LCIS): NOT IDENTIFIED. HISTOLOGIC MODIFIED SCARFF-BLOOM-RICHARDSON GRADE: 2/3. MARGINS. MARGINS UNINVOLVED BY INVASIVE CARCINOMA. DISTANCE FROM CLOSEST MARGIN: 2.0cm (DEEP). MARGINS UNINVOLVED BY DCIS. DISTANCE FROM CLOSEST MARGIN: GREATER THAN 2.0cm (DEEP). MICROCALCIFICATIONS: PRESENT IN DCIS. TREATMENT EFFECT: RESPONSE TO NEOADJUVANT THERAPY. IN THE BREAST: NO KNOWN PRESURGICAL THERAPY. IN THE LYMPH NODES: NO KNOWN PRESURGICAL THERAPY. VENOUS / LYMPHATIC INVASION: NOT IDENTIFIED. SKIN / DERMAL LYMPHATIC INVASION: NOT IDENTIFIED. LYMPH NODES: NUMBER OF SENTINEL LYMPH NODES EXAMINED: 3. TOTAL NUMBER OF LYMPH NODES EXAMINED (SENTINEL AND NONSENTINEL): 4. NUMBER OF LYMPH NODES WITH MACROMETASTASES (>0.2 CM): 0. NUMBER OF LYMPH NODES WITH MICROMETASTASES (>0.2 MM TO 0.2 CM AND/OR >200 CELLS): o. NUMBER OF LYMPH NODES WITH ISOLATED TUMOR CELLS (0.2 MM AND 200 CELLS): 0. SIZE OF LARGEST METASTATIC DEPOSIT (IF PRESENT): o. EXTRANODAL EXTENSION: N/A. METHOD OF EVALUATION OF SENTINEL LYMPH NODES: H&E, MULTIPLE LEVELS. NOTE: ER/ PR/ HER-2/ MIB-1 RESULTS: SEE PRIOR REPORT. MACROSCOPIC. SPECIMEN TYPE: TOTAL BREAST. PROCEDURE: TOTAL MASTECTOMY. LYMPH NODE SAMPLING: SENTINEL LYMPH NODES WITH PARTIAL AXILLARY DISSECTION. SPECIMEN INTEGRITY: SINGLE INTACT SPECIMEN. SPECIMEN SIZE: 27 x 17 x 3.5 cm. LATERALITY: RIGHT. TUMOR SITE: 12 O'CLOCK POSITION. AJCC PATHOLOGIC STAGE (AJCC 7TH ED.): (pT2, pNO). B. SENTINEL LYMPH NODE #1 HOT: ONE (1) REACTIVE LYMPH NODE. NO METASTATIC CARCINOMA IDENTIFIED. c. SENTINEL LYMPH NODE #2 HOT: ONE (1) REACTIVE LYMPH NODE. NO METASTATIC CARCINOMA IDENTIFIED. D. SENTINEL LYMPH NODE #3 HOT: ONE (1) REACTIVE LYMPH NODE. NO METASTATIC CARCINOMA IDENTIFIED. CLINICAL DIAGNOSIS AND HISTORY. Right breast cancer. See. right breast Ca. GROSS DESCRIPTION. The specimen is received fresh in four containers labeled with the patient's name, medical record number, and identified as A. ""Right Total Mastectomy"", B. ""Sentinel Lymph Node #1 Hot"", C. ""Sentinel Lymph Node #2 Hot"" and D. ""Sentinel Lymph Node #3. Hot"". Specimen A consists of a mastectomy (811.1 grams, 27 x 17 x 3.5 cm) with a 22 x 9.5 cm skin ellipse and a centrally located. unremarkable 1.2 cm nipple. The specimen has been oriented by the surgeon with a stitch indicating the tail of the specimen. The. deep margin is inked black. The specimen is serially sectioned to reveal an irregular firm tan colored mass with focal hemorrhage. and calcification (3.4 x 3 x 2.5 cm) in the 12:00 position, 2 cm to the deep margin, 1.2 cm to the anterior skin margin, and 2 cm to. the nipple. The remaining breast parenchyma appears grossly unremarkable. One 0.7 cm lymph node is identified in the tail of the. specimen. The specimen is submitted representatively as follows: A1 thru A3, tumor, A4-tumor and anterior skin, A5-anterior skin. margin, A6-posterior deep margin, 7-nipple, A8 and A9-lateral upper quadrant, A10 and A11-lateral lower quadrant, A13-medial. upper quadrant, A14 and A15-medial lower quadrant, 16-0.7 cm lymph nodes, bisected. Specimen B consists of a 2.2 cm sentinel lymph node. The lymph node is serially sectioned and submitted entirely in two cassettes. labeled B1 and B2. Specimen C consists of a 2.5 cm sentinel lymph node. The lymph node is serially sectioned and submitted entirely in two cassettes. labeled C1 and C2. Specimen D consists of a 1 cm sentinel lymph node with fibroadipose tissue. Lymph nodes are serially sectioned and submitted. entirety in two cassettes labeled D1 and D2. the diagnosis(es) related thereto."
